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Abstract 
Introduction: Type 2 diabetes continues to be one of the most common non-communicable 
diseases worldwide and complications due to type 2 diabetes, such as cardiovascular disease 
(CVD) can cause severe disability and even death. Despite advances in the development and 
validation of cardiovascular risk scores, those used in clinical practice perform inadequately 
for people with type 2 diabetes. Research has suggested that particular non-traditional 
biomarkers and novel omics data may provide additional value to risk scores over-and-above 
traditional predictors.  
Aims: To determine whether a small panel of non-traditional biomarkers improve prediction 
models based on a current cardiovascular risk score (QRISK2), either individually or in 
combination, in people with type 2 diabetes. Furthermore, to investigate a set of 228 
metabolites and their associations with CVD, independent of well-established cardiovascular 
risk factors, in order to identify potential new predictors of CVD for future research. 
Methods: Analyses used the Edinburgh Type 2 Diabetes Study (ET2DS), a prospective 
cohort of 1066 men and women with type 2 diabetes aged 60-75 years at baseline. 
Participants were followed for eight years, during which time 205 had a cardiovascular event. 
Additionally, for omics analyses, four cohorts from the UCL-LSHTM-Edinburgh-Bristol 
(UCLEB) consortium were combined with the ET2DS. Across all studies, 1005 (44.73%) 
participants had CVD at baseline or experienced a cardiovascular event during follow-up. 
Results: In the ET2DS, higher levels of high sensitivity cardiac troponin (hs-cTnT) and N-
terminal pro-brain natriuretic peptide (NT-proBNP) and lower levels of ankle brachial 
pressure index (ABI) were associated with incident cardiovascular events, independent of 
QRISK2 and pre-existing cardiovascular disease (odds ratios per one SD increase in 
biomarker 1.35 (95% CI: 1.13, 1.61), 1.23 (1.02, 1.49) and 0.86 (0.73, 1.00) respectively). 
The addition of each biomarker to a model including just QRISK2 variables improved the c-
statistic, with the biggest increase for hs-cTnT (from 0.722 (0.681, 0.763) to 0.732 (0.690, 
0.774)). When multiple biomarkers were considered in combination, the greatest c-statistic 
was found for a model which included ABI, hs-cTnT and gamma-glutamyl transpeptidase 
(0.740 (0.699, 0.781)). 
In the combined cohorts from the UCLEB consortium, a small number of high-density 
lipoprotein (HDL) particles were found to be significantly associated with CVD: 
  v 
concentration of medium HDL particles, total lipids in medium HDL, phospholipids in 
medium HDL and phospholipids in small HDL. These associations persisted after adjustment 
for a range of traditional cardiovascular risk factors including age, sex, blood pressure, 
smoking and HDL to total cholesterol ratio.  
Conclusions: In older people with type 2 diabetes, a range of non-traditional biomarkers 
increased predictive ability for cardiovascular events over-and-above the commonly used 
QRISK2 score, and a combination of biomarkers may provide the best improvement. 
Furthermore, a small number of novel omics biomarkers were identified which may further 
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1 Introduction: Type 2 diabetes mellitus, 
cardiovascular disease and biomarkers 
1.1 Diabetes Mellitus and Type 2 Diabetes 
Diabetes mellitus (commonly referred to as diabetes) is one of the most common 
non-communicable diseases in the world. Between 1980 and 2014 the number of 
people with diabetes increased from 108 million to 422 million (World Health 
Organization, 2016) and the mortality and morbidity directly linked to clinical 
complications such as cardiovascular disease and renal failure accounted for 
approximately five million deaths in 2015, 14.5% of global all-cause mortality in 
adults (International Diabetes Federation, 2015). Furthermore, the number of people 
with diabetes worldwide is predicted to rise to 642 million by 2040 (International 
Diabetes Federation, 2015). As well as resulting in loss of life, diabetes 
complications can cause severe disability and drastically reduce quality of life. It was 
estimated that in 2015 the cost of health spending on diabetes was at least USD 673 
billion – approximately 11% of the total amount of money spent on health worldwide 
in the adult population (International Diabetes Federation, 2015).  
The World Health Organization (WHO) defines diabetes as a “metabolic disorder of 
multiple aetiology characterised by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, 
insulin action, or both” (World Health Organization, 2014). In other words, diabetes 
is a long-term metabolic disorder with multiple causes which is characterised by a 
persistent excess of glucose in the blood.  
There are generally accepted to be two main types of diabetes: type 1 and type 2 
diabetes. Type 1 diabetes, commonly referred to as “insulin-dependent diabetes”, is 
caused by an autoimmune destruction of insulin-producing β-cells. It usually 
presents during early childhood or adolescence and requires patients to undergo 
regular, lifelong insulin injections. Type 2 diabetes can be caused by either a defect 
in insulin secretion or resistance to the action of insulin. It is by far the most common 
type of diabetes (representing 90% of diabetes cases worldwide) and usually 
develops in adulthood, although numbers are increasing in children and adolescents 
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(Pulgaron and Delamater, 2014). The development of type 2 diabetes is strongly 
related to obesity, lack of physical activity and bad diet (Kahn et al., 2006; Sigal et 
al., 2004). Type 2 diabetes can often be controlled using diet, exercise and weight 
loss alone, and in fact recent studies have suggested that type 2 diabetes could be 
reversible through the use of an extreme calorie-restrictive diet (Steven et al., 2016). 
However, in the majority of cases a combination of diet and exercise and either oral 
antidiabetic drugs (for example, sulphonylureas or biguanides) or the addition of 
insulin injections is eventually necessary.  
The symptoms of type 2 diabetes are non-specific and may be minimal or not present 
for years, making the diagnosis of type 2 diabetes difficult. These symptoms can 
include increased urination, thirst or hunger, unexplained weight loss, numbness in 
the extremities, pain in the feet, blurred vision or recurring infections. In extreme 
cases loss of consciousness due to ketoacidosis can occur, though this is much more 
common in patients with type 1 diabetes. In order for clinicians to diagnose type 2 
diabetes, an abnormal blood test can be used in conjunction with the presence of 
symptoms. If fasting plasma glucose concentration is greater than 7mmol/L 
(126mg/dL) then this is taken as confirmation of type 2 diabetes (World Health 
Organization, 2016). Furthermore, a test for glycated haemoglobin (HbA1C) can be 
used to help diagnose type 2 diabetes. HbA1C is an approximate measure of glucose 
control in the previous 2-3 months. The WHO recommend that an HbA1c of 6.5% or 
greater should be used as a diagnosis for diabetes, although a lower HbA1c does not 
exclude diabetes in the presence of a high glucose test (World Health Organization, 
2011). 
Treatment of type 2 diabetes aims to relieve or reverse symptoms and also to delay or 
prevent complications. Complications of diabetes occur due to damage to the small 
(microvascular) and large (macrovascular) blood vessels of the body caused by the 
chronic elevation of blood glucose:  microvascular complications include retinopathy 
(damage to the eyes which can lead to blindness), nephropathy (damage to the 
kidneys which can lead to renal failure) and neuropathy (damage to the nerves which 
can lead to impotence and diabetic foot disorders) (Fowler, 2008). Macrovascular 
disease includes cardiovascular complications such as myocardial infarction (MI), 
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stroke, angina or transient ischaemic attack (TIA) (Fowler, 2008). Due to the risk of 
these problems, patients with type 2 diabetes require regular examination and 
screening (for example, eye exams, urine tests and foot care), as well as adequate 
education about potential complications in order to self-monitor for symptoms 
(NICE NG28, 2015). 
The difficulty in diagnosing diabetes, the severe complications that require regular 
monitoring and the rapidly increasing number of diagnoses and diabetes-related 




1.2 Cardiovascular disease 
Cardiovascular disease (CVD) is a general term which refers to a group of diseases 
of the heart and blood vessels (World Health Organization, 2015a). According to the 
WHO, CVD includes coronary heart disease (CHD), also referred to as coronary 
artery disease or ischaemic heart disease (IHD), cerebrovascular disease and 
peripheral arterial disease (PAD). CHD occurs when the blood flow to the heart 
muscle is blocked or reduced by a build-up of fatty deposits on the inner walls of the 
coronary arteries – a process referred to as atherosclerosis. As the arteries harden and 
swell, restricted blood flow to the heart can cause angina (chest pain). If eventually 
the artery is completely blocked then the heart is starved of oxygen which results in 
muscle cell death, or myocardial infarction (commonly known as a heart attack). 
Cerebrovascular disease encompasses both ischaemic stroke (cerebral cell death due 
to a lack of blood supply) and haemorrhagic stroke (bleeding from a cerebral blood 
vessel into the brain), as well as transient ischaemic attack (temporary reduction of 
blood flow to the brain without cell death, commonly called a “mini stroke”). 
Finally, PAD occurs when the blood vessels supplying the limbs, most commonly 
the legs, narrow due to atherosclerosis.  
Despite considerable advances in the treatment of CVD, it remains the leading cause 
of death worldwide. Moreover, the rates of CVD and CVD deaths are expected to 
increase as the world population ages (Deaton et al., 2011). The incidence of and 
mortality due to CVD is particularly high in certain groups of the population, 
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including elderly people with type 2 diabetes (Halter et al., 2014). It is widely 
accepted that CVD is best prevented and treated in its early stages. Identifying 
patients who are most likely to benefit from an intervention and those for whom 
treatment is unnecessary can reduce patient morbidity, mortality and complications 
from unwanted side effects. 
In the UK, CVD was the second most common cause of death in 2014, accounting 
for 27% of all deaths, according to the British Heart Foundation Cardiovascular 
Disease Statistics 2015 (Townsend N., 2015). The main causes of CVD deaths were 
CHD (45% of cardiovascular deaths) and stroke (25% of cardiovascular deaths). Of 
the four nations in the UK, Scotland had the highest CVD death rate for men and 
women, both combined and separately. Furthermore, CVD accounted for almost 1.7 
million episodes in National Health Service (NHS) hospitals throughout the UK in 
2015, a number which has been increasing in all UK nations over the last few years, 
and the incidence of CVD in the four nations is highest in Scotland among both men 
and women. Finally, recent studies have found that the CVD burden in the UK which 
can be attributed to diabetes is increasing (Kelly et al., 2009). 
1.3 Conventional cardiovascular risk factors 
Conventional cardiovascular risk factors can be categorised into two main groups: 
those which are non-modifiable (age, sex and ethnicity) and those which are 
modifiable (hypertension, dyslipidaemia, obesity, smoking, physical inactivity and, 
as previously discussed, diabetes).  
It is well established that age is one of the biggest non-modifiable contributors to risk 
of CVD, with risk increasing as both sexes age (Castelli, 1984). Among adults, men 
are approximately twice as likely to develop or die from CVD as women (Lerner and 
Kannel, 1986). However, this difference between the sexes tends to reduce as women 
age and, in particular, reach the menopause (Kannel et al., 1976). Individuals from 
particular ethnic groups are known to be at an increased risk of CVD compared with 
those from other groups. For example, in the UK the prevalence of CHD is highest 
among Indian and Pakistani men (6% and 8% respectively). The incidence rate of MI 
is higher in South Asians than non-South Asians for both sexes and the stroke 
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incidence rate is higher in the Black ethnic group than in the White ethnic group for 
both sexes (Scarborough et al., 2010).  
Modifiable risk factors can be categorised into two further general groups: high 
blood pressure and abnormal blood lipid measures, and lifestyle factors such as 
obesity, smoking and physical inactivity. High blood pressure, or hypertension, is 
one of the most powerful contributors to risk of CVD across all age groups and both 
sexes (Kannel, 1974), increasing risk by a factor of, on average, between 2- and 3-
fold (Kannel, 1996). Abnormal blood lipid measures, also known as dyslipidaemia, 
occur when total cholesterol, low-density lipoprotein (LDL) cholesterol or 
triglyceride levels are raised, or alternatively when levels of high-density lipoprotein 
(HDL) cholesterol, a protective lipid, are low. The Prospective Studies Collaboration 
carried out in 2012 found a positive association between total cholesterol and CVD 
among adults, across all blood pressure levels, though no statistically significant 
association was found for stroke (Prospective Studies Collaboration, 2012).  
The link between lifestyle factors and risk of CVD is well known. Obesity is most 
commonly measured using body mass index (BMI), the ratio of total body weight 
over height squared (kg/m
2
), and individuals with a BMI greater than 30kg/m
2
 are 
considered to be obese. The global prevalence of obesity has increased dramatically 
over the last few decades, doubling between 1980 and 2008 (Bastien et al., 2014), 
and it has previously been shown that obesity is an independent risk factor for CVD 
(Poirier et al., 2006). The association between smoking and CVD is also well 
described and smoking is considered to be one of the most preventable causes of 
CVD (Lakier, 1992). A 50-year prospective cohort study carried out in the UK found 
that mortality rates tripled due to prolonged cigarette smoking, and specifically the 
mortality rate for CVD increased with smoking (Doll et al., 2004). Finally, it has 
been shown that increased physical activity has a protective effect for the 
development of CVD (Berlin and Colditz, 1990). A recent study found that physical 
inactivity causes 6% of the burden of disease worldwide that is due to CHD (Lee et 
al., 2012). 
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1.4 Non-traditional biomarkers 
Although the assessment of conventional cardiovascular risk factors remains vital for 
disease prediction and prevention, better risk stratification using additional 
biomarkers may allow for more targeted use of current prevention strategies and new 
treatments and the reduction of people on unnecessary treatment. Recent studies have 
suggested that there is the potential for a range of physical and circulating 
biomarkers (beyond the conventional risk factors already mentioned), to add value to 
vascular risk prediction (Gerszten and Wang, 2008). Such biomarkers, which will be 
discussed in the following sections, include the ankle brachial index (ABI), N-
terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin 
T (hs-cTnT), gamma-glutamyl transpeptidase (GGT) and a group of inflammatory 
biomarkers – C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor 
alpha (TNF-α) and fibrinogen. This panel of non-traditional biomarkers was selected 
based on the available vascular biomarkers measured in the Edinburgh Type 2 
Diabetes Study (ET2DS), which was used for statistical analyses in this thesis. 
Whilst the ET2DS was originally designed to investigate risk factors for vascular 
cognitive impairment, it has been developed over 10 years to include a wide range of 
topical and relevant biomarkers relating to macrovascular risk prediction, through 
collaboration with clinical and biochemical experts in this field. Three available 
biomarkers were excluded from the panel in order to reduce the dimensionality of the 
data and allow the thorough investigation of a small number of predictors. 
Apolipoproteins A1 and B were included in the metabolomics data set which was 
used later in this thesis. Carotid intima-media thickness was only measured at year 1 
of the ET2DS which would have resulted in a large number of missing data, 
impacting the investigation of all other biomarkers, and there was not compelling 
evidence in the literature of an association with cardiovascular events to support its 
inclusion in analyses. 
1.4.1 Ankle Brachial Index 
ABI (also referred to as ankle brachial pressure index, ABPI) is the ratio between the 
systolic blood pressure (sBP) in the ankle and that in the upper arm (the brachium), 
and is used clinically in the assessment of PAD of the lower limbs since low blood 
   
 7 
pressure in the legs, in comparison to the arm, suggests narrowed arteries due to 
atherosclerosis. The Scottish Intercollegiate Guidelines Network (SIGN) clinical 
guidelines state that an ABI of less than 0.9 indicates PAD (SIGN, 2006). However, 
a very large ABI is also considered to be abnormal, indicating that the walls of the 
arteries have become hardened (a process referred to as calcification) and are 
incompressible. The exact upper cut-off point which marks an abnormal ABI 
measurement is debated, though a value of 1.4 is most commonly supported in the 
literature (Allison et al., 2008). As well as indicating PAD, it has been suggested that 
ABI is a marker of generalised CVD. A recent meta-analysis including nearly 50,000 
people found that a low ABI was associated with total mortality, cardiovascular 
mortality and major coronary outcomes even after adjusting for the Framingham 
Risk Score (Fowkes et al., 2008). 
1.4.2 NT-proBNP 
Brain natriuretic peptide (BNP) is a 32 amino acid polypeptide which is released by 
the heart in response to increased stress on the heart wall. On secretion, BNP splits 
into the biologically active peptide and non-functional N-terminal fragment (NT-
proBNP). Both plasma BNP and NT-proBNP levels are currently used in clinical 
practice to diagnose patients with heart failure, and to assess how severe the heart 
failure may be. Raised levels of BNP or NT-proBNP are typical in patients with 
acute heart failure and the National Institute for Health and Care Excellence (NICE) 
guidelines recommend that this measure is used in patients presenting with new 
suspected heart failure (NICE CG187, 2014). Several general population cohort 
studies have shown that NT-proBNP is also strongly associated with the risk of CVD 
and appears to have added prognostic value independent of conventional risk factors 
(Welsh et al., 2013; Linssen et al., 2010; Kistorp et al., 2005; Wang et al., 2004).  
1.4.3 Troponin 
Troponin is a complex of three proteins, troponin C, troponin I and troponin T, that 
are part of both skeletal and cardiac muscle. Cardiac troponin levels increase in 
response to clinical and subclinical myocardial ischaemia. In recent years, cardiac 
troponin T has been introduced to clinical practice in order to aid the diagnosis of MI 
in patients presenting with chest pain (NICE DG15, 2014). Specifically, high 
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sensitivity laboratory analysis now allows for precise measurements at very low 
concentrations of cardiac troponin T (hs-cTnT) (Hillis et al., 2014). In a number of 
general population studies, troponin has been shown to be strongly associated with 
the risk of CVD over and above the contribution of conventional risk factors 
(Saunders et al., 2011; Everett et al., 2011). 
1.4.4 GGT 
GGT is an enzyme most commonly found in the liver and is an important diagnostic 
biomarker in liver disease, since levels increase when the liver is damaged. In recent 
years two large general population cohort studies have found a significant association 
between GGT and CVD (Lee et al., 2006a and Jousilahti et al., 2000). Furthermore, a 
cohort study of 283,438 participants found an association between increased GGT 
and all types of cardiovascular mortality in both men and women (Kazemi-Shirazi et 
al., 2007). 
1.4.5 Inflammatory biomarkers 
A group of inflammatory biomarkers which can be measured to assess internal injury 
(CRP, IL-6, TNF-α and fibrinogen) are all proteins circulating in the blood whose 
levels increase in response to systemic inflammation. The potential of these non-
traditional biomarkers as predictors of CVD risk has been investigated in recent 
studies, but their added value over and above conventional risk factors or even other 
non-traditional biomarkers remains unclear (Olsen et al., 2007; Wannamethee et al., 
2011; Bettencourt et al., 2011; Berg and Scherer, 2005; The Emerging Risk Factors 
Collaboration, 2012). 
1.5 Metabolomics  
Omics data collectively describe the structure, function and dynamics of the body. 
They range from the genome, the most stable type of omics data, through the 
epigenome, transcriptome, proteome to the metabolome, the most unstable type of 
omics data (Chadeau-Hyam et al., 2013). Modern biological technologies are able to 
take advantage of well-phenotyped cohorts with stored biological samples and 
provide extensive omics data sets for novel analysis (Gehlenborg et al., 2010). 
Metabolomics are measurements of small molecules in biological samples, such as 
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blood, urine, saliva or tissue, and represent end products of cellular processes. 
Currently metabolomics data can be measured using two major technologies: nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (Larive et al., 2015; 
Keun and Athersuch, 2011; Di Girolamo et al., 2013). NMR is the only technique 
which does not require destruction of the biological sample, which can therefore be 
re-used for further analysis. Other key advantages of NMR are that it is highly 
reproducible and requires very simple sample preparation. However, it can be 
insensitive compared to the mass spectrometry technique which is highly sensitive. 
Mass spectrometry requires destruction of the sample, is less reproducible than NMR 
and produces complex data which can be difficult to analyse.  
Recent studies have shown that a number of specific metabolites measured using 
omics technology are strongly associated with both all-cause mortality and specific 
cardiovascular outcomes independent of traditional risk factors (Soininen et al., 
2015, Fischer et al., 2014). It has been suggested that the use of metabolomics data 
may help to add value to cardiovascular risk prediction and, in particular, lead to 
better prediction than the use of conventional lipid measurements such as total or 
HDL cholesterol (Würtz et al., 2012, Wurtz et al., 2015). Relevant investigations to 
date have been limited to a small number of metabolites and have not focused on the 
subgroup of the population with type 2 diabetes. 
1.6 Cardiovascular risk scores 
There are many different scoring systems that have been developed over the last few 
decades in order to estimate the risk of an individual developing CVD. Such scores 
rely heavily on conventional cardiovascular risk factors and are discussed in detail in 
this thesis in a systematic review of the literature in Chapter 4. However, only a few 
of these risk scores have been developed specifically for populations with type 2 
diabetes, whereas most others have used general populations to create a risk score, 
which can then be applied to a subgroup of people with diabetes provided that the 
model development includes diabetes as a predictor. Furthermore, in general, current 
risk scores appear to perform inadequately for people with type 2 diabetes, either 
under- or over-estimating the risk of cardiovascular events (Simmons et al., 2009, 
van der Heijden et al., 2009, van Dieren et al., 2012).  
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The most well-known cardiovascular risk score is the Framingham Risk Score, 
which was developed using data from the Framingham Heart Study (Mahmood et al., 
2014). The Framingham Heart Study is an on-going observational study, which 
began in 1948 with 5209 adult participants from the town of Framingham, USA, and 
is now on its third generation of subjects. The Framingham Heart Study has 
produced a wide range of interesting and useful results, many of which were 
previously unknown and are now well-accepted in public health. It also produced the 
Framingham Risk Score, first published in 1998 (Wilson et al., 1998), which is an 
algorithm that calculates the ten-year cardiovascular risk of an individual. The 
current version of the Framingham Risk Score was published in 2002 (Framingham 
Heart Study, 2002). The first version of the risk score included age, sex, LDL 
cholesterol, HDL cholesterol, blood pressure (and also whether the patient is treated 
or not for hypertension), diabetes and smoking. The updated version was modified to 
include dyslipidaemia, age, hypertension treatment, smoking and total cholesterol. 
Other examples of cardiovascular risk scores developed in general populations are 
SCORE and DECODE. SCORE is the Systematic Coronary Risk Evaluation Project 
risk score, which was developed by The European Society of Cardiology (Conroy et 
al., 2003). It is a large dataset derived from 12 prospective European cohort studies 
(total number of participants is 205,178) and predicts ten-year risk of fatal 
atherosclerotic cardiovascular events. This risk estimation uses gender, age, smoking, 
sBP and total cholesterol as risk factors, but no diabetes variable. DECODE is the 
Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe 
Study Group (Balkau et al., 2004). It consists of 14 European studies (a total of 
25,413 subjects) and calculates both the five- and ten-year risk scores for 
cardiovascular mortality. The risk factors included in the models were age, 
cholesterol, smoking status, sBP, BMI and, for the first time in a risk score, fasting 
and 2-hour glucose measures.  
A UK-specific risk score for the general population that has been developed is the 
QRISK2 score calculator (Hippisley-Cox et al., 2008). The QRISK2 calculator was 
developed by doctors and academics working in the UK NHS and is updated 
annually to keep it as accurate as possible. It is noted that although QRISK2 has been 
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developed for use in the UK, it can and is being used internationally. For non-UK 
use, since social status is based on UK postcodes, it is highlighted that users should 
be aware that CVD risk is likely to be under-estimated in patients from deprived 
areas and over-estimated for patients from affluent areas. QRISK2 calculates the 10-
year risk of having MI or stroke and includes diabetes as one of 14 risk factors 
(including age, sex, ethnicity, social status and smoking status). 
One example of a risk score which has been developed specifically in patients with 
type 2 diabetes is the UK Prospective Diabetes Study (UKPDS). UKPDS was a 
randomised trial involving 5102 participants with newly diagnosed type 2 diabetes 
which ran for twenty years between 1977 and 1997. In 1997 all surviving UKPDS 
patients were entered into a ten-year, post-trial monitoring programme. Data from the 
UKPDS was used to develop the UKPDS Risk Engine (Bannister et al., 2014), a type 
2 diabetes specific risk score which can calculate the 10-year risk for non-fatal and 
fatal CHD, or non-fatal and fatal stroke. The models are based on current age, sex, 
ethnicity, smoking status, presence or absence of atrial fibrillation and levels of 
HbA1c, sBP, total cholesterol and HDL cholesterol. 
This thesis explores the incorporation of biomarkers into cardiovascular risk scores 
aimed at improving the prediction of cardiovascular risk in people with type 2 
diabetes. The specific aims and objectives are outlined in Chapter 3. In the following 
chapter (Chapter 2) statistical methods which are used to develop and evaluate risk 
scores are introduced and discussed. 
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2 Statistical methods for risk prediction 
2.1 Characteristics of risk prediction models 
Prediction models formally combine multiple predictors in order to calculate the risk 
of a chosen future outcome (this contrasts with a diagnostic model, which aims to 
identify an existing, but unknown, disease). Building prediction models requires a 
thorough and complex process. Moons et al., 2009, propose a three-stage procedure 
when developing new prediction models: development studies, validation studies and 
impact studies. Development studies allow for the initial building of a multivariate 
prediction model; validation studies are used to evaluate the chosen model’s 
predictive performance; and then impact studies quantify whether the model is able 
to improve treatment in a practical clinical setting. Impact studies can also be used to 
explore the effect of using a prediction model on clinical management, patient 
outcome and cost effectiveness of treatment.  
Prediction models use a combination of multiple variables to predict the risk of 
future disease outcomes for groups of patients or individuals. They are able to 
identify whether newly discovered risk factors can contribute to risk prediction. The 
results from such models inform patients about their future and can be used to guide 
treatment decisions for both the patient and their doctor. The use of prediction 
models also extends to the selection of patients for clinical trials and the comparison 
of the performance of different hospitals or health centres.  
Since the clinical implications are significant, care must be taken when building a 
prediction model. This begins at the design stage of a study even before any 
statistical analysis takes place. Moons et al., 2009, outline the principles of a 
prediction study and state the following guidelines. The objective of a prediction 
study is to determine the risk of a future health outcome in a population using 
predictor variables. The ideal study design for a prediction study is a prospective 
cohort study. This is because prospective cohort studies are best suited to collecting 
complete and accurate data on the outcome and multiple predictors. Cohort studies 
also allow several different disease outcomes to be investigated. The outcome of 
interest should be specified in advance and be relevant to patients in a practical 
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setting. A range of predictors may be considered, but these must be well-defined, 
standardised, reproducible and measured using methods which are applicable in 
clinical practice. This allows the results of an eventual model to be utilised in a 
clinical setting and therefore directly benefit patients. The population under 
investigation should be clearly defined and the study sample is described as a group 
of people at risk from the specified outcome.  
Once reliable and accurate data have been collected, a model can then be built using 
the outcome of interest and a selection of predictors. The predictor variables must be 
chosen from a potentially large list and Royston et al., 2009, give some proposals as 
to how this can best be done. They suggest that variables that have already been 
confirmed to be predictive should usually be included in a model. In general, 
predictors should only be included if measurements are high quality and can be 
compared across doctors and study centres. Royston et al., 2009, advise that 
continuous variables should not be dichotomised as otherwise valuable predictive 
information can be lost. There are various methods that can be used to select 
variables for a model, but Royston et al., 2009, warn that significance testing 
produces selection bias and over-optimistic results. Finally, it is recommended that 
once a final model has been chosen all the coefficients should be included in any 
reporting of results in order for the risk scores to be reproduced in other populations. 
In general, a prediction model should be simple and easy to interpret, particularly for 
doctors if clinical use is the goal. It is rarely the case that one predictor gives an 
acceptable estimate of risk, therefore models will usually be multivariable. Prediction 
models require updating so that existing markers which inadequately predict risk can 
be removed or replaced. Furthermore, changes in treatment or clinical management 
over time may change health outcomes independently of the predictors in a 
prediction model. 
2.2 Selecting biomarkers for risk prediction models 
As previously discussed, in the study of CVD, modification of traditional vascular 
risk factors has a vital role to play in disease prevention. However, more recently, 
additional biomarkers have been explored as a means of supplementing information 
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obtained from the conventional risk factors (Gerszten and Wang, 2008). These new 
biomarkers require thorough investigation in order to assess and quantify any 
improvement in risk prediction that they may add to an existing risk prediction 
model. It should be noted that biomarkers can be categorised as predictive or causal, 
and that these categories can overlap to give a biomarker that is both predictive and 
causal. In this thesis I am interested in predictive biomarkers which may not 
necessarily contribute to the causal pathway. There are four key requirements that a 
new predictive biomarker must meet before it should be accepted in a model: 
statistical significance, large effect size, independent contribution over-and-above 
other measured risk factors and usefulness in a clinical setting (Pencina et al., 2008, 
Pencina et al., 2010). The most basic of these requirements is that there should be a 
statistically significant association between the predictor and the outcome of interest. 
This reduces the possibility that the association observed is due to chance, although it 
should be noted that this does not guarantee clinical relevance. A large effect size 
observed in a particular predictor usually indicates that there is some “gain” in the 
performance of the model. It is important to check that a new marker is associated 
with the outcome of interest independently of other existing risk factors, and this 
should be accounted for in the statistical analysis. An example of how this can be 
achieved is to use multivariate models that adjust for other known risk factors. 
Clinical significance, as well as statistical significance, should always be considered. 
In general we are most interested in whether a new biomarker, alone or in 
combination with established predictors, is able to more accurately categorise people 
into clinically meaningful high or low risk groups. It is also important to establish 
whether invasive or expensive markers have significant added value in comparison to 
cheaper or easily obtained predictors (Moons et al., 2009).  
However, an important question to ask is how much improvement in a model is 
really possible. It should be expected that new markers are highly correlated with the 
original predictors already included in the model (Hand, 2006). If this is the case, the 
new marker’s contribution to the model may be diminished and there will be a 
limited amount of gain in model performance. Furthermore, models are built using 
baseline variables which may change during the follow-up period, as may clinical 
practice. Both of these effects can limit the application of a developed model. 
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Pencina et al., 2010, conclude that due to these factors lack of perfection may be an 
inherent feature of risk prediction models, although this should not discourage future 
research into the subject. 
The most commonly used and well-known variable selection methods are stepwise 
regression methods. Steyerberg outlines these techniques in his book “Clinical 
Prediction Models” (Steyerberg, 2009). In general terms, stepwise regression 
methods are automated processes of building a model. A final model is chosen by 
successively adding or removing candidate variables based on some pre-specified 
criterion such as an F- or t-test, the coefficient of determination (R
2
), Akaike 
Information Criterion (AIC) (Akaike, 2011) or Bayes Information Criterion (BIC) 
(Neath and Cavanaugh, 2012). There are three main approaches to stepwise 
regression: forward selection, backwards selection (also known as elimination) and a 
combination of both forward and backward selection. Forward selection begins with 
no candidate variables in the model and adds the most significant candidate variable. 
This process is repeated until no significant variable remains outside the model. Once 
a variable enters the model it cannot be removed. Backward selection begins with a 
full model including all the candidate variables and removes the least significant 
candidate variable. Again, this process is repeated until no non-significant variables 
remain in the model. Forward and backward selection modifies the procedure of 
forward selection: after each iteration of the process all candidate variables currently 
included in the model are checked to see if their significance has dropped below the 
pre-specified level. If this is the case then the non-significant variable is removed 
from the model.  
Several issues must be considered when choosing a stepwise regression approach. 
Forward selection can be an appropriate choice when carrying out an initial 
screening on a large number of variables in order to obtain a smaller panel of 
potential predictors. Furthermore, if multicollinearity, where two variables are highly 
correlated, is a concern then it is likely that forward selection will include neither 
variable in the model. However, this can result in important predictors being 
excluded from the model and therefore backward selection may be preferred. 
Backward selection may be preferred in the case of a smaller set of candidate 
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variables which have already been fine-tuned and which you wish to reduce further. 
Backward selection also has the advantage of starting with the full model which 
means that the effects of all candidate variables can be assessed simultaneously. One 
disadvantage of backwards selection is that variables which are not really necessary 
may end up in the final model.  
An extension of stepwise regression approaches is the “all subsets regression” or 
“best subsets regression”. In this approach all possible models derived from all 
possible combinations of candidate variables are assessed and the subset of 
predictors that does the best, according to a pre-specified criterion, is selected. All 
subsets regression has a key advantage over stepwise regression in that it can identify 
combinations of predictors not found by these forward or backward selection 
approaches. It also enables the identification of variables which consistently appear 
in most or all of the “best” models. However, Steyerberg warns that over fitting 
(where the model performs well on the original data, but performs poorly for future 
observations) can be a problem. Furthermore, different pre-specified criteria can 
result in different “best” models. Therefore it is vitally important that all subsets 
regression is not misused by claiming that it results in the one best model: rather, it 
provides a useful screening tool to reduce the number of possible regression models 
to a manageable amount which can be further explored, evaluated and refined in 
order to finally select one model. As discussed above, automatic methods are useful 
when the number of candidate variables is large, in which case it is not efficient to fit 
all possible models.  
2.3 Omics data in risk prediction modelling 
Specialised statistical methods must be used when dealing with omics data. This type 
of data creates the “n < p” situation where the number of predictors (p) is larger than 
the number of outcomes, or even the number of subjects (n). In this case the 
commonly used linear model no longer applies and, in general, standard statistical 
methods risk over fitting the data and/or observing false positives. For the situation 
of more predictors than outcomes, standard methods may lead to over fitted models 
that produce inaccurate results, so analysis must be carried out carefully (Pavlou et 
al., 2015).  
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Three approaches are presented by Chadeau-Hyam et al. in their paper “Deciphering 
the Complex: Methodological Overview of Statistical Models to Derive OMICS-
Based Biomarkers” for analysing omics data appropriately: a univariate approach, 
dimension reduction and variable selection (Chadeau-Hyam et al., 2013). These three 
approaches are discussed in detail in the following sections. 
2.3.1 Univariate approach 
A univariate approach considers one predictor at a time, assuming the predictors to 
be independent. This approach is computationally efficient, accommodating 
extremely large numbers of predictors. It also allows for greater modelling flexibility 
than the other approaches, since the correlation structure between the predictors does 
not need to be modelled. It is straightforward to adjust models for potential 
confounders and models can be adapted to cope with all types of predictors and 
outcomes. However, since only the marginal effect of each predictor on the outcome 
is described, the models do not account for potential combined effects of predictors 
which may have an important role.  
In a univariate approach the same model is fitted to each predictor, giving p models 
and p-values, where p is the total number of predictors. Each p-value is compared to 
an arbitrary threshold, α, which defines the risk of wrongly rejecting the null 
hypothesis (Type I Error). This leads to p conclusions regarding the significance of 
the associations. However, as the number of tests increases, the size of α also 
increases. Therefore the number of tests performed must be accounted for during 
analysis. Multiple testing corrections can be achieved either by adjusting the p-values 
or by altering α, and are usually carried out based on two main methods: using the 
Family Wise Error Rate (FWER) or the False Discovery Rate (FDR). The FWER is 
the probability of obtaining at least one false positive, and is a more severe control 
than the FDR which is the expected proportion of false positives among all 
significant associations. To use the FWER, a per-test significance level (a new α') is 
defined. An example of a multiple testing correction using the FWER is the 
commonly used Bonferroni correction which defines a new α' = α/p (Bland and 
Altman, 1995). However, the Bonferroni correction can be too stringent (Simes, 
1986) and so alternatively, provided tests can be assumed as independent, the Šidák 
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correction can be used which defines a new α' = 1-(1- α)
1/p
 (Sidak, 1967). To use the 
FDR a per-test significance level, α', is defined ensuring that the FDR is bounded 
above by a desired value. An example of a multiple testing correction using the FDR 
is the Benjamini-Hochberg correction which is a step-up procedure comparing p-
values sorted in ascending order to increasingly stricter cut-off values (Benjamini 
and Hochberg, 1995). 
2.3.2 Dimension reduction 
The aim of dimension reduction is to map the original predictors into a lower 
dimension using components which accurately reconstruct the structure of the 
original data. Dimension reduction approaches allow the visualisation of high 
dimensional data and are useful if there are irrelevant features of the data, such as 
noise features. They also permit the correlation structure of the data to be taken into 
account during the analysis, removing potential multi-collinearity. However, the key 
disadvantage of data reduction is that the interpretation of the new components can 
be difficult and unintuitive, especially given many original predictors. One option to 
improve interpretation is to ensure sparse results (that is, constraining the number of 
predictors included in a model), which will be discussed below. 
There are two types of methods which can be used in dimension reduction: 
unsupervised and supervised methods. Unsupervised methods do not guarantee that 
the components are explanatory of the outcome and may be driven by noise in the 
data. However, a well-known example of an unsupervised method is Principal 
Components Analysis (PCA) (Everitt et al., 2013). The PCA procedure is to compute 
the correlation or covariance matrix and perform an eigen-analysis. This provides a 
set of new variables, or components, made up of uncorrelated linear combinations of 
the original variables. The resulting eigenvalues give the variance of each component 
and the eigenvectors give the loading of each component, which can be considered in 
order to establish appropriate interpretation for the independent components. By 
construction the components are independent and the total variance is preserved 
under the principal component transformation. Dimension reduction is usually 
achieved without substantial loss of information by working with the first k 
components. PCA is computationally efficient to perform, even for hundreds or 
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thousands of variables, and can cope with both continuous and discrete data. An 
extension of PCA is the sparse PCA which aims to remove irrelevant variables by 
computing sparse components. This can aid interpretation of components, as 
mentioned above.  
An alternative supervised method for dimension reduction is Partial Least Squares 
(PLS) (Chadeau-Hyam et al., 2013) which chooses components in order to maximise 
the covariance between the predictors and the outcome. Therefore the final 
components will be those that are most correlated with the outcome. The method is 
an iterative procedure: in the first iteration, the linear combination of predictors 
which best describes the outcome is calculated, then subsequent iterations are 
performed to incorporate any further structure in the data. As with PCA, PLS can be 
extended to sparse PLS which selects only the relevant predictors by penalising the 
loading vector. 
2.3.3 Variable selection 
Variable selection aims to identify a sparse set of predictors that jointly predict the 
outcome. This means that variable selection approaches implicitly correct for 
multiple testing. Penalised regression is a general variable selection approach which 
estimates the model coefficients under certain constraints. It is computationally 
efficient, provides easily interpretable results and accommodates all outcome types. 
Two particular methods of penalised regression are ridge regression and Least 
Absolute Selection and Shrinkage Operator (LASSO) models (Chadeau-Hyam et al., 
2013, Steyerberg, 2009). Ridge regression penalises the size of the regression 
coefficients, shrinking them towards zero. Specifically, given a response vector Y 
with n outcomes and a predictor matrix X with p predictors, the ridge regression 
coefficient β
ridge
 is defined as the value of β which minimises 
              
         
 
 
   
 
   
 
where λ is a tuning parameter which controls the strength of the penalty term. Ridge 
regression has the advantage of being numerically stable when n < p and is beneficial 
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in the presence of multicollinearity, but it does not guarantee sparsity. LASSO 
models ensure sparsity of results through the following constraint which minimises 
              
           
 
   
 
   
  
where again λ is a tuning parameter. The nature of this constraint causes some 
coefficients to be shrunk all the way to zero and therefore allows LASSO to perform 
variable selection by removing unnecessary predictors.  
Elastic Net is a flexible combination of ridge regression and LASSO where the 
constraint is defined as a weighted sum of both ridge regression and LASSO 
constraints. This method has the advantage that it is both numerically stable and 
sparse, but comes at the cost of an additional parameter to tune. 
Both ridge regression and LASSO models require a tuning parameter, λ, to be 
selected which controls the strength of the penalty. The choice of λ can be 
determined using a cross-validation procedure where the optimal value of λ will be 
chosen to minimise the prediction mean square error. For LASSO models, as λ 
increases, the number of variables selected in the final model decreases. In the case 
of ridge regression, when λ = 0 the solution is similar to an ordinary least squares 
approach. 
2.4 Assessing a prediction model 
After biomarkers have been selected and a prediction model has been built, but 
before application in a clinical setting, it is vital to assess the performance of a 
prediction model in order to quantify its usefulness in statistical and clinical terms. 
There are numerous reasons why a model may not predict well: bad original study 
design, poor choice of modelling methods, over fitting, the absence of a key 
predictor or differences in either populations or methods of measurement. In 
prediction models the concepts of discrimination and calibration are of key interest 
as they both provide ways to assess the performance of a model, and these are 
discussed in detail in the following sections. It should be noted that there is always a 
trade-off between discrimination and calibration – a model cannot be perfect in both 
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(Cook, 2007). Therefore, both calibration and discrimination should be assessed 
when carrying out a model evaluation. 
2.4.1 Discrimination 
Discrimination describes the model’s ability to distinguish between those patients 
who do or do not experience the health outcome of interest (Tripepi et al., 2013). 
Discrimination can be assessed in a number of different ways, ranging from the 
commonly used receiver operating characteristic (ROC) curves and c-statistics 
(Cook, 2008), to reclassification tables (Kerr et al., 2014), to more novel techniques 
such as net reclassification index (NRI) (Pencina et al., 2008), integrated 
discrimination improvement (IDI) (Pencina et al., 2008) or predictiveness curves 
(Pencina et al., 2010).  
The most popular method of assessing discrimination is the ROC curve and the 
corresponding area under the curve (also referred to as the c-statistic). In order to 
calculate these measures we need to obtain the sensitivity and specificity of a model. 
Sensitivity is the probability of a “positive test” among those patients who do 
experience the outcome of interest. Specificity is the probability of a “negative test” 
among those patients who do not experience the outcome of interest. Here a “test” 
could be the result of a single binary prognostic test, but it could also be defined as 
the observation of a binary outcome, in which case we are interested in the 
classification of individuals into risk categories for the outcome. When comparing 
models, we favour those with higher sensitivity values, or a higher probability of 
classifying a patient who does have an event into a high risk category, and also those 
with higher specificity values, or a higher probability of classifying a patient who 
does not have an event into a low risk category. Specificity and sensitivity are 
unaffected by disease prevalence, though they can be effected by case mix, severity 
of disease, selection of control subjects, measurement technique, quality of the gold 
standard and risk factors (Cook, 2008, Cook, 2007). Additionally, specificity may be 
affected by the characteristics (for example age, gender, prevalence of risk factors) of 
people who do not experience the outcome of interest. The ROC curve is then a plot 
of sensitivity against 1-specificity (Figure 2-1) which provides a summary of 
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sensitivity and specificity, assessing how well a model separates individuals into two 
groups.  
The c-statistic is the area under the ROC curve and is equal to the probability that a 
prediction model assigns a higher probability of an event, or higher risk score, to 
those who do actually experience an event or do actually belong in the high risk 
group. The c-statistic is based on the ranks of the predicted probabilities and 
compares these ranks in patients who do and do not experience the outcome of 
interest. The range of the c-statistic is between 0.5, which indicates no predictive 
ability in the model (marked by a green dotted line in Figure 2-1), and 1, which 
indicates that the model has perfect discrimination (marked by a blue solid line in 
Figure 2-1). Perfect discrimination only occurs if the scores for all those who do 
suffer from an event are higher than those who do not, with no overlap. 
There is some discussion in the literature over the usefulness of the c-statistic in the 
statistical evaluation of prediction models. Cook, 2008, showed that the c-statistic 
can be insensitive when adding a new predictor to a model if the odds ratio (OR) for 
that marker is not extremely large (e.g. >16 per 2 standard deviations). Although a 
new predictor may have an independent and statistically significant contribution to a 
Figure 2-1: Comparison of three ROC curves with varying discriminative abilities 
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prediction model, there can be very little improvement in the ROC curve. This is 
particularly noticeable when the basic model being used for comparison includes 
strong predictors and has a large c-statistic. The impact of the new predictor on the c-
statistic will be lower since it is always hard to greatly improve a good model 
(Pencina et al., 2010). Finally, the c-statistic does not take the distribution of patients 
in terms of risk level into account, for example if there are a small number of patients 
who are at high risk and a large number of patients who are at very low risk (Cook, 
2007). The conclusion of these papers is that researchers should not solely rely on the 
c-statistic when evaluating the discriminative ability of a prediction model, as novel 
biomarkers could still lead to a more accurate risk score despite little change in the c-
statistic. However, it should still be valued as a summary of a model’s discriminative 
ability, and is particularly useful when the goal is to estimate an optimal threshold for 
clinical use. 
A further issue that can arise with regards to the c-statistic is in the case of time to 
event data and subsequent survival analysis. Ignoring the information captured by the 
time to event can result in a biased c-statistic. Therefore, an alternative statistic was 
proposed by Harrell et al., 1996, called the concordance index. The concordance 
index is defined as the proportion of usable pairs of patients, one with and one 
without the outcome of interest, in which the patient who did experience the event 
has a higher predicted probability. An unusable pair is regarded as a case where the 
patient with the shorter follow-up time did not experience the event and hence the 
true order of the pair remains unknown (Gerds et al., 2013). Similar to the c-statistic 
described above, the concordance index ranges from 0.5 (no discrimination) to 1 
(perfect discrimination). Harrell et al., 1996, warn that, as with the c-statistic, the 
concordance index is not sensitive to minor differences between the discriminative 
abilities of two models.  
Two alternative measures of discrimination were proposed by Pencina et al., 2008: 
the NRI and the IDI. The NRI evaluates the proportions of people moving up and 
down risk categories and calculates these proportions by examining people who do 
and do not experience the outcome of interest separately. The NRI can be used to 
measure the change in predictive performance when a new biomarker is added to a 
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basic model. It is only affected by people who change risk categories, since the 
model would give the same prediction for those who remain in the same category. A 
movement upwards in risk category for someone who has the outcome of interest is 
deemed as improving risk classification, because we want to increase the predicted 
probability of an event for someone who does indeed experience that event. For 
people who do not experience an event, downwards movement results in better risk 
classification. Pencina et al., 2008, suggest using the NRI as a simple, but 
meaningful check of classification accuracy. The NRI is calculated using the 
following formula: 
NRI = [Proportion(up|event) – Proportion(down|event)] 
– [Proportion(up|no event) – Proportion(down|no event)] 
Pencina et al., 2008, highlight a key disadvantage of the NRI: that the method is 
dependent on the choice of risk categories. It is useful if clinically relevant risk 
categories already exist, but otherwise an alternative method is required. This 
alternative measure is the IDI, which is an extension of the NRI when no risk 
categories are established. The integrated sensitivity (IS) is defined as the integral of 
sensitivity between 0 and 1, and can be considered as the average sensitivity. The 
integrated specificity (IP) is the integral of ‘1-specificity’ between 0 and 1, and can 
be considered as the average ‘1-specificity’. The IDI is then the difference in 
differences between the integrated sensitivity and 1-specificity for models with and 
without the new marker and is calculated as follows: 
IDI = (ISnew – ISold) – (IPnew – IPold) 
where “new” is the model including the new marker of interest and “old” is the basic 
model without the marker. The IDI is equal to the difference between improvement 
(or decline) in average sensitivity and improvement (or decline) in average 1-
specificity. Pencina et al., 2008, conclude that they still suggest that the c-statistic 
should be the first check of discrimination, but that, due to some of the 
aforementioned issues with that measure, NRI and IDI should also be taken into 
consideration. 
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A recent paper by Kerr et al., 2014, also cautions the use of NRI. They warn that care 
must be taken when interpreting the NRI, because although it combines four 
proportions, the NRI is not a proportion itself. They also highlight the fact that 
irrelevant information is included in the NRI, since the NRI does not account for the 
size of changes in predicted risk – a small and clinically irrelevant change in risk 
score will still contribute to the NRI. In the case of more than two risk categories, a 
move from the lowest category to the middle category is treated as the same as a 
move from the lowest category to the highest category. Furthermore, there is a 
danger that an uninformative new biomarker could appear to have considerable 
predictive value, even if the NRI is calculated using a large, independent validation 
dataset. This is not a problem for the c-statistic. The authors suggest that the 
presentation of reclassification tables may give a more informative summary of the 
classification with a new biomarker. One approach to the NRI could be to use it as a 
descriptive tool after model checking to demonstrate what would happen to risk 
scores in a clinical setting if the new model was used, but not to rely on it as a formal 
model comparison tool. 
Other measures of discrimination are the positive and negative predictive values. The 
positive predictive value (PPV) is the probability of the outcome of interest given a 
“positive test” result. The negative predictive value (NPV) is the probability of no 
event given a “negative test” result. The PPV and NPV can be useful measures to 
complement sensitivity and specificity, although they are dependent on the 
prevalence of disease (Cook, 2008).  
Even more novel ways to explore discrimination than the NRI have been proposed, 
such as using predictiveness curves, which are a general method of assessing the 
usefulness of a prediction model and the classification performance of that model. 
The curves are constructed by ordering all the predicted probabilities from lowest to 
highest and plotting them against the observed risk percentiles (Figure 2-2) (Pepe et 
al., 2008). The ideal shape of a predictiveness curve is one that stays close to the 
horizontal axis and then increases rapidly (Pencina et al., 2010). 
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In summary, there are numerous ways of assessing the discriminative ability of a 
prediction model. Although there is no agreed procedure for this evaluation, the 
literature gives the impression that a suitable approach would be to first calculate the 
ROC curve and corresponding c-statistic and also to present a reclassification table. 
The importance of this table should not be ignored, since a key concern for clinicians 
is whether or not a new biomarker accurately classifies patients into higher or lower 
clinically meaningful risk categories. It may be useful to report the positive and 
negative predictive values, as well as information on the context of the situation e.g. 
prevalence rates, alongside the sensitivity and specificity. An additional measure 
such as NRI could be used to supplement this information, in order to show how the 
risk score would change in a real life setting, but this should not be used alone and 
the weaknesses of this measure should be noted. 
2.4.2 Calibration 
As well as discrimination, calibration should be assessed when evaluating a new 
prediction model. Calibration is a model’s ability to correctly estimate the risk of a 
future event and is a measure of how well the predicted probabilities agree with the 
observed risk that later develops (Tripepi et al., 2010). Calibration directly compares 
observed and predicted event rates for groups of patients. If a model is well 
calibrated then the event rates predicted by the model should closely correspond with 
those that are observed in practice. As with discrimination, there are various ways to 
evaluate calibration. The Hosmer-Lemeshow test (Lemeshow and Hosmer, 1982) can 
be used, or alternatively less formal methods such as plotting observed events against 
predicted events for different ranges of predicted risk. 
Figure 2-2: Predictiveness curves for two competing models. Adapted from Pencina et al., 2010. 
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The Hosmer-Lemeshow test is the most widely used measure of calibration and 
assesses the “goodness-of-fit” of a model, by comparing the observed number of 
events with the number predicted by the model. The null hypothesis assumes a well 
calibrated model and states that the predicted and observed probabilities of the event 
do not differ. The test is performed by forming subgroups of the data and, within 
each subgroup, computing the estimated and observed probabilities of an event for 
each subject. The test statistic is calculated using the following formula: 
    
                     
 
         
 
   
 
and follows a χ
2
 distribution with g-2 degrees of freedom, where g is the number of 
subgroups (Lemeshow and Hosmer, 1982). However, there are weaknesses with the 
Hosmer-Lemeshow test which researchers should be aware of when using it to assess 
model calibration. The Hosmer-Lemeshow test is sensitive to the choice of 
subgroups (Hosmer et al., 1997) and can be seen as a fairly crude measure since we 
cannot know the underlying risk for each patient, but only observe whether they 
experience an event or not (Cook, 2008). Kramer and Zimmerman, 2007, advise that 
caution should be taken when interpreting the results of the Hosmer-Lemeshow test. 
Although they do suggest that an evaluation of model calibration should include the 
test, a significant result does not always mean that the model is not useful. They 
suggest that additional information could be presented, such as the overall number of 
patients and the observed and predicted probabilities within each decile. A further 
issue with the Hosmer-Lemeshow test is that it can be over-sensitive to large samples 
because it has high power to detect small differences in risk which may not be 
clinically relevant (McGeechan et al., 2008). McGeechan et al., 2008, propose that 
the result of the Hosmer-Lemeshow test can be accompanied by a bar chart showing 
the average observed and expected risks for deciles of risk, allowing inspection of 
whether the differences between the two measures are large enough to be clinically 
significant. 
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2.4.3 Global measures of fit 
Global measures of fit combining both calibration and discrimination are also 
available. The AIC and BIC tell us the likelihood that the fitted model would produce 
the data that is observed in practise. These measures both impose penalties for 
increasing numbers of covariates in order to discourage over fitting, but they do not 
give any indication of how clinically useful the addition of a biomarker is and so 
should not be used on their own (McGeechan et al., 2008). The Brier score measures 
the accuracy between the predicted and observed events (Steyerberg, 2009). It is a 
quadratic scoring rule and is computed by squaring the differences between the 
observed and expected outcome probabilities. The range of the Brier score is 
between 0 (perfectly fitted model) and 0.25 (uninformative model) and it is possible 
to adjust the score in order to apply it to time dependent data that include censored 
results (Steyerberg et al., 2010). Finally, we can also consider using a pseudo R
2
 
measure of goodness of fit (Cameron and Windmeijer, 1997), a measure of model 
performance in terms of the proportion of variability in the data that is explained by 
the model.  
2.5 Validating a prediction model 
In order for a model to be useful for clinical practice, we need to know that it can be 
generalised to other groups of patients and that it will perform well for them. This 
process will require some degree of clinical judgement, but can also be assessed by 
carrying out a validation study on some form of new data. Altman et al., 2009, 
explore three methods of using new data to validate a model: internal validation, 
temporal validation and external validation. In internal validation the original dataset 
is split randomly into two groups (often in a 2:1 ratio). The first group is referred to 
as the “training set” and is used to build the prediction model. The second group, the 
“test set”, is then used to assess the accuracy of the predictions from that model. 
Although internal validation can be helpful, it can produce optimistic results and, 
since it is carried out using one dataset, the model produced cannot be generalised to 
other populations. Temporal validation can be seen as a compromise between 
internal and external validation. It evaluates the prediction model on new patients 
sampled from the same centre. Although this new data is independent of the original 
   
 29 
set and model, the patients are likely to have certain characteristics in common. 
External validation uses new data from a different population and is able to properly 
assess the generalizability of the model. Steyerberg et al., 2013, state that a newly 
developed model must be validated using external validation before being 
implemented in clinical practice in order to ensure that it is reliable. 
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3 Aims and objectives 
3.1 Aims  
The overall aim of this thesis was to explore the incorporation of multiple biomarkers 
into existing cardiovascular risk scores in people with type 2 diabetes, in order to 
develop models which better predict the risk of major cardiovascular events in this 
high risk group of individuals.  
Specific objectives were to: 
1. Determine whether a panel of pre-selected biomarkers, either individually or 
in combination, add value to a cardiovascular risk score currently used in 
people with type 2 diabetes. In order to achieve this, record linkage to 
identify incident cardiovascular events in an established prospective cohort 
study, the ET2DS, was undertaken, followed by detailed data analysis. 
2. Determine associations between CVD and a large number of cardiometabolic 
metabolites measured using omics technology, in order to identify potential 
new biomarkers which may improve risk prediction models in people with 
type 2 diabetes in the future. In order to achieve this, data from multiple 
cohort studies in the University College London-London School of Hygiene 
and Tropical Medicine-Edinburgh-Bristol (UCLEB) consortium were 
harmonised and analysed statistically. 
3.2 Thesis outline 
Background information on the clinical topics of type 2 diabetes and CVD, together 
with information on statistical modelling approaches suitable for risk prediction 
research has already been provided (Chapters 1 and 2). The next chapter (Chapter 4) 
is a systematic review of cardiovascular risk scores that can be used in people with 
type 2 diabetes. The results from this review informed my choice of risk score as the 
basic predictive model for subsequent analyses.  
The methods chapter (Chapter 5) describes the design and data collection used in the 
individual epidemiological studies included in this thesis (the ET2DS and the 
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suitable cohorts from the UCLEB consortium), together with the statistical methods 
for the two key aims. Chapter 6 provides relevant descriptive results from the ET2DS 
and Chapters 7 and 8 present results of statistical modelling to meet the two key aims 
respectively.  
The thesis concludes with a discussion (Chapter 9) summarising the key findings of 
the research, discussing the strengths and limitations of the studies and the analyses 
carried out and comparing the findings of this thesis with previous studies. Finally, 
recommendations for future research on this topic are outlined. 
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4 Systematic Review: Cardiovascular risk scores for 
people with type 2 diabetes 
4.1 Background 
Although there are numerous risk scores available for clinical use, it is not clear 
which score should be used to guide the treatment of patients with type 2 diabetes. A 
systematic review by van Dieren et al., 2012, provided an overview of all CVD 
models which could be applied to people with type 2 diabetes. It found a total of 45 
models, 12 of which were specifically developed in diabetic cohorts and 33 of which 
were developed in a general population but included diabetes as a risk factor in the 
score. However, this systematic search was carried out in 2011 and since then new 
models have been developed both in diabetes and in general populations which can 
be used for patients with type 2 diabetes. The van Dieren et al., 2012, paper used a 
search strategy which was deemed to capture a suitably wide range of papers and the 
criteria used to select and reject papers was appropriate for the purpose of this 
review. 
4.2 Aim 
The aim of this systematic review was to update the original van Dieren et al., 2012, 
review in order to identify and summarise all the available cardiovascular risk scores 
that can be applied to people with type 2 diabetes. A final score was then chosen 
from this list, using a set of pre-specified criteria, for use as a basic model to which 
non-traditional biomarkers were added to assess their added predictive ability. 
4.3 Methods 
4.3.1 Inclusion and Exclusion Criteria 
The following inclusion criteria were based on the original van Dieren et al., 2012, 
search strategy. A study was included when: 
(1) The prediction model was either developed in people with type 2 diabetes or 
included diabetes as a predictor. 
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(2) The outcome of the prediction model was a ‘hard’ cardiovascular end-point. 
Accepted outcomes were stroke, heart failure, MI or a general CVD category 
which included some or all of these events, such as CHD. 
(3) It presented a prediction model which was not developed exclusively in 
patients with previous CVD or other vascular condition such as hypertension. 
In other words, the study had not set out to recruit only subjects with previous 
CVD. 
(4) It presented a new mathematical model for the risk score, rather than focusing 
on the added predictive value of new risk factors to an existing prediction 
model. 
The two main exclusion criteria, which were built into the search strategy, were non-
human studies and non-English studies. 
4.3.2 Search strategy 
The search strategy followed by van Dieren et al., 2012, was described in their paper 
as follows: 
((Validat$ OR Predict$.ti. OR Rule$) OR (Predict$ AND (Outcome$ OR Risk$ OR 
Model$)) OR (Decision$ AND (Model$ OR Clinical$ OR Logistic Models/)) OR 
(Prognostic AND (History OR Variable$ OR Criteria OR Scor$OR Characteristic$ 
OR Finding$ OR Factor$ OR Model$)) OR (“risk score”[All fields] OR “prediction 
model”[All fields] OR “prediction rule”[All fields] OR “risk assessment” [All fields] 
OR “algorithm”[All fields])) AND (cardiovascular OR coronary OR cerebrovascular 
OR heart OR stroke) AND (diabetes OR “diabetes mellitus” OR “type 2 diabetes”) 
NOT (Animals[MeSH] NOT Humans[MeSH]. 
The first challenges in replicating the search were that some details had not been 
specified (for example, which fields certain terms had been searched in) and also 
some of the search syntax was not consistent with the current Ovid Medline code. A 
test search was carried out, following the original search strategy as strictly as 
possible. The search was restricted to results between 2 April 2011 and 1 May 2015, 
and it was assumed that the field used was “All fields” unless otherwise specified. 
The start date of the search was chosen to directly follow on from the van Dieren 
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search dates, which were from beginning of database to 1 April 2011. This initial test 
search returned a considerably larger number of potentially eligible papers (8091) 
than expected for the time frame, given the result of the earlier search by van Dieren 
(6803 papers identified from beginning of database to 1 April 2011). Therefore, it 
was concluded that the search strategy needed to be modified to make it more 
specific. 
The first step taken was to change all the fields to “mp” (the multipurpose field 
which searches the Title, Original Title, Abstract, Subject Heading, Name of 
Substance, and Registry Word fields). A further restriction was placed on the 
“cardiovascular” search terms, requiring them to appear within 5 words of the 
“prediction” search terms. Finally, the arrangement of the “prediction” search terms 
was modified in order that the search focused more strictly on papers which were 
relevant to prediction modelling. Creating a search strategy for articles about 
prediction is a particularly challenging task as there is a range of interchangeable 
words and phrases used across the literature. 
After the search strategy had been modified it was tested against the original search 
by van Dieren. This was done by changing the dates to match the original search 
(beginning of database to 1 April 2011) and searching for key papers identified by 
van Dieren et al., 2012. The results showed that all of these papers in the original 
review would still have been captured using the modified search strategy. In addition 
this search resulted in approximately the same number of papers as identified by van 
Dieren et al., 2012. This led to the conclusion that the final search strategy was a 
reasonable replication of the original. 
The final search terms used in the MEDLINE search were as follows: 
(("risk score" or "prediction model" or "prediction rule" or "risk assessment" or 
((Predict$ or prognos$) and (Outcome$ or Risk$ or Model$ or Rule$ or 
"algorithm")) or (Decision$ and (Model$ or Clinical$ or Logistic Models)) or 
(Prognostic and (History or Variable$ or Criteria or Scor$ or Characteristic$ or 
Finding$ or Factor$ or Model$))) adj5 (cardiovascular or coronary or 
cerebrovascular or heart or stroke)).mp. AND (diabetes or "diabetes mellitus" or 
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"type 2 diabetes").mp. AND (201104* or 201105* or 201106* or 201107* or 
201108* or 201109* or 20111* or 2012* or 2013* or 2014* or 2015*).ed. NOT 
Animals/ not Humans/ LIMIT to (dutch or english) 
The systematic review update search was carried out on 13/05/2015 in Ovid 
MEDLINE. 
4.3.3 Selection of studies 
I screened all titles and abstracts, and then the full text of the articles. (Although this 
process would ideally have been carried out by two reviewers working 
independently, as per Cochrane guidelines (Higgins and Green, 2011), this was not 
practical for my PhD project). 
4.3.4 Data extraction and management 
Data were extracted from the final articles and put into results tables (Table 4-1 and 
Table 4-2), containing the following information: title of paper and reference, 
population under study, recruitment method, number of events and total size of 
sample, type of statistical model used, predicted years modelled, number and full list 
of predictors included in model, model evaluation (discrimination and calibration), 
model validation and style of model presentation. These tables were split depending 
on whether the score was developed in a general population or specifically in patients 
with type 2 diabetes.  
4.4 Results 
4.4.1 Study selection 
The updated systematic review search returned 3069 results, which were exported to 
Endnote. Figure 4-1 describes the systematic selection process. The total number of 
duplicated papers identified using Endnote was 370. 185 papers were therefore 
removed due to duplication. This left the number of articles to be screened at 2832. 
These 2832 papers were screened by title and abstract and 2787 records were 
removed as they were irrelevant to the systematic review. This resulted in 45 records 
remaining for a full-text assessment based on the eligibility criteria discussed above. 
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After examination of the full texts, 12 studies remained. Two of the final studies 
were developed specifically for a diabetic population (see Table 4-1 for a summary 
of these models) and 10 included diabetes as a factor in the model (see Table 4-2). 
Nine of the final models were developed in European, American or combined 
populations, two models were developed in Asian populations and one model was 
developed in an Australian population. The majority of the scores were developed for 
a general cardiovascular outcome such as CVD or CHD, although three studies 
restricted the outcome to stroke and one to heart failure. The development study 
samples ranged from 607 to 3.6 million participants. 33 articles were excluded (see 
Table 4-3 for full details of exclusions) as they violated at least one of the four 
inclusion criteria. 
4.4.2 Results tables 
3069 records identified 
through MEDLINE search 
2832 records after 
duplicates removed 
185 duplicate records 
identified and 
removed 
45 full-text articles 
assessed for eligibility 
2787 articles removed 
based on title and 
abstract as irrelevant to 
review 
12 articles included in final 
review 
33 articles excluded at 
full-text screening  
Figure 4-1 Flow chart of systematic review of studies presenting a cardiovascular risk score 
for use in people with type 2 diabetes 
   
 37 
Table 4-1 Cardiovascular risk models specifically developed in patients with type 2 diabetes 
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heart disease risk 







Patients from the 




Cox CVD 5 7 Age, sex, duration 
of diabetes, 
smoking status,  
non–HDL 







validation of a 
risk score for 
hospitalization 
for heart failure 
in patients with 







Patients from the 






5 6 Age, BMI,  coronary 
heart disease 
during follow-up, 






















Patients from the 




Cox Stroke 5 4 Age, history of CHD, 











disease events in 








All subjects with type 
2 diabetes and 
registered with a GP 
in Tayside, Scotland 
(diabetes ascertained 
using the Diabetes 




Weibull CHD 10 9 Age at diagnosis, 







0.71 0.54 External Original 
model 




















Cox CHD 10 19 Age, ethnicity, sBP, 
BMI, waist-to-hip 
ratio, smoking 
status, total and 





factor VIII, sport 
activity, residual 













UKPDS 60: risk of 
stroke in type 2 
diabetes 











Patients referred by 
GPs in the catchment 








Stroke 10 7 Age, sex, duration 
of diabetes, sBP, 
smoking status, AF 
and chol:HDL ratio 







The UKPDS risk 
engine: a model 
for the risk of 
coronary heart 









Patients referred by 
GPs in the catchment 








CHD 10 8 Age, sex, duration 
of diabetes, 
ethnicity, smoking 
status, sBP, HbA1c 
and total chol:HDL 
ratio 
























Respondents from a 
random sample of the 














ACR: albumin creatinine ratio 
AF: atrial fibrillation 
CAD: coronary artery disease 
CIMT: carotid intima-media thickness  
ECG: electrocardiogram  
eGFR: estimated glomerular filtration rate 
FEV: forced expiratory volume 
H-L: Hosmer-Lemeshow test 
LV: left ventricular 
NR: not reported 
WBC: white blood cell 
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Table 4-2 Cardiovascular risk models developed in general populations with diabetes as a predictor 























New studies identified in this update 
Heart failure risk 







USA GP Recruited from 6 
towns in the USA, 
aiming to capture 
equal number of 
males and females 






Cox HF 5 8 Age, sex, sBP, heart 
rate, BMI, smoking 
status,  NT-proBNP  
and diabetes 










family history of 
coronary heart 





Italian GP Data from three 
independent 
population-based 




Cox CHD 20 10 Age, sBP, smoking 
status, family 


















Development of a 
point-based 
prediction model 
for the incidence 




Japanese GP Study cohorts 
established in 9 public 
health-center areas. 
Study population 









0.73 Good External  



























from family general 
practices in the UK, 




Cox CVD 5 10 Age, sex, sBP, 






treatment and  
diabetes 
 






QStroke score for 
predicting risk of 
ischaemic stroke 
in primary care 
and comparison 









Open cohort of 
patients aged 25-84 
years at the study 























kidney disease and 
type 1 diabetes, 




NR External Original 
model 


























to walk 500 m, 
regular exercise, 
vegetable/fruit 









A score for the 
prediction of 
cardiovascular 

















Cox CVD NR 7 Age, sex, family 
history of heart 




physical activity and 
diabetes 
medication 

















Patients from 18 
hospitals enrolled in 
single centre studies.  
14 datasets consisted 
of consecutive 
patients enrolled in a 
prospective study for 
other research 
objectives. 4 datasets 
consisted of patients 
retrospectively 






Logistic CAD NR 8 Age, sex, 
hypertension, 




score and diabetes 
0.88 NR External Original 
models 

















USA GP Participants came 









Cox CHD 5 11 Age, sex, family 
history of MI, 
combined with 
serum levels of 
seven biomarkers 
(CTACK, Eotaxin, 
Fas Ligand, HGF, IL-
16, MCP-3, and 
sFas) and diabetes 

























history of MI or 
stroke and family 








Studies identified in van Dieren et al., 2012, review 
Constructing the 
prediction model 
for the risk of 
stroke in a 
Chinese 
population: 
report from a 




Chinese GP Study participants 
were residents of the 
Chin-Shan area in 
Taiwan and recruited 
using contact with 
local population 





Cox Stroke 10 7 Age, sex, sBP, dBP, 
family history of 
stroke, AF and 
diabetes 









evaluation of a 
new QRISK model 
to estimate 







Cox et al., 
2010 
British GP A prospective cohort 
study recruiting 
primary care patients 










ratio, AF, family 
history of CHD in 
first degree relative 




kidney disease and 









disease risk in 
multiple regions 





n et al., 
2011 
GP from 52 
countries 
Cases of first MI 
admitted to coronary 










ratio and diabetes 
0.71 0.0004 Internal Original 
model 
Development and 








Japanese GP A long-term 
prospective cohort 
study recruiting 




Cox CVD 14 7 Age, sex, sBP, 
smoking status, HDL 
cholesterol, LDL 
cholesterol and  
diabetes 












Japanese GP Residents of 12 rural 
districts in Japan 
recruited by local 
government offices, 
who issued invitations 
255/ 
12,276 
Cox Stroke 10 5 Sex, age, sBP, 
smoking status and  
diabetes 









JMS Cohort Study 
to all people who 
were eligible for the 
mass screening for 
CVD program in Japan 
Risk charts 
illustrating the 






JMS Cohort Study 
Matsumot
o et al., 
2009 
Japanese GP Residents of 12 rural 
districts in Japan 
recruited by local 
government offices, 
who issued invitations 
to all people who 
were eligible for the 
mass screening for 
CVD program in Japan 
92/ 
12,323 

















USA GP Respondents from a 
random sample of the 





Cox CVD 30 8 Sex, age, sBP, 










risk profile for 





o et al., 
2008 
USA GP Respondents from a 
random sample of the 































Cox et al., 
2008 
British GP A prospective cohort 
study recruiting 
primary care patients 




Cox CVD 10 14 Age, sex, ethnicity, 
hypertension, sBP, 
BMI, smoking 
status, AF, family 




Good Internal Original 
model 





database 3 degree relative 






Assessing risk of 
myocardial 
infarction and 









German GP Employees of 52 














10 CHD: 6 
Stroke: 5 






Stroke: age, sex, 
sBP, smoking status 















risk in women: 




USA GP Derived from the 
Women’s Health 
Study, a nationwide 
cohort of US women 
504/ 
24,558 
Cox CVD 10 9 Age, sBP, smoking 
status, parental 




HbA1c, CRP and 
diabetes 




family history to 
cardiovascular 
risk assessment: 
the ASSIGN score 
from the Scottish 
Woodwar
d et al., 
2007 
Scottish GP Includes overlapping 
studies: the Scottish 
Heart Health Study, 
which recruited 
random samples of 
residents across 25 
districts of Scotland, 
422/ 
13,297 






















Edinburgh and north 
Glasgow. 
and  diabetes 
Coronary risk 
prediction for 





, 2006 Asian GP Study participants 
came from the Asia 
Pacific Cohort Studies 
Collaboration, which 
is an overview of 
cohort studies carried 




















disease in a 
population with 
high prevalence 








American Indian men 
and women were 
recruited form 13 
Indian 
tribes/communities in 
Arizona, North and 




















A coronary heart 








USA GP Data came from the 
Atherosclerosis Risk 
In Communities study 











ia, family history, 
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ia and diabetes 
Estimation of 10-






Wu et al., 
2006 
Chinese GP Participants were 
randomly selected in 
clusters e.g. villages, 
household or 























in a low incidence 
population. 
Assessing 










based cohorts in 
different regions of 
Italy, where random 




Cox CHD 10 8 Age, sBP, smoking 
status, family 






















Italian GP Data came from 9 
population-based 
studies provided by 




Weibull CVD 5, 10, 15 9 Age, sex, BMI, 
blood pressure, 
heart rate, smoking 
status, HDL 
cholesterol, non-
HDL cholesterol and 
diabetes 







Prediction of the 
risk of 
cardiovascular 







Data came from 
population-based 





5, 10 6 Age, sBP, smoking 
status, cholesterol, 
fasting and 2-h 
glucose (including 
cases of known 
diabetes), fasting 
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as a risk factor 
(DECODE study) 
glucose alone 
(including cases of 
known diabetes) 
Predictive value 
for the Chinese 








Liu et al., 
2004 
Chinese GP Participants came 
from 16 centers in 11 
provinces of China, 
and a multi-stage 
sampling method was 
used (centers were 
non-randomly 
selected and then 
stratified random 
sampling was 

























Heart to Heart: a 
computerized 
decision aid for 
assessment of 
coronary heart 
disease risk and 








NR Respondents from a 
random sample of the 
adult population of 
Framingham, 
Massachusetts 
NR NR CHD 5, 10 8 Age, sex, sBP, 
smoking status, 
total cholesterol, 
HDL cholesterol, LV 
hypertrophy and 
diabetes 






validation of a 
model to 
estimate stroke 




NR Model was developed 
based on over 100 
relevant articles and 
information from 
appropriate 
organisations e.g. the 
American Heart 
NR NR Stroke NR 8 Age, sex, ethnicity, 
hypertension, 
smoking status, AF, 
IHD and diabetes 
NR NR External Risk 
software 






risk of acute 
coronary events 
based on the 10-










Employees of 52 







Cox CHD 10 8 Age, sBP, smoking 
status, family 
history of 




















from random samples 







Cox Stroke 5 9 Age, sBP, ECG 
diagnosis of AF, ECG 
diagnosis of LVH, 
confirmed history 
of CVD, creatinine, 











The risk functions 
incorporated in 
Riskard 2002: a 
software for the 
prediction of 
cardiovascular 
risk in the general 
population based 




Italian GP Data came from 9 
population-based 
studies provided by 








5 9 Age, sex, blood 
pressure, heart 
rate, BMI, smoking 
status, HDL 
cholesterol, non-
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Prediction of 

























0.69 p>0.5 Internal Original 
model 
















Data from two 
randomly-sampled 
Danish population 
studies were pooled 
509/ 
24,508 

































10 9 Age, blood 
pressure, smoking 
status, LVH and 




















US GP Respondents from a 
random sample of the 























disease in clinical 
practice. 
Recommendation
s of the Second 
Joint Task Force 

























Indian GP Data came from a 
pair-matched case-
control study at the 



















USA GP Respondents from a 
random sample of the 











Variable 6 Blood pressure, 
smoking status, 
total cholesterol, 
HDL cholesterol and 
diabetes 


















USA GP Respondents from a 
random sample of the 


















AF: atrial fibrillation 
CAD: coronary artery disease 
CVA: cerebrovascular accident 
ECG: electrocardiogram  
GP: general population 
HF: heart failure 
H-L: Hosmer-Lemeshow test 
LDL: low-density lipoprotein 
LV: left ventricular 
LVH: left ventricular hypertrophy 
NR: not reported 
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Table 4-3 Papers excluded at the full-text stage 




Details of why inclusion criteria was not met 
Risk scoring system to predict 3-year survival in 
patients treated for asympotomatic carotid 
stenosis 
Alcocer et al., 
2013 
2, 3 (2) Outcome is not cardiovascular specific (3-year all-cause 
mortality)  
(3) The model was developed exclusively in patients with 
previous CVD (patients treated for asymptomatic carotid 
stenosis) 
Simple risk model predicts incidence of atrial 
fibrillation in a racially and geographically diverse 
population: the CHARGE-AF consortium 
Alonso et al., 
2013 
2 (2) Outcome is a surrogate end-point (atrial fibrillation) 
One-month to 10-year survival in the Copenhagen 
stroke study: interactions between stroke severity 
and other prognostic indicators 
Andersen and 
Olsen, 2011 
2, 3 (2) Outcome is mortality  
(3) The model was developed exclusively in patients with 
previous CVD (stroke) 
Heart failure prognostic model Axente et al., 
2011 
3 (3) The model was developed exclusively in patients with 
previous CVD (heart failure diagnosis) 
A novel risk classification paradigm for patients 
with impaired glucose tolerance and high 
cardiovascular risk 
Bethel et al., 
2013 
2 (2) Outcome is incident diabetes onset, not CVD 
Survival of patients undergoing rescue 
percutaneous coronary intervention: development 
Burjonroppa 3 (3) The model was developed exclusively in patients with 
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and validation of a predictive tool et al., 2011 previous CVD (continuing or recurrent MI) 
Validation of continuous clinical indices of 
cardiometabolic risk in a cohort of Australian 
adults 
Carroll et al., 
2014 
1 (1) The model was not developed in people with diabetes, and 
also did not include diabetes as a predictor  
New prognostic score for stable coronary disease 
evaluation 
Coutinho 
Storti et al., 
2011 
3 (3) The model was developed exclusively in patients with 
previous CVD (patients with stable multi-vessel coronary artery 
disease and preserved ventricular function) 
Prospective development and validation of a 
model to predict heart failure hospitalisation 
Cubbon et al., 
2014 
3 (3) The model was developed exclusively in patients with 
previous CVD (patients with stable chronic heart failure) 
Semi-parametric risk prediction models for 
recurrent cardiovascular events in the LIPID study 
Cui et al., 2010 3 (3) The model was developed exclusively in patients with 
previous CVD (history of MI or hospitalization for unstable 
angina 3-36 months previously) 
CHADS2 score predicts functional outcome of 
stroke in patients with a history of coronary artery 
disease 
Hoshino et al., 
2013 
4 (4) The paper does not present a new model - it aims to 
evaluate the CHADS2 scoring system 
Risk score for predicting recurrence in patients 




3 (3) The model was developed exclusively in patients with 
previous CVD (stroke) 
The ADVANCE cardiovascular risk model and 
current strategies for cardiovascular disease risk 
evaluation in people with diabetes 
Kengne, 2013 4 (4) The paper does not present a new model - it aims to 
evaluate the ADVANCE risk model  
Prediction of stroke or TIA in patients without 
atrial fibrillation using CHADS2 and CHA2DS2-VASc 
Mitchell et al., 4 (4) The paper does not present a new model - it aims to 
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scores 2014 evaluate the CHADS2 and CHA2DS2-VAs scores 
Validation of the atherosclerotic cardiovascular 
disease Pooled Cohort risk equations 
Muntner et al., 
2014 
4 (4) The paper does not present a new model - it aims to 
evaluate the Pooled Cohort risk equations 
Prediction of major vascular events after stroke: 
the stroke prevention by aggressive reduction in 
cholesterol levels trial 
Ovbiagele et 
al., 2014 
3 (3) The model was developed exclusively in people with 
previous CVD (stroke or TIA) 
Cardiovascular risk prediction in diabetic men and 
women using hemoglobin A1c vs diabetes as a 
high-risk equivalent 
Paynter et al., 
2011 
4 (4) The paper does not present a new model - it aims to improve 
current risk scores by adding HbA1c to the models 
Risk for cardiovascular events in an Italian 
population of patients with type 2 diabetes 
Pellegrini et 
al., 2011 
4 (4) The paper does not present a new model - it aims to 
compare four current risk scores (Framingham, UKPDS, Riskard 
and Progetto Cuore) 
A clinical risk score for heart failure in patients 
with type 2 diabetes and macrovascular disease: 
an analysis of the PROactive study 
Pfister et al., 
2013 
3 (3) The model was developed exclusively in people with 
previous CVD (history of MI or stroke, percutaneous coronary 
intervention or coronary artery bypass surgery, acute coronary 
syndrome, or objective evidence of coronary artery disease or 
obstructive arterial disease in the leg) 
Metabolic syndrome model definitions predicting 
type 2 diabetes and cardiovascular disease 
Povel et al., 
2013 
1 (1) Outcome is developing type 2 diabetes 
Prognostic models for stable coronary artery 
disease based on electronic health record cohort 
of 102 023 patients 
Rapsomaniki 
et al., 2014 
3 (3) The model was developed exclusively in patients with 
previous CVD (stable angina, patients with history of MI, 
coronary artery bypass graft , or percutaneous coronary 
intervention prior to the start of the study period and patients 
with a diagnosis of ACS within the study period (unstable angina 
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or acute MI)) 
New Zealand Diabetes Cohort Study cardiovascular 
risk score for people with Type 2 diabetes: 
validation in the PREDICT cohort 
Robinson et 
al., 2012 
4 (4) The paper does not present a new model - it aims to validate 
the New Zealand adaptation of the Framingham score 
A new risk scheme to predict ischemic stroke and 
other thromboembolism in atrial fibrillation: the 
ATRIA study stroke risk score 
Singer et al., 
2013 
3 (3) The model was developed exclusively in patients with 
previous CVD (atrial fibrillation) 
Validation of the ABCD3-I score to predict stroke 
risk after transient ischemic attack 
Song et al., 
2013 
4 (4) The paper does not present a new model - it aims to validate 
the ABCD(3)-I score 
A new scoring system for evaluating the risk of 
heart failure events in Japanese patients with atrial 
fibrillation 
Suzuki et al., 
2012 
3 (3) The model was developed exclusively in patients with 
previous CVD (atrial fibrillation) 
Does aortic stiffness improve the prediction of 




4 (4) The paper does not present a new model - it aims to improve 
the Framingham model 
An international model to predict recurrent 
cardiovascular disease 
Wilson et al., 
2012 
3 (3) The model was developed exclusively in people with 
previous CVD 
A new model for 5-year risk of cardiovascular 
disease in Type 1 diabetes; from the Swedish 
National Diabetes Register  
Cederholm et 
al., 2011 
1 (1) The model was developed in patients with type 1 diabetes 
   
 60 
An evidence-based score to detect prevalent 
peripheral artery disease (PAD) 
Duval et al., 
2012 
2 (2) Outcome is not a hard CV end-point (development of PAD) 
Personalized prediction of lifetime benefits with 
statin therapy for asymptomatic individuals: a 
modeling study 
Ferket et al., 
2012 
1 (1) Only some models include diabetes as a predictor (CHD, 6-
months CHD event mortality and other CVD mortality); Also, the 
study gives statins as an intervention and therefore is not an 
appropriate type of study for this review. 
Risk equations to predict life expectancy of people 
with Type 2 diabetes mellitus following major 
complications: a study from Western Australia. 
Hayes et al., 
2011 
2 (2) Outcome is not CV-specific (death) 
Cardiovascular risk prediction models for people 
with severe mental illness: results from the 
prediction and management of cardiovascular risk 
in people with severe mental illnesses (PRIMROSE) 
research program 
Osborn et al., 
2015 
1 (1) The development population has an unrelated disease 
(severe mental illness) so is not relevant to this review 
Contemporary model for cardiovascular risk 
prediction in people with type 2 diabetes 
Kengne et al., 
2011b 
NA The paper was already included in the original van Dieren search 
ACS: acute coronary syndrome; CHD: coronary heart disease; CV: cardiovascular; CVD: cardiovascular disease; MI: myocardial infarction; NA: not applicable; PAD: 
peripheral arterial disease; TIA: transient ischemic attack 
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4.5 Discussion 
van Dieren et al., 2012, identified a total of 45 models, 12 of which were specifically 
developed in diabetic cohorts and 33 of which were developed in a general 
population but included diabetes as a risk factor in the score. They found that 
although there were a number of cardiovascular risk scores available for use in 
people with type 2 diabetes, less than a third of these had been externally validated.  
Only a few models demonstrated excellent discriminative ability (c-statistic greater 
than 0.80) and most models developed in general populations showed poor 
calibration. 
Only two new risk scores developed specifically in patients with type 2 diabetes were 
found in this updated review in addition to those already identified by van Dieren et 
al., 2012. The first of these was the score developed by Mukamal et al., 2013, in 782 
patients with type 2 diabetes living in the USA. Participants were aged 65 years or 
older and were recruited from Medicare-eligibility lists in four states in the USA. 
The score predicts the 10 year risk of a cardiovascular event and has been externally 
validated. The second new score developed specifically in patients with type 2 
diabetes was developed by Park et al., 2015, in a sample of 607 patients living in 
Seoul, South Korea. The score predicts the 5 year risk of a coronary artery disease 
event and shows good discrimination and calibration, though validation has not yet 
been carried out. It should be noted that both these studies captured relatively small 
numbers of events (83 and 265 respectively). 
Ten new risk scores developed in general populations, but including diabetes as a 
predictor in the model, were found in the updated review. A variety of cardiovascular 
endpoints were used: six scores had a general outcome such as CVD or CHD, three 
used stroke or TIA and one used heart failure. The length of follow-up of the studies 
ranged from five to 20 years and the sample sizes ranged from 3956 to 3.6 million. 
Eight of the models were developed in European, American or combined 
populations, one model was developed in a Japanese population and one model was 
developed in an Australian population. When reported, all models showed moderate 
to good calibration and discrimination. Validation was carried out for eight of the 
scores. 
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A notable feature of the results from all studies, including those found in the van 
Dieren et al., 2012, review, is that, in most cases, the predictors used in each score 
remain very similar across the models. Age, sex, blood pressure, hypertension, 
cholesterol, smoking status and family history of CVD are common across the vast 
majority of models, both for those developed in general and diabetes populations. In 
the models developed specifically for patients with type 2 diabetes the following 
additional variables are also included in most scores: duration of diabetes, HbA1c 
and a measure of kidney disease such as microalbuminuria or albumin-creatinine 
ratio. One score found in the updated review, the National FINRISK Study (Qiao et 
al., 2012), took a different approach to building a risk prediction model for the 
general population. The aim was to develop a simple model which a patient could 
use themselves, without the assistance of a clinician. Therefore, although some of the 
conventional risk factors are used in the model such as age, blood pressure, 
hypertension and smoking status, there are a number of uncommon predictors 
included: happy marriage, ability to walk 500m, regular physical activity and fruit 
and vegetable intake.  
Another notable feature of the risk scores is the lack of non-traditional biomarkers 
included in most of the models: in total, seven of a potential 57 scores (12%) used 
non-traditional biomarkers in the set of predictors. The first risk score developed in a 
general population to include such a predictor was the Reynolds Risk Score (Ridker 
et al., 2007), which was developed from the Women’s Health Study, a cohort of 
women living in the USA, and included apolipoprotein B, apolipoprotein A1 and 
CRP. The INTERHEART Modifiable Risk Score (McGorrian et al., 2011), a general 
population study including participants from 52 countries, included apolipoprotein B 
and A1 as a ratio. Prior to these studies, the ARIC score (Folsom et al., 2003), which 
used a sample of patients with type 2 diabetes living in the USA, included fibrinogen 
in the prediction model as a marker of inflammation. The CHD Risk Assessment 
score (Cross et al., 2012) developed in a general North American population, 
combined traditional cardiovascular risk factors with a larger panel of seven protein 
biomarkers: cutaneous T cell-attracting chemokine, Eotaxin, Interleukin 16, 
monocyte chemotactic protein-3, hepatocyte growth factor, Fas Ligand and sFas. 
Most recently, Mukamal et al., 2013, included CRP in their model for elderly 
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patients with type 2 diabetes living in the USA and the MESA score (Chahal et al., 
2012) included NT-proBNP in their study of a general USA population. 
Finally, there is a clear trend in the improvement of the quality of evaluation and 
validation of the risk prediction models. The earliest papers identified in the original 
van Dieren et al., 2012, review did not carry out or report any type of model 
evaluation measures, such as the c-statistic for model discrimination or the Hosmer-
Lemeshow test for model calibration. Furthermore no validation, either internal or 
external, was investigated as part of the model development. In contrast, the majority 
of papers published since around 2002 include measures to evaluate at least one of 
discrimination and calibration, and also include some form of validation. There are 
exceptions throughout the articles, but overall the reporting of model evaluation and 
validation has greatly improved over time. The most recent models, developed in the 
last five years, tend to include a variety of measures which summarise the calibration 
and discrimination. All 12 papers from the current review update reported a measure 
of model discrimination (c-statistic) greater than 0.6 which indicates moderate 
discriminative ability. Six papers (50%) reported a value greater than 0.8, which 
shows excellent discriminative ability. Nine papers (75%) carried out some form of 
model validation: five of these (42%) used external validation which, as discussed at 
the end of Chapter 2, is considered essential for a reliable risk prediction model 
(Steyerberg et al., 2013). 
In terms of papers which were excluded at the full-text stage, most of these 
exclusions were made based on a violation of either inclusion criterion number three 
(presenting a model which was not developed exclusively in patients with previous 
CVD) or number four (presenting a new mathematical model for the risk score). In 
the case of papers which developed a model exclusively in patients with previous 
CVD, the definition of CVD varied widely. Definitions included heart failure, MI 
and angina, stroke and TIA, atrial fibrillation or a general CVD category. Many 
papers were excluded as the aim of the study was to evaluate or improve an existing 
cardiovascular risk score (such as the ADVANCE, Framingham or CHADS2 scores), 
rather than develop a new mathematical model. Four papers were excluded because 
the outcome of the risk score was not a hard cardiovascular end-point, which was the 
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requirement of inclusion criterion number two. Alonso et al., 2013, and Duval et al., 
2012, used surrogate end-points (atrial fibrillation and development of PAD 
respectively) as the outcome, Hayes et al., 2011, used all-cause mortality as the 
outcome and Bethel et al., 2013, studied incident diabetes onset as the outcome, not 
CVD. In addition, two papers (Alcocer et al., 2013 and Andersen and Olsen, 2011) 
violated both inclusion criteria numbers two and three: Alcocer et al., 2013, studied 
all-cause mortality as the outcome and developed the model in patients with previous 
CVD; Andersen and Olsen, 2011, also studied mortality as the outcome and 
developed the model in patients who had previously suffered from stroke. Five 
papers were excluded because they violated the first inclusion criterion (model 
development was in people with type 2 diabetes or included diabetes as a predictor). 
Furthermore, Cederholm et al., 2011, developed a cardiovascular risk score for 
patients with type 1 diabetes using the Swedish National Diabetes Register and 
Osborn et al., 2015, studied a development population which had an unrelated 
disease (severe mental illness) and therefore both papers were not relevant to the 
specific aim of this review. Finally, the model developed by Kengne et al., 2011a, 
was already included in the original van Dieren et al., 2012, search and was therefore 
removed from the final list. 
The difficulty of updating the original van Dieren et al., 2012, search strategy has 
been discussed above. The insufficient information reported regarding the search 
terms meant that the updated search strategy could not replicate exactly what had 
been done previously. However, all efforts were made to replicate the search as 
closely as possible. Furthermore, there is an intrinsic difficulty in carrying out this 
type of search due to the large number of interchangeable terms which are used by 
authors. For example, when referring to a risk score an author may use the term 
“score”, but they may also use any number of “model”, “rule”, “algorithm” or 
“assessment”. An author may also use only one of “predict”, “prognosis” or “risk”. 
Therefore a search with this particular aim needs to be wide enough to capture all 
relevant articles, but not too general so that the number of papers to be screened is 
impractical. Considering all of these factors, the final search strategy updated the van 
Dieren et al., 2012, search as accurately as possible. 
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4.6 Choosing a risk score 
As stated in Section 4.2, one of the aims of this review was ultimately to select a risk 
score to be used as the basis of a basic model to which non-traditional biomarkers 
could be added. A set of characteristics which the “perfect” risk score would have 
was devised. These were based on the recommendations for the development of 
prediction models outlined by Moons et al., 2009, in their four-part publication and 
also on the desire for the results of the research to be clinically useful. The risk score 
should have been: 
 Developed using sound methodology 
 Recently evaluated, showing good calibration and discrimination 
 Externally validated 
 Developed for a general CVD outcome, rather than restricted to one specific 
type of cardiovascular event such as stroke or MI 
 Recommended in the clinical guidelines 
Based on these characteristics, three scores from the full list of 57 were considered 
for use as the basic model for subsequent analyses: the ADVANCE, UKPDS and 
QRISK2 scores. The ADVANCE score was developed in 2011 in 11,140 participants 
with established type 2 diabetes from 20 countries. The model shows good 
discrimination and calibration and has been both internally and externally validated. 
The score predicts the 4-year risk of CVD and includes 10 risk factors (age at 
diagnosis of diabetes, sex, duration of diabetes, pulse pressure, hypertension, atrial 
fibrillation, non-HDL cholesterol, HbA1c, albumin-creatinine ratio and retinopathy). 
The UKPDS score was developed in 2001 in 4549 newly diagnosed patients with 
type 2 diabetes in the UK. Although calibration, discrimination and external 
validation were not carried out during the original development, multiple studies 
have since shown that the UKPDS has moderate to poor discrimination and 
calibration in people with type 2 diabetes (van Dieren et al., 2011; Simmons et al., 
2009; Guzder et al., 2005). There are two versions of the UKPDS score: the 10-year 
risk of CHD and the 10-year risk of stroke. To obtain overall CVD risk the two 
scores could be added together, though this is not recommended (UKPDS, 2011). 
   
 66 
The QRISK2 score is updated annually and was developed in 3.6 million participants 
in England and Wales (48,889 participants had type 2 diabetes at baseline). The 
model shows good discrimination and calibration for both general and diabetic 
populations, and has been both internally and externally validated (Hippisley-Cox et 
al., 2014). The score predicts the 10-year risk of CVD and, importantly, is 
recommended by the NICE clinical guidelines for use in patients with or without 
type 2 diabetes (NICE CG181, 2016). Although ADVANCE and UKPDS met many 
of the characteristics outlined above, it was for this final key reason that the QRISK2 
score was selected for use in subsequent analysis. 
4.7 Conclusion 
This systematic review presents an overview of all cardiovascular risk scores up to 
May 2015 which are suitable for use in patients with type 2 diabetes: either 
developed in a type 2 diabetes population or including diabetes as a predictor in the 
model. A systematic review carried out in 2011 (van Dieren et al., 2012) found 12 
models which were specifically designed for people with type 2 diabetes and 33 
models developed in general populations but which included diabetes as a predictor. 
This systematic review aimed to update the original review in order to provide a 
current summary of all available risk scores. Two new models were found which 
were developed exclusively in people with type 2 diabetes and ten new models were 
found which were developed in a general population but were suitable for use in 
people with type 2 diabetes. Almost all papers in the update include a variety of 
measures which summarise the calibration and discrimination of the model, and 
report on either internal or external validation. These results are in marked contrast to 
the earliest papers found in the van Dieren et al., 2012, review which did not report 
any measures of either calibration or discrimination, or carry out any model 
validation, either internal or external. These two findings mark the extreme ends of a 
trend of vast improvement in model evaluation and validation over time.  
Inspecting the predictors in the risk scores also highlights the lack of non-traditional 
biomarkers which are included in model development. Traditional cardiovascular 
risk factors such as age, sex, blood pressure and smoking are favoured in the 
majority of risk scores. However, more recently a select few biomarkers such as NT-
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proBNP, CRP and IL-6 have been assessed and included in risk scores. This suggests 
a gap in the research for further investigation of additional biomarkers, including 
those which are now available through omics data such as metabolomics. New 
studies should consider the added benefit of biomarkers which have previously not 
been considered for inclusion. For any findings to be reliable, it is also essential that 
these studies follow the trend discussed above and report appropriate measures of 
model performance and validation.  
Finally, using a set of pre-specified characteristics for the ideal cardiovascular risk 
score, the QRISK2 score was selected for use throughout this thesis as the basic 
model to which additional biomarkers will be added. Further discussion on the 
implementation of QRISK2 as the basic model for subsequent analyses in this thesis 
can be found in the next chapter, Chapter 5. 
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5 Data sources and methods 
This chapter details the methodology of the studies used as data sources in this thesis. 
The design of the Edinburgh Type 2 Diabetes Study (ET2DS) is described, as well as 
the data relevant to this thesis which were collected at the baseline, year 1 and year 4 
phases of the study, prior to the research reported in this thesis. Data collection and 
derivation of variables for the eight-year follow-up phase of the study and methods 
of retrieving missing data are also described, both of which I carried out. The 
methods of the ET2DS have been described in accordance with the REporting of 
studies Conducted using Observational Routinely-collected Data statement for 
reporting observational studies (RECORD, 2015). Additionally, the statistical 
analysis plan is presented for the use of the ET2DS data to investigate the added 
predictive value of a panel of non-traditional biomarkers to a current cardiovascular 
risk score (Chapters 6 and 7).  
The designs of the cohorts from the UCLEB consortium which were used in this 
thesis are also outlined, and the relevant data are described as well as the statistical 
analysis plan. The data from these studies (including the ET2DS) were used for the 
analysis of potential associations between 228 metabolites and CVD (Chapter 8).  
5.1 Edinburgh Type 2 Diabetes Study 
The ET2DS is a population-based prospective cohort study of 1066 men and women 
aged between 60 and 75 years at baseline (2006-2007) with established type 2 
diabetes, living in the Lothian region in Scotland. The original aim of the study was 
to investigate the role of potential risk factors in complications of diabetes, such as 
micro and macrovascular disease, cognitive impairment and non-alcoholic fatty liver 
disease. Although it is possible to use a retrospective cohort design to study risk 
prediction, prospective cohort studies are preferable and allow for the well-defined 
selection of participants, clear and consistent definitions of predictors and outcomes 
and the addition or exclusion of particular variables during follow-up (Steyerberg, 
2009). The paper published by Price et al., 2008, provides a detailed description of 
the full study protocol for the ET2DS and has been used, along with other published 
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material and my own experience in collecting follow-up data, as the basis for the 
following sections.  
5.1.1 Study population 
Potentially eligible participants for the ET2DS were selected from the Lothian 
Diabetes Register (LDR), an automated database established in 2001 which contains 
clinical information on almost all patients with known type 2 diabetes living in 
Lothian, central Scotland. Although the register defines diabetes according to WHO 
criteria, the study required re-validation of type 2 diabetes in order to ensure that the 
diagnosis was robust. In order to obtain further confirmation of type 2 diabetes, 
several different diagnoses were accepted: 
 individual was taking oral anti-diabetic medication and/or insulin  
 if the individual was managing their diabetes via dietary modification alone 
then they had an HbA1c measure of > 6.5% at the baseline clinic.  
Individuals who were controlling diabetes through diet and who had an HbAlc 
measurement below 6.5% had their clinical records reviewed by a consultant 
diabetologist to confirm a diagnosis. Furthermore, individuals who started insulin 
treatment within one year of diagnosis, reported evidence of pancreatic disease at the 
clinic or those who were treated with insulin and aged under 35 years at diagnosis, 
were carefully reviewed. If it was not possible to confirm a clinical diagnosis of type 
2 diabetes by review of hospital and/or GP records then such individuals were 
excluded. Additionally, non-English speakers, individuals with poor eyesight 
(corrected visual acuity worse than 6/36 for distance vision or unable to read large 
print text), individuals unable or unwilling to provide consent and those who were 
physically unable to complete all assessment elements were excluded. The 
requirements of English and adequate eyesight were necessary in order to allow 
participants to complete the cognitive tasks. 
The study aimed to recruit 1000 subjects, which would allow 90% power at the two-
sided 5% significance level to detect a Pearson correlation coefficient of ≥ 0.10 
between a continuous outcome measure and predictor variable. This sample size was 
also estimated to allow for detection of any risk factor that contributed 1% or more to 
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 August 2006, people aged between 60 and 74 years were identified on the 
LDR, and grouped by sex and 5-year age bands. Between 20
th
 June 2006 and 1
st
 June 
2007, 5454 potential participants were contacted by mail through the custodians of 
the LDR. Of the 3286 individuals who responded, 1252 people expressed an interest 
in participating in the ET2DS, and 1077 of these attended the baseline research 
clinic. Of the 1077 individuals attending the baseline clinics, four people were 
subsequently excluded as they were too physically or emotionally distressed and it 
was not appropriate to continue with the physical or cognitive examinations. Seven 
people did not meet the strict criteria for type 2 diabetes and were also excluded. In 
practice no one had to be excluded from the study for the other pre-specified 
exclusion criteria. This resulted in 1066 participants who were willing and eligible to 
take part in the ET2DS. An overview of this process is summarised in Figure 5-1. 
Figure 5-1 ET2DS recruitment flow diagram. Adapted from Price et al., 2008 
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In order to assess the impact of non-responders, demographic characteristics and 
clinical features of study participants and non-respondents were compared. This 
analysis showed that the ET2DS population is largely representative of all patients 
aged between 60 and 75 years with type 2 diabetes living in Lothian (Marioni et al., 
2010).  
5.1.2 Data collection 
To date the ET2DS has had four phases of data collection: a baseline clinic (2006-
2007), a liver sub-study clinic after one year, and 4 and 8 year follow-up phases. 
Table 5-1 provides a summary of the data collection at each phase of the study. 
Baseline visit 
Baseline research clinics were carried out at the Wellcome Trust Clinical Research 
Facility, Western General Hospital, Edinburgh, UK. In order to ensure that all 
individuals who had agreed to participate were assessed, taxis to and from the clinic 
were arranged if required, travel expenses were reimbursed and flexibility in the date 
and time of appointments or rescheduling was offered. Participants were required to 
undergo an overnight fast before attending the clinic, undergo venepuncture to 
provide a blood sample, provide a urine sample and undergo a 12-lead 
electrocardiogram (ECG). Physical examinations were performed by six specially 
trained research nurses and measurement technicians, who were following pre-
specified standard operating procedures and data collection forms, ensuring 
consistency both between and within the nurses’ assessment. Participants also 
returned completed questionnaires which included information on demographic 
characteristics, diabetes history and treatment, CVD, medications and smoking 
habits. 
At baseline, data linkage to the Scottish Morbidity Records (SMR01) scheme (acute 
hospital discharge records) was carried out via the Information Services Division 
(ISD) of NHS Scotland to provide information for all participants on all medical and 
surgical discharges from wards in Scottish hospitals between 1981 and September 
2007. These data were used to confirm self-reported history of CVD and other 
medical conditions such as atrial fibrillation and rheumatoid arthritis. Additionally, 
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selected historical data held on the LDR were retrieved, such as HbA1c, blood 
pressure, serum cholesterol levels and estimated glomerular filtration rate (eGFR).  
1 year clinic 
One year after recruitment to the study, all surviving participants were invited to 
return for further examination at a 1 year clinic. The primary purpose of this clinic 
was to assess liver function, however it also provided the opportunity for further 
vascular assessment and venous blood sampling. A total of 940 participants attended 
the 1 year clinic (88.18% of the baseline study participants); 17 of the original 
ET2DS participants had died, 8 had indicated that they did not wish to be re-
contacted when attending the baseline clinic or were considered unsuitable for 
further contact by the study team, 61 were unable or unwilling to attend and 40 either 
could not be contacted or did not attend their clinic appointment. For the purposes of 
subsequent analyses in this thesis, a very small number of specific biological 
measurements taken at year 1 (total cholesterol for one participant, HDL cholesterol 
for three participants and GGT for three participants) have been considered as 
baseline data since it is assumed that changes in these variables will not be clinically 
significant over the course of one year (Morling et al., 2015, Morling et al., 2014a, 
Morling et al., 2014b). 
4 year follow-up 
In 2010, appointments for a 4 year clinic visit were arranged, with the primary aim of 
assessing the development of CVD during the follow-up period. 974 participants 
were invited to the 4 year clinic (11 participants had withdrawn from the study after 
the baseline clinic and 81 had died). Of those invited, 830 participants attended the 4 
year clinic (77.86% of the baseline study population). 15 participants were not 
contactable, 100 participants declined to attend and 30 participants withdrew from 
the study.  
Physical examinations were carried out by four researchers and included fasting 
blood sampling, ultrasound scanning and a 12-lead ECG. Self-completed 
questionnaires were also returned by participants at the clinics. Data linkage via the 
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ISD was carried out to provide information on all hospital discharges and death 
certificates during the follow-up period, and access to clinical case notes was 
obtained if required. 
8 year follow-up 
In March 2015, repeat ISD record linkage was carried out and I was responsible for 
obtaining these data and subsequently identifying and confirming new cardiovascular 
events that had occurred since the 4 year follow-up phase. I submitted a successful 
application for Privacy Advisory Committee (PAC) approval to ISD, shown in 
Appendix B Information was obtained on all hospital discharges and death 
certificates for participants since the 4 year follow-up using probabilistic record 
linkage based on the participants’ full name, address, date of birth and gender. 
Table 5-1 Summary of data collection in the Edinburgh Type 2 Diabetes Study 






Data collection type 
    General questionnaire 
    Cardiovascular questionnaire 
    Physical examination 
    Fasting venous blood sample 
    ECG 
    Data linkage 
 
5.1.3 Variable measurement and definitions 
This section describes the measurement procedures and the definitions used for those  
ET2DS variables used in this thesis; the numerous other data collected as part of the 
ET2DS are outlined in Price et al., 2008. 
5.1.3.1 Demographics 
At baseline, subjects were required to complete a questionnaire prior to attending the 
clinic. This questionnaire included questions on date of birth (for age), sex and 
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ethnicity. Deprivation was assessed using the Scottish Index of Multiple Deprivation 
(SIMD) 2006 which was calculated from the participants’ home postcodes at 
baseline and for this study was grouped by quintile (The Scottish Government, 
2012). The SIMD is a composite index which combines 38 indicators across seven 
domains, covering income; employment; health; education, skills and training; 
housing; geographic access; and crime. 
5.1.3.2 Diabetes and other medical history 
The self-report questionnaire at baseline included a question about the date of 
diagnosis of diabetes, which was used to calculate the duration of diabetes. 
The definition of diabetes treatment type used a combination of answers from the 
baseline self-report questionnaire and medication lists which were brought to the 
clinic. Treatment type was defined as: (i) diet controlled only, (ii) oral anti-diabetic 
medication only (including metformin, sulphonylureas and thiazolidinediones), and 
(iii) insulin use (possibly with oral anti-diabetic medication additionally).  
The self-report questionnaire at baseline also asked participants about their medical 
history and current medications. This information was used in combination with ISD 
record linkage and/or physical examinations to confirm previous diagnosis of atrial 
fibrillation, rheumatoid arthritis or hypertension. Atrial fibrillation was recorded if a 
subject self-reported use of digoxin, had the relevant hospital discharge code (ICD-
10 code I48) or if atrial fibrillation was present on the ECG at baseline. Rheumatoid 
arthritis was recorded from a combination of self-report and linkage to ISD medical 
and surgical discharge records (ICD-10 code M06). Hypertension was defined as 
self-report of anti-hypertensive medication. 
5.1.3.3 Physical examination 
In order to obtain BMI, height (in metres) was measured without shoes using a wall-
mounted vertical ruler and weight (in kilograms) was measured without outdoor 
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sBP was measured in the right arm to the nearest 2 mmHg, with the participant in the 
supine position. In order to obtain the ABI, the sphygmomanometer cuff was placed 
around the arm and inflated to 30mmHg above the estimated sBP. The pressure was 
reduced at a rate of 2-3mmHg per second and the sBP was recorded when the first 
clear sound was detected. This process was repeated in both arms and both ankles 
(dorsalis pedis and posterior tibial arteries) and subsequently ABI was calculated as 
the lowest ankle pressure divided by the highest arm (brachial) pressure. 
5.1.3.4 Blood samples 
At baseline, plasma from fasting venous blood samples was frozen for storage. 
Subsequently total cholesterol, HDL cholesterol, HbA1c and eGFR were measured, 
all determined using a Vitros Fusion chemistry system (Ortho Clinical Diagnostics, 
Bucks, UK) at the Western General Hospital, Edinburgh, UK. 
Chronic kidney disease (CKD) was defined as an eGFR of less than 60ml/min on 
two of three consecutive measurements in the 12 to 24 months prior to baseline. 
Fasting venous blood samples were also assessed for measurement of potential 
cardiovascular biomarkers: NT-proBNP, hs-cTnT, GGT, CRP, fibrinogen, IL-6 and 
TNF-α. Plasma NT-proBNP and hs-cTNT were measured using the Elecsys 2010 
electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK) and 
calibrated using the manufacturer’s reagents. The manufacturer’s controls were used 
with limits of acceptability defined by the manufacturer. GGT was analysed using a 
Vitros Fusion chemistry system (Ortho Clinical Diagnostics, High Wycombe, UK) at 
the Western General Hospital, Edinburgh, UK. Assays for plasma TNF-α, IL-6, CRP 
and fibrinogen were carried out in the University Department of Medicine, Glasgow 
Royal Infirmary. TNF-α and IL-6 antigen levels were determined using high-
sensitivity ELISA kits (R&D Systems, Oxon, UK). CRP was assayed using a high-
sensitivity immunonephelometric assay. Fibrinogen assays were performed using 
stored plasma anticoagulated with trisodium citrate and the automated Clauss assay 
(MDA-180 coagulometer, Organon Teknika). 
Finally, fasting venous blood samples from baseline were used to obtain 
metabolomics data using an automated high-throughput serum NMR platform. The 
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process of metabolomics measurement using this platform is described in detail by 
Soininen et al., 2015. The platform provides information on 228 metabolic measures 
which can be summarised using the following 11 molecular groups: 
 Very low-density lipoprotein (VLDL) 
 Intermediate-density lipoprotein (IDL) 
 Low-density lipoprotein (LDL) 
 High-density lipoprotein (HDL) 
 Lipoprotein particle sizes (for each subclass of lipid above) 
 Apolipoproteins, namely apolipoprotein A-1 (ApoA-1) and apolipoprotein B 
(ApoB) 
 Fatty acids, including omega fatty acids, saturated fatty acids and total fatty 
acids 
 Glycolysis related metabolites produced during the process of extracting 
energy from glucose, including glucose, glycerol and lactate 
 Amino acids, including glutamine and glycine 
 Ketone bodies produced by the liver from fatty acids, including acetate and 
acetoacetate 
 Fluid balance molecules, namely creatinine and albumin 
 Inflammation, measured by glycoprotein levels, mainly a1-acid glycoprotein 
5.1.3.5 Smoking 
A questionnaire on smoking was self-completed at baseline. Participants were asked 
whether they currently smoked, and if so how many cigarettes, cigars and/or ounces 
of tobacco they typically smoked per week. If participants did not currently smoke, 
they were asked about their smoking history. Participants who reported having quit 
smoking in the previous six months were considered to be current smokers for the 
analyses in this thesis (Marioni et al., 2010). Smoking of cigars and pipes was 
relatively uncommon, and these quantities were converted to equivalent numbers of 
cigarettes based on estimated tobacco content (one cigar equivalent to four cigarettes 
and one ounce of tobacco equivalent to 50 cigarettes (Feinkohl et al., 2015)). 
Smoking was then defined categorically in line with the QRISK2 definition of 
smoking (Hippisley-Cox et al., 2010) as follows: (1) non-smoker, (2) ex-smoker, (3) 
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light current smoker (<10 cigarettes or equivalent/day), (4) moderate current smoker 
(10-19 cigarettes or equivalent/day), (5) heavy current smoker (20+ cigarettes or 
equivalent/day). 
5.1.3.6 Prevalent cardiovascular events 
Prevalent cardiovascular events were identified using multiple sources in order to 
ensure that all possible information was included. At baseline, participants self-
reported medical diagnoses and/or treatment (either surgical or medication) for 
angina, MI, stroke or PAD, and completed a WHO chest pain questionnaire. A 
resting 12-lead ECG was carried out and coded using the Minnesota coding system. 
Events identified using these methods were further confirmed with data linkage from 
ISD. Any events that were not self-reported by subjects but were identified on ISD 
linkage data were recorded. If necessary, notes from general practitioners (GP) and 
hospitals were obtained in order to confirm events. 
The following pre-determined criteria were used to define prevalent cardiovascular 
events: 
MI: (1) primary or secondary diagnosis ICD-10 code (World Health Organization, 
2015b) for MI (I21-I23, I252) on discharge record, and either self-report of a doctor 
diagnosis of MI, positive confirmation of MI on the WHO chest pain questionnaire, 
report of MI on GP notes or ECG evidence of MI; or (2) clinical criteria for MI met 
following inspection of hospital and/or GP notes. 
Angina: (1) primary or secondary diagnosis ICD-10 code for angina (I20-I25) on 
discharge record; or (2) at least 2 of (a) self- report of a doctor diagnosis of angina or 
of taking angina medication, (b) ECG confirmation of angina, and (c) positive 
confirmation of angina on the WHO chest pain questionnaire; or (3) clinical 
diagnosis of angina on inspection of hospital notes. 
Stroke: (1) primary diagnosis ICD-10 code for stroke (I61, I63-I66, I679, I694) on 
discharge record; or (2) clinical criteria for stroke met on inspection of hospital notes 
in subjects with either self-report of stroke or a non-primary ICD-10 hospital 
discharge/death code for stroke. 
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Transient ischemic attack (TIA): (1) primary or secondary diagnosis ICD-10 code 
for TIA (G45, G659) on discharge record; or (2) clinical criteria for TIA met on 
inspection of hospital notes in subjects with either self-report of stroke (such as “mini 
stroke” or “slight stroke) or with non-primary ICD-10 discharge code for stroke or 
TIA.  
Coronary intervention: Office of Population Censuses and Surveys -4 code  (Office 
of Population Censuses and Surveys, 1993) for coronary intervention (K40-K44, 
K49) on discharge record. 
5.1.3.7 Incident cardiovascular events 
Four year follow-up 
After four years, incident or recurrent cardiovascular events were identified using 
repeat self-reported questionnaires completed at the four year clinic, GP 
questionnaires, ECG results and record linkage from ISD (Morling et al., 2015). If 
required, hospital notes were searched for further information and if there were 
doubts regarding whether criteria had been met, particular cases were discussed by a 
panel of researchers and a consensus decision was made. 
The following pre-defined criteria were used to define incident or recurrent 
cardiovascular events between baseline and year four: 
Fatal MI: (1) primary or secondary ICD-10 code for MI on death certificate; or (2) 
clinical criteria for non-fatal MI within 4 weeks of unexplained/sudden death. 
MI: (1) ICD-10 code for new MI on discharge record after baseline; or (2) at least 
one of self-report of doctor diagnosis of MI after baseline, new confirmation of MI 
on the WHO chest pain questionnaire, ECG evidence for MI that was not present at 
baseline or GP report of MI; or (3) clinical criteria for MI met following inspection 
of hospital and/or GP notes for subjects with one or more individual indicators of a 
possible MI but not meeting the full criteria. 
Angina: no indication of angina at baseline plus either (1) ICD-10 code for angina as 
primary diagnosis code on discharge record after baseline; or (2) at least two of self-
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report of doctor diagnosis or taking medication for angina after baseline, new ECG 
evidence for angina or new confirmation of angina on the WHO chest pain 
questionnaire; or (3) clinical criteria for angina met following inspection of hospital 
and/or GP notes for subjects with one or more individual indicators of a possible 
angina but not meeting the full criteria. 
Fatal stroke: (1) ICD-10 code for stroke on death certificate; or (2) clinical criteria 
for non-fatal stroke within 6 weeks of unexplained or sudden death. 
Non-fatal stroke: (1) ICD-10 code for stroke as primary diagnosis on discharge 
record after baseline; or (2) self-report of stroke confirmed by inspection of clinical 
notes; or (3) non-primary ICD-10 codes for stroke confirmed by inspection of 
clinical notes. 
TIA: (1) ICD-10 code for TIA as primary diagnosis on discharge record after 
baseline; or (2) self-report of stroke confirmed as TIA on inspection of clinical notes; 
or (3) non-primary ICD-10 code for stroke or TIA confirmed as TIA on inspection of 
clinical notes. 
Coronary intervention: Office for Population Censuses and Surveys -4 code for 
coronary intervention on discharge record. 
Fatal other IHD: subject did not meet any of the criteria for fatal MI and had an 
ICD-10 code for IHD (I209, I249, I258, I259) as primary cause of death. 
Eight year follow-up 
Eight years after baseline, a further ISD data linkage was carried out. I identified 
possible cardiovascular events, operations and procedures since the four year follow-
up based on ICD-10 codes and developed criteria for new incident or recurrent 
events. If there was doubt as to whether criteria had been met, hospital notes were 
obtained and individual cases were discussed by researchers and clinicians to reach a 
consensus. 
The following pre-specified criteria were used to define incident or recurrent 
cardiovascular events between year four and year eight follow-up phases (note that 
   
 80 
these definitions differ from the year four cardiovascular event definitions, since data 
sources were limited to ISD linkage and clinical notes at the year eight follow-up): 
Fatal MI: (1) ICD-10 code for MI (I21-I23) as primary cause of death; or (2) non-
primary ICD-10 code for MI on death record confirmed with inspection of clinical 
notes. 
MI: (1) ICD-10 code for MI (I21-I23) as primary diagnosis on discharge record; or 
(2) ICD-10 code for MI or old MI (I252) as non-primary diagnosis confirmed with 
inspection of clinical notes. 
Angina: no indication of angina at baseline or year four follow-up plus ICD-10 code 
for angina (I20) as diagnosis code on discharge record. 
Fatal stroke: (1) ICD-10 code for stroke (I61, I63-I64) as primary cause of death; or 
(2) non-primary ICD-10 code for stroke on death record confirmed with inspection 
of clinical notes. 
Non-fatal stroke: (1) ICD-10 code for stroke (I61, I63-I64) as primary diagnosis on 
discharge record; or (2) ICD-10 code for stroke as non-primary diagnosis confirmed 
with inspection of clinical notes. 
TIA: (1) ICD-10 code for TIA (G45) as primary diagnosis on discharge record; or 
(2) non-primary ICD-10 code for TIA confirmed on inspection of clinical notes. 
Coronary intervention: Office for Population Censuses and Surveys -4 code for 
coronary intervention (K40-44, K49) on discharge record. 
Fatal other IHD: subject did not meet any of the criteria for fatal MI and had an 
ICD-10 code for IHD (I209, I249, I258, I259) as primary cause of death. 
After combining year four and year eight follow-up data, incident cardiovascular 
events were defined as the first fatal or non-fatal MI, diagnosis of angina, fatal or 
non-fatal stroke, TIA, coronary intervention or fatal other IHD experienced by a 
participant since baseline.  
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5.1.4 Ethical approval 
All participants gave informed consent prior to data collection. Ethical approval for 
the study was granted by the Lothian Medical Research Ethics Committee. 
Furthermore, full ethical permission was granted for ISD data linkage performed at 
baseline and all follow-up waves. 
5.1.5 Data management, cleaning and security 
Data from the baseline, year 1 and year 4 questionnaires and data collection forms 
were coded and manually entered into a master database using Microsoft Access 
2003/2010, Microsoft Corporation, Washington, USA. Laboratory data were 
included in the same file, obtained either from paper records or electronic files 
provided by the participating laboratories. At baseline all of the data from paper 
records were double entered into the database, and any discrepancies were resolved 
by referring back to the original paper documents. At year 4 a random 10% sample 
of the data was double entered and the error rates were found to be low for all 
variables so it was felt that there was no necessity to double enter the remaining 
records. Data from the year 4 and year 8 ISD record linkages were coded from the 
original electronic files and entered into a master database using SPSS v19.0 (SPSS 
Inc., Illinois, USA).  
After data entry, descriptive analyses were carried out on measurement data and 
inspected for outliers and missing values. Specious results (those which were 
considered inaccurate based on medical knowledge or laboratory detection limits) 
were scrutinized by referring back to the original paper records and correcting 
mistakes in data entry if required.  
The master databases are held and backed up on a secure university server, requiring 
electronic permission to access the storage drive via a unique username and 
password. Paper records are stored in secured filing cabinets in a locked office with 
only authorized access permitted. 
5.1.6 Missing data 
Despite previous data cleaning, the baseline variables used for this thesis still 
included missing data and, prior to carrying out formal analysis, I undertook a 
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missing data retrieval process in order to ensure a minimum amount of missing data 
in the final dataset. Original paper records were checked for missing data on 
medications, sBP, BMI and laboratory measurements such as cholesterol. Previously 
missing values were changed if this information was available.  
Retrieving missing BMI values 
One subject had a missing BMI value due to being heavier than the scale maximum 
and so this value was changed to a BMI of 48.2 based on the known scale maximum 
of 160kg and a year four home weight measurement of 151kg.  
Retrieving missing CKD values 
Five subjects had a missing CKD value because no routine data records prior to 
baseline were available. In these cases, a decision on whether the subject had CKD 
or not was taken based on an eGFR value less than 60ml/min from the baseline clinic 
visit alone. One subject had a missing CKD value due to a glitch in the hospital 
record linkage process, and this was rectified by obtaining the correct records prior to 
baseline and completing the missing data. 
Retrieving missing laboratory measurements 
A number of subjects were missing one or more laboratory measurement, such as 
serum total or HDL cholesterol or one of the pre-selected biomarkers. If missing data 
persisted after checking the original baseline clinic records, the value was taken as 
the closest routinely collected measurement within the previous or subsequent 6 
months from the baseline clinic, or, if no such measurement was available, from the 
year 1 clinic measurements if available. 
5.1.7 Data analysis  
5.1.7.1 Developing a basic model 
As discussed in the systematic review in Chapter 4, the QRISK2 score was chosen as 
the basis for an initial model in the ET2DS to which additional biomarkers would 
subsequently be added. This section describes the process of building a basic model 
based on this score. 
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Model updating procedure 
There are various options for updating a given statistical model such as QRISK2, 
from applying the original prediction model to re-estimating all parameters and 
extending the model to include additional parameters (Steyerberg, 2009). Since the 
model coefficients for the QRISK2 score are not made publicly available it was not 
possible to carry out some of the intermediary steps which may initially be desirable 
in this context, such as applying the original model or updating the intercept term. 
Therefore, the decision was taken to recalibrate the QRISK2 model by building a 
new model for the ET2DS data which followed the QRISK2 variables as closely as 
possible. 
QRISK2 variables not in the ET2DS 
The QRISK2 model includes the following 14 risk factors: age, sex, ethnicity, social 
status, smoking status, diabetes status, family history of CVD, CKD, atrial 
fibrillation, hypertension, rheumatoid arthritis, ratio of total to HDL cholesterol, BMI 
and sBP. Family history of CVD is not available for the ET2DS as this data was not 
collected and all participants are confirmed to have type 2 diabetes, so these two 
variables were dropped from the model. 
Information on ethnicity was collected as part of the ET2DS, but due to low numbers 
of non-white participants (n=17), the model was restricted to Caucasian participants 
only (n=1049). It was considered that the ET2DS did not provide enough variability 
in the ethnicity of the participants to justify including this categorical variable in a 
statistical model. 
 
Variable definitions in QRISK2 vs ET2DS 
The QRISK2 score uses the Townsend index (Townsend et al., 1988) as the measure 
of social status. The Townsend index is an area-based score of social deprivation 
incorporating four factors (unemployment, non-car ownership, non-house ownership 
and household crowding). However, the Townsend index is only calculated for 
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England and Wales and therefore is not available for the ET2DS participants who all 
live in the Lothian region of Scotland. The measure of social status which is 
available for the ET2DS is the SIMD. As previously described, the SIMD is also an 
area-based score of social deprivation, but it incorporates a different set of factors 
(current income, employment, health, education, skills and training, housing, 
geographic access and crime) which make the basis for calculations of Townsend 
and SIMD completely different and hence the final scores incomparable. In order to 
investigate the issue of social status in the ET2DS, a model was created with no 
measure of social deprivation included and then the SIMD was added in for 
comparison. The model performance improved with the addition of SIMD (c-statistic 
and pseudo R
2
 increased from 0.683 to 0.706 and 7.59% to 10.3% respectively), so 
the SIMD was included as a measure of social status in the basic model for the 
ET2DS. 
The definition of CKD used in QRISK2 was given as a clinical diagnosis of CKD 
based on clinical codes (Hippisley-Cox et al., 2010). However, the list of clinical 
codes is not made publicly available. Using a similar doctor-diagnosis definition 
based on hospital and surgical discharge records, a variable for CKD was created for 
the ET2DS. This variable identified 1.7% of the cohort as suffering from CKD. 
Although this was similar to the result found in the subgroup with type 2 diabetes in 
the QRISK2 development cohort (Hippisley-Cox et al., 2014), it is much lower than 
the anticipated rate of CKD among an elderly population with type 2 diabetes, which 
would be expected to be approximately a third (Retnakaran et al., 2006, Koro et al., 
2009). A second variable for CKD was already available in the ET2DS, based on 
eGFR and discussed in section 5.1.3.4. This definition is equivalent to Stage 3-5 
CKD (Levey and Coresh, 2012). This new variable identified 24.4% of the cohort as 
suffering from CKD, which is in line with what would be expected for this 
population. A comparison was made between models including the QRISK2 
definition and the new ET2DS definition, and the latter was shown to improve model 
performance (c-statistic and pseudo R
2
 increased from 0.687 to 0.699 and 7.90% to 
9.11% respectively). Therefore, as this was considered to be a more accurate 
definition of CKD, and one that would be used by a GP in clinical practice, it was 
used to build the basic model for the ET2DS. 
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Accounting for prevalent CVD and lipid lowering medication 
In addition to the variables discussed above, the basic model was extended to include 
two additional covariates: prevalence of CVD and lipid lowering medication. 
QRISK2 excluded participants who had previous CVD or were taking statins, but as 
a large proportion of the ET2DS cohort had prevalent CVD (n=367, 35%) or took 
lipid lowering medication at baseline (n=912, 86%), representing the situation in the 
target population of elderly people with type 2 diabetes, this exclusion method was 
not considered feasible while retaining adequate statistical power for analyses.  
Modelling method 
Although QRISK2 used Cox hazard regression modelling to build their risk score, 
the decision was taken to use logistic regression to build the ET2DS basic model. 
This was for a number of reasons: 
 The additional underlying assumption of proportional hazards was not 
required for logistic regression. This assumption was violated for some of the 
key covariates. 
 Although the scope of the analysis plan changed during the course of my PhD 
due to time constraints, complex variable selection methods for analysing 
multiple biomarkers (such as LASSO regression) using Cox regression had 
not yet been fully developed, and I wanted to keep the model choice 
consistent throughout my PhD project. 
 Previously published cardiovascular risk scores have used differing 
modelling methods, including logistic regression (Park et al., 2015; Davis et 
al., 2010; Genders et al., 2012, Alssema et al., 2012; McGorrian et al., 2011). 
In addition, I carried out a sensitivity analysis on the initial models produced, 
comparing the results of logistic and Cox regression, and found that the results were 
very similar. Therefore, binary logistic regression models were used to build the 
basic model and then evaluate the relationships between each biomarker and 
cardiovascular events. It should be noted that participants who died from non-CVD 
causes (n=121) were not excluded from statistical analyses and are regarded as 
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having had ‘no event’ in order to retain adequate statistical power. Such participants 
would be regarded as censored observations for the purposes of Cox regression 
analysis. 
The added predictive value of including each biomarker in the model, over and 
above the QRISK2 variables, was assessed. The c-statistic was calculated for all 
models to provide a measure of model discrimination. Additionally, the net 
reclassification (NR) was calculated separately for participants who did experience a 
cardiovascular event and those who did not. The NR compares two models (here, the 
basic model and a new model incorporating one or more non-traditional biomarkers) 
and gives the increase or decrease in the proportion of subjects correctly classified by 
the new model, according to pre-specified cardiovascular risk categories (0-10%, 10-
20% and >20%). Calibration was assessed using the Hosmer-Lemeshow test in 
which the null hypothesis assumes a well-calibrated model, so a p-value > 0.05 
indicates good calibration.  In this thesis the test is reported for 10 subgroups, though 
a number of group sizes for this test were run in order to check for a consistent 
overall result. Three global measures of model fit were calculated, the AIC, deviance 
and a pseudo R
2
 value for logistic regression. 
All subsets regression was used to compare all possible combinations of biomarkers 
and obtain the best five models, according to a pre-specified statistical criterion (the 
AIC). In addition, a model was fitted which included the QRISK2 risk factors and 
the full panel of biomarkers. 
A p-value of <0.05 was taken to be statistically significant. 
5.1.7.2 General inflammation factor 
The four inflammation biomarkers selected for analysis in the ET2DS (TNF-α, IL-6, 
CRP and fibrinogen) are highly correlated (see Table 7-2 in Chapter 7). For this 
reason, recent studies have suggested that they can be combined into one general 
factor which describes the overall inflammatory burden and reduces the 
dimensionality of the data from four to one (Alman et al., 2013; Kumar et al., 2016; 
Hsu et al., 2009; Bedenis et al., 2014). The four inflammatory biomarkers were 
combined into one general inflammation factor, g, using an unrotated PCA. All four 
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biomarkers loaded quite strongly onto the first principal component (Table 5-2), 
which explained 49% of the total variability, and this was used to calculate g.  
Table 5-2 PCA output for the ET2DS general inflammation factor g 





TNF-α 0.44 1 49 
IL-6 0.75 2 25 
CRP 0.80 3 15 
Fibrinogen 0.76 4 11 
n=1021 
Log transformed values were used for TNF-α, IL-6 and CRP 
 
5.2 UCLEB consortium cohorts 
The UCLEB consortium was established in order to facilitate in-depth exploration of 
genetic associations using the Metabochip array (Shah et al., 2013b). The consortium 
involves 12 UK-based, well-established prospective observational studies and 
consists of over 30,000 participants in total. Metabolomics data were available in 
seven of the participating studies: the British Regional Heart Study (BRHS), the 
British Women’s Heart and Health Study (BWHHS), the Caerphilly Prospective 
Study (CaPS), the ET2DS, the Medical Research Council National Survey of Health 
and Development (MRC NSHD), the Southall and Brent Revisited Study (SABRE) 
and the Whitehall-II Study (WHII). The following sections describe the process of 
data collation, the available variables and the design and key features of the studies 
which were analysed for this thesis. The design of the ET2DS has been described in 
detail previously in this chapter. 
5.2.1 Contributing UCLEB studies 
Six of the seven UCLEB studies with metabolomics data measured the panel of 228 
metabolites detailed in section 5.1.3.4 of this chapter. However, CaPS measured a 
different set of metabolites which included additional metabolites not found in the 
panel of 228 and excluded some metabolites which were in this panel. Additionally, 
CaPS did not have data for most of the outcome variables (prevalent MI, 
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revascularisation, angina or stroke, or incident angina) or some key cardiovascular 
risk factors (ethnicity, anti-hypertensive medication and lipid lowering medication). 
Finally, CaPS contributed only 34 participants to the collated data, so any adjustment 
for cohort would be likely to produce a poor estimate. For all of these reasons, CaPS 
was excluded prior to analysis.  
MRC NSHD was also excluded prior to analysis based on the fact that metabolomics 
data were collected between 2006 and 2010, seven to eleven years after the 
collection of data on prevalent diabetes, risk factors and CVD which was carried out 
in 1999. Therefore, most importantly, at the time of metabolomics measurement it 
was not known whether participants had the outcome of CVD. Furthermore, MRC 
NSHD only contributed 25 participants to the combined data. 
Therefore, the final studies chosen to be analysed in this thesis were BRHS, 
BWHHS, ET2DS, SABRE and WHII. 
5.2.2 BRHS 
The BRHS is a prospective study of 7735 middle-aged men recruited from general 
health practices in 24 towns around the UK (Shaper et al., 1981). Participants, aged 
40-59, were recruited between 1978 and 1980 and continue to be followed-up over 
30 years later. At baseline and at intervals thereafter, a wide range of risk factors 
were measured such as HDL and total cholesterol, blood pressure and BMI. 
Demographic data such as age, social status and ethnicity were also collected, as well 
as information on smoking habits and medication. Between 1998 and 2000 the blood 
samples subsequently used for NMR metabolomics measurements were collected 
(Shah et al., 2013b) and risk factors were re-measured, including key components of 
QRISK2, as well as the presence or absence of diabetes and prevalent CVD. Follow-
up for cardiovascular events includes data on incident fatal and non-fatal MI 
(Wannamethee et al., 2016). A non-fatal MI was diagnosed according to WHO 
criteria and evidence of non-fatal MI was obtained through informal reports from 
GPs and inspection of hospital notes and clinical correspondence.  
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5.2.3 BWHHS 
The BWHHS is a prospective cohort study of 4286 women aged between 60-79 
years at baseline, who were recruited from general practices in 23 towns in England, 
Scotland and Wales between 1999 and 2001 (Lawlor et al., 2003). The study began 
the fourth wave of follow-up in 2010. Physical examinations were carried out at 
baseline clinics in order to assess prevalent diabetes and also to measure a range of 
physical risk factors including BMI, blood pressure, cholesterol and creatinine. 
Blood samples taken at baseline were subsequently used for NMR metabolomics 
measurement (Shah et al., 2013b). Self-completed questionnaires were completed in 
order to provide information on participant demographic data such as age, sex, social 
status and ethnicity, as well as smoking habits and medications. Prevalent CVD was 
determined using a combination of self-reported diagnosis and GP records with 
confirmation from a doctor in the practice for major events such as MI and stroke. 
Incident cardiovascular events were determined using a combination of review of 
medical records, self-report questionnaires and linkage to the NHS Central Register 
for death records (Shah et al., 2013a). 
5.2.4 SABRE 
SABRE is a prospective cohort study of 4858 participants aged 40-69 years at 
baseline, who were recruited from GP practices and workplaces in west and north-
west London between 1988 and 1991 (Tillin et al., 2012). Participants have been 
followed for a total of 25 years. At baseline, participants attended a clinic where 
physical examinations were carried out in order to assess prevalent diabetes, blood 
pressure, BMI, total and HDL cholesterol and creatinine. Blood samples taken at the 
clinics were subsequently used for NMR metabolomics measurement. Prior to 
examination, participants completed self-report questionnaires to provide 
demographic data such as age, sex, social status and ethnicity, as well as information 
on smoking habits and medications. Prevalent cardiovascular events were identified 
using either ECG abnormalities at baseline or an indication of pre-baseline CVD on 
primary care records at follow-up. Incident cardiovascular events were determined 
using a combination of ICD-10 codes on hospital discharge and death records and 
self-report questionnaires, either completed by the participant themselves or by their 
GP if the participant had moved outside the local area (Tillin et al., 2012). The ICD-
   
 90 
10 codes used to define cardiovascular events have been described in detail by Tillin 
et al., 2014.  
5.2.5 WHII 
WHII is a prospective cohort study of 10,308 participants aged 35-55 at baseline, 
who were recruited from the British Civil Service in London between 1985 and 1988 
(Ferrie et al., 2002). Participants have been followed-up every five years, and this is 
expected to continue until 2030. At baseline clinics, physical examinations were 
undertaken in order to collect data on blood pressure, BMI and HDL and total 
cholesterol levels. Questionnaires were used to collect demographic information such 
as age, sex, social status and ethnicity, as well as information on smoking habits and 
medication. Between 1997 and 1999, during phase 5 of the study, the blood samples 
used subsequently for NMR metabolomics measurement were collected, and repeat 
measures of cardiovascular risk factors were made as well. The presence or absence 
of diabetes and prevalent CVD was also reassessed. Incident cardiovascular events 
were determined using a combination of record linkage to routinely collected data, 
self-report questionnaires, physical examinations and clinical notes. The paper by 
Hinnouho et al., 2015 describes in detail the methods for determining incident 
cardiovascular events: non-fatal MI was assessed using self-report questionnaires, 
ECGs, cardiac biomarkers and clinical notes; diagnosis of new angina since baseline 
was assessed based on self-reports of symptoms, confirmed by inspection of clinical 
notes or ECG abnormalities; and stroke was confirmed using ICD-10 codes on 
hospital discharge records and included TIAs. 
5.2.6 Data analysis  
The definitions of “incident” events across the studies and across event types was not 
consistent. In the ET2DS and for angina in all studies, incident events were defined 
as the first event during follow-up and therefore were either incident or recurrent 
events. In all other cases, incident events were defined as the first ever event and 
therefore included prevalent events. Since the raw data was not available for all 
studies in order to re-code the events to be consistent with the ET2DS definitions 
(including participants with recurrent events), there were two options for the 
cardiovascular outcome used for subsequent analyses: either to exclude all 
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participants with prevalent cardiovascular events or to combine prevalent and 
incident events into a general CVD outcome. However, excluding all participants 
with prevalent cardiovascular events would not have been possible while retaining 
adequate statistical power for the subsequent analysis of a large metabolomics data 
set. Although it was not my initial intention, and I would have preferred to use only 
incident or recurrent events, a general CVD outcome was considered to be the best 
use of the data given its limitations. Therefore, the outcome of interest for this 
analysis was CVD diagnosed at baseline or developing during the study follow-up 
period. This definition involved a participant experiencing one or more of the 
following: prevalent MI, prevalent revascularisation, prevalent angina, prevalent 
stroke, incident angina, incident fatal or non-fatal MI, incident revascularisation, 
incident fatal or non-fatal stroke or any incident fatal or non-fatal CHD. 
Binary logistic regression models were used to evaluate the relationships between 
each metabolite and CVD and results were summarised using ORs and Manhattan-
style plots (Miquel, 2016) showing corresponding p-values. The level of statistical 
significance was adjusted for multiple comparisons using three different methods: a 
FDR of 1%, a FDR of 5% and a Bonferroni correction. 
Analyses explored four different models for the combined UCLEB data: a model 
adjusted only for cohort; a model adjusted for cohort, age and sex; a model adjusted 
additionally for the most widely accepted traditional cardiovascular risk factors 
(cohort, age, sex, HDL to total cholesterol ratio, sBP, smoking status, anti-
hypertensive medication and lipid lowering medication); and a model adjusted for a 
small panel of additional key risk factors included in the majority of previously 
developed cardiovascular risk scores in either diabetic or general population studies 
(social status, BMI, eGFR and ethnicity), as discussed in the systematic review in 
Chapter 4. This final model did not match the basic ET2DS model discussed in this 
chapter in section 5.1.7.1, since the same variables were not available in all the 
UCLEB cohorts. A number of intermediary models could have been carried out 
using the variables listed above, but to avoid over-analysing the data statistical 
analyses were restricted to these four models.  
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5.2.7 Variable definitions, data collation and missing data 
Based on the above four models, the following variables were desirable from each of 
the chosen UCLEB studies (in addition to robust data on prevalent diabetes): age, 
sex, HDL and total cholesterol, sBP, smoking status, anti-hypertensive medication, 
lipid lowering medication, social status, BMI, eGFR and ethnicity. In addition the 
outcome variables of prevalent MI, revascularisation, angina, stroke and incident 
angina, MI, revascularisation, stroke and CHD were required. These data were 
extracted, where available, from each study for those participants with prevalent type 
2 diabetes at baseline by the ET2DS Data Manager. The UCLEB consortium 
definition for prevalent type 2 diabetes is any one of: self-report of type 2 diabetes at 
baseline; type 2 diabetes found on medical history review; participant taking glucose 
lowering medication at baseline; or participant fasting glucose level greater than 
7mmol/L at baseline. Relevant data on all subjects from the ET2DS were extracted 
since every participant in this study has type 2 diabetes at baseline. The extracted 
data for each study was saved on the secure UCLEB server at University College 
London, in a folder only accessible by those working on this project. All analyses on 
the UCLEB cohorts were carried out on this external server. 
Table 5-3 shows the data available for each UCLEB cohort and details the definitions 
for these variables. The majority of these definitions are set by UCLEB in order to 
achieve consistency across the studies. However, the definition of the social status 
variable was not harmonised across all studies used in this thesis. The UCLEB social 
status variable, based on occupation, is defined by six categories: unskilled; semi-
skilled; manual skilled; non-manual skilled; managerial and lower professional; and 
professional. BRHS, BWHHS and SABRE use this definition, with an extra seventh 
category for armed forces in BRHS. Social status data from the ET2DS is coded 
according to the National Statistics Socio-economic classification (Office for 
National Statistics, 2010) which defines five groups as follows: semi-routine and 
routine occupations; lower supervisory and technical occupations; small employers 
and own account workers; intermediate occupations; managerial, administrative and 
professional occupations. Finally, WHII, a cohort recruited from civil servants in 
London, defines social status according to three categories: clerical and support; 
administrative; and professional and executive. In order to be able to adjust the final 
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model for social status, I decided to collapse the original UCLEB variable down to 
three groups: unskilled; skilled (including semi-, manual and non-manual skilled); 
and professional (including managerial, lower professional and professional). In the 
ET2DS, participants in semi-routine and routine occupations were classified as 
unskilled, participants in lower supervisory and technical operations were classified 
as skilled and all other participants were classified as professional. In WHII, 
participants in the clerical, support and administrative categories were classified as 
skilled and the remaining participants as professional. Finally, the four individuals in 
BRHS who were in the armed forces were coded as missing, since not enough 
information was available (i.e. ranking within the military) in order to classify these 
participants according to the new system. 
Information on eGFR was not available for the BRHS and WHII cohorts, and a 
number of CVD outcomes were not available for BRHS. Since eGFR is only 
included as a risk factor in the final multivariable model, the decision was taken to 
drop the BRHS and WHII cohorts from analysis at this stage. Despite the missing 
CVD outcome types in the BRHS cohort, the available cardiovascular events were 
considered to be a subgroup of the overall cardiovascular condition. Therefore, rather 
than exclude this cohort from analysis, the outcome for BRHS was defined as a 
participant experiencing one or more of the following: prevalent MI, prevalent 
stroke, incident fatal or non-fatal MI or incident revascularisation. 
Missing data retrieval for the ET2DS has been discussed in detail in section 5.1.6 of 
this chapter. Although the other UCLEB cohorts were subject to missing values, 
missing data retrieval was not possible for most of the other UCLEB cohorts since 
there was no direct access to the original data sources. However, after contacting the 
researchers at WHII, information on the data collection of medication variables was 
obtained and a large proportion of missing values for these variables (anti-
hypertensive and lipid lowering medication) were changed to ‘no’. 
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Table 5-3 Variables available in the UCLEB cohorts 











Age Age (years)      
Sex Gender (male/female)      
Total cholesterol Total cholesterol (mmol/l)      
HDL cholesterol High-density lipoprotein cholesterol 
(mmol/l) 
     
sBP Systolic blood pressure (mmHg)      
Smoking status Participant ever smoked (yes/no)      
Anti-hypertensive 
medication 
Participant taking anti-hypertensive 
medication (yes/no) 
     
Lipid lowering 
medication 
Participant taking lipid lowering 
medication (yes/no) 
     
BMI Body mass index (kg/m2)      
eGFR Estimated glomerular filtration rate 
(ml/min)  
NA    NA 
Ethnicity 1: White; 2: Asian; 3: Afro-
Caribbean; 4: Chinese/Oriental; 5: 
Other 
     
Social status 1: Unskilled; 2: Skilled; 3: 
Professional 
     
Prevalent MI MI prior to baseline      
Prevalent 
revascularisation 
Revascularisation prior to baseline 
NA     
Prevalent angina Diagnosis of angina prior to baseline NA     
Prevalent stroke Stroke prior to baseline      
Incident angina Diagnosis of angina during follow-up 
period 
NA     
Incident fatal or 
non-fatal MI or 
revascularisation 
Fatal or non-fatal MI or 
revascularisation during follow-up 
period 
     
Incident fatal or 
non-fatal stroke 
Fatal or non-fatal stroke during 
follow-up period 
NA     
Incident fatal or 
non-fatal CHD 
Fatal or non-fatal coronary heart 
disease event during follow-up 
period 
NA     
n: number of participants with prevalent type 2 diabetes at baseline 
BMI: body mass index; BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CHD: coronary 
heart disease; eGFR: estimated glomerular filtration rate; ET2DS: Edinburgh Type 2 Diabetes Study; HDL: high-density 
lipoprotein; MI: myocardial infarction; NA: not available; SABRE: Southall and Brent Revisited Study; sBP: systolic blood 
pressure; WHII: Whitehall-II Study 
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6 Results I: Characteristics of ET2DS and 
descriptive statistics for cardiovascular events and 
biomarkers 
This chapter describes the baseline characteristics and representativeness of the 
ET2DS study population. Incident or recurrent cardiovascular events which occurred 
during follow-up are also summarised and descriptive statistics are presented for the 
panel of non-traditional biomarkers discussed in section 1.4 of Chapter 1, which will 
be included in subsequent analysis. Finally, missing data is discussed and 
summarised.  
6.1 Baseline demographic characteristics 
Baseline characteristics of the ET2DS cohort are presented in Table 6-1. The 
baseline cohort comprised of 1066 individuals, with an average age of 67.9 years. 
547 (51.31%) participants were male. 127 (11.91%) were in the first quintile of the 
SIMD (most deprived), 208 (19.51%) were in the second quintile, 188 (17.64%) 
were in the third quintile, 194 (18.20%) were in the fourth quintile and 349 (32.74%) 
were in the top quintile (least deprived). At baseline, 912 (85.55%) participants were 
taking lipid lowering medication and 872 (81.80%) were taking anti-hypertensive 
medication. Baseline prevalences of MI, angina, stroke, TIA and coronary 
intervention were 150 (14.07%), 298 (27.95%), 62 (5.82%), 31 (2.91%) and 110 
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Table 6-1 Baseline characteristics of the ET2DS population 
Variable  
Age (years) 67.91 ± 4.20 
Sex (male) 547 (51.31) 
Lipid-lowering medication 912 (85.55) 
Anti-hypertensive medication 872 (81.80) 
Smoking status  
Non-smoker 419 (39.31) 
Ex-smoker 499 (46.81) 
Current smoker – light (<10 cigarettes/day) 31 (2.91) 
Current smoker – moderate (10-19 cigarettes/day) 48 (4.50) 
Current smoker – heavy (20+ cigarettes/day) 69 (6.47) 
Atrial fibrillation 69 (6.47) 
Chronic kidney disease 260 (24.39) 
Rheumatoid arthritis  39 (3.66) 
Scottish Index of Multiple Deprivation  
Quintile 1 127 (11.91) 
Quintile 2 208 (19.51) 
Quintile 3 188 (17.64) 
Quintile 4 194 (18.20) 
Quintile 5 349 (32.74) 
Body mass index (kg/m2) 31.43 ± 5.69 
Systolic blood pressure (mmHg) 133.29 ± 16.44 
Total cholesterol (mmol/L) 4.31 ± 0.90 
High-density lipoprotein cholesterol (mmol/L) 1.29 ± 0.36 
Cardiovascular disease at baselinea  
Myocardial infarction 150 (14.07) 
Angina 298 (27.95) 
Stroke 62 (5.82) 
Transient ischemic attack 31 (2.91) 
Coronary intervention 110 (10.32) 
Data are presented as means ± SD or n (%) 
a
Note that there is overlap among these subgroups 
Maximum n = 1066 
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6.2 Representativeness 
At baseline researchers in the ET2DS assessed the representativeness of the recruited 
ET2DS population (Marioni et al., 2010). Table 6-2 compares the key socio-
demographic and clinical characteristics of the people recruited into the study against 
the people invited from the LDR, but who did not participate in the final study (“non-
responders”). Marioni et al., 2010, found no statistically significant differences 
between the ET2DS population and non-responders for age, duration of diabetes, 
HbA1c, diabetes treatment by insulin or social status (assessed using SIMD). 
Although they did find a statistically significant difference between the ET2DS 
population and non-responders for sex, sBP and total cholesterol, the actual sizes of 
these differences were small and the authors question the clinical significance of 
these differences. Furthermore, the authors investigated the similarities between non-
responders and ET2DS participants in these characteristics by sex and 5-year age 
bands and found similar conclusions.  
6.3 Incident cardiovascular events 
Outcome events were defined as the first fatal or non-fatal cardiovascular event a 
participant experienced during the eight year follow-up period. Therefore events 
could be true incident events, if the participant had not experienced this type of 
outcome prior to baseline, or could be a recurrent event, if the participant had 
experienced this type of outcome prior to baseline. During the eight year follow-up 
period a total of 208 outcome events were recorded (19.51% of the study 
population). The breakdown according to type of cardiovascular event is shown in 
Table 6-3. 
6.4 Descriptive statistics of biomarkers 
Table 6-4 presents descriptive statistics for baseline biomarkers. The distributions of 
NT-proBNP, hs-cTNT, GGT, TNF-α, CRP and IL-6 were skewed (shown in Figure 
6-1) and therefore a log transformation (using the natural logarithm) has been used in 
all subsequent analyses. ABI has a reverse J-shaped relationship with cardiovascular 
risk and values greater than 1.4 measure medial arterial calcinosis rather than 
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atherosclerosis, so in line with previous studies participants with an ABI > 1.4 




Table 6-2 Demographic and clinical characteristics of the ET2DS population and non-
responders. Adapted from Marioni et al., 2010. 
 ET2DS population Non-responders 
n 1066 4386 
Age (years) 67.9 ± 4.2 67.9 ± 4.4 
Sex (male) 547 (51.3) 1839 (41.9)** 
Duration of diabetes   
Up to 5 years 516 (48.4) 2315 (48.7) 
≥ 5 years 550 (51.6) 2251 (51.3) 
HbA1c 7.4 (1.1) 7.4 (1.4) 
Insulin treatment 185 (17.4) 704 (16.1) 
sBP (mmHg) 133.3 ± 16.4 137.2 ± 18.2** 
Total cholesterol (mmol/l) 4.3 (0.9) 4.2 (0.9)* 
Scottish Index of Multiple Deprivation 
Quintile 1 127 (11.9) 736 (16.8) 
Quintile 2 208 (19.5) 1134 (25.9) 
Quintile 3 188 (17.6) 820 (18.7) 
Quintile 4 194 (18.2) 782 (17.8) 
Quintile 5 349 (32.7) 897 (20.5) 
Data are presented as means ± SD or n (%) 
* p-value < 0.01; ** p-value < 0.001 for χ
2
 test for independence or t test for differences between groups  
HbA1c: glycated haemoglobin 




   
 99 
Table 6-3 Summary of first incident or recurrent cardiovascular events in the ET2DS 
Cardiovascular Event Type n (%) 
Myocardial infarction (fatal/non-fatal) 61 (5.72) 
Angina 38 (3.56) 
Stroke (fatal/non-fatal) 53 (4.97) 
Transient ischemic attack (fatal/non-fatal) 12 (1.13) 
Coronary intervention 26 (2.44) 




Table 6-4 Descriptive statistics of baseline biomarkers in ET2DS 
Biomarker   
Ankle brachial index 1.0 ± 0.2 
N-terminal pro-brain natriuretic peptide (pg/ml) 75.0 (37.0, 169.3) 
High-sensitivity cardiac troponin T (ng/l) 9.6 (6.9, 13.8) 
Gamma-glutamyl transpeptidase (U/L) 18.0 (11.0, 32.0) 
C-reactive protein (mg/l) 1.9 (0.9, 4.4) 
Interleukin-6 (pg/ml) 2.9 (2.0, 4.5) 
Tumor necrosis factor alpha (pg/ml) 1.1 (0.7, 1.6) 
Fibrinogen (g/L) 3.6 ± 0.7 
Data are presented as means ± SD or median (lower IQR, upper IQR) 
Maximum n = 1066 
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6.5 Missing data 
Missing data on baseline risk factors and biomarkers are summarised in Table 6-5, 
including the amount of missing data for each variable before and after final retrieval 
of data missing from the ET2DS database by myself for the purposes of this analysis, 
and reasons for remaining missing data where available. Data was complete for age, 
sex, social status, smoking status, atrial fibrillation, arthritis and prevalent events. 
The remaining variables had very little missing data (4.13% of cases missing due to 
one or more missing value after retrieving missing data).  










Reason for remaining 
missing data (if 
available) 
Chronic kidney disease 6 0  
Anti-hypertensive medication 7 0  
Lipid lowering medication 2 0  
Body mass index 2 1 
Participant was unable 
to stand at baseline 
clinic 
Systolic blood pressure 2 0  
Total cholesterol 8 0  
HDL cholesterol  8 1  
Ankle brachial index 7 7 
1 amputation below the 
knee and remaining 
participants found it too 
painful to have blood 
pressure taken 




High-sensitivity cardiac troponin T 12 12  
Gamma-glutamyl transpeptidase 11 1  
C-reactive protein 24 24  
Interleukin-6 2 2  
Tumor necrosis factor alpha 3 3  
Fibrinogen 3 3  
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It is not possible to test whether the pattern of missing data is missing at random 
(MAR) (Steyerberg, 2009), but in order to determine whether the remaining missing 
data was missing completely at random (MCAR), associations between key 
predictors (age and sex) and missingness were assessed. Additionally, the association 
between cardiovascular outcomes and missingness was investigated. No statistically 
significant associations were found, so the assumption of MCAR required for 
complete case analysis was not violated (Baraldi and Enders, 2010). Furthermore, 
since the loss of cases due to missing data was less than 5%, the risks associated with 
complete case analysis of biased estimates or reduced statistical power were 
considered to be negligible (Graham, 2009).  
 
  
   
 103 
7 Results II: Improving cardiovascular risk 
prediction using individual and combined 
biomarkers in the ET2DS 
This chapter presents analyses of the panel of non-traditional biomarkers added, 
individually and in combination, to the basic risk prediction model based on 
QRISK2. The basic model is summarised and the pairwise correlations among 
biomarkers are presented. The results of adding the non-traditional biomarkers to the 
basic model one at a time are then shown, followed by the results of an all subsets 
regression which considered the biomarkers in combination. 
7.1 Basic model 
The basic model used for subsequent analyses was based on QRISK2, adapted for 
use in the ET2DS cohort, as outlined previously. In order to allow consistent 
comparisons between subsequent models, only subjects with complete data for all 
basic model variables and biomarkers were used (n=989). Table 7-1 summarises the 
exponentiated coefficients (the ORs) for each variable in the basic model. A set of 
model summary measures is also presented. The c-statistic for the basic model was 
0.722 (95% CI: 0.681, 0.763) and the model showed good calibration (Hosmer-
Lemeshow test non-significant). The pseudo R
2
 measure gives the variability 
explained by the basic model as 17.08%.  
7.2 Associations between biomarkers at baseline 
At baseline, moderate to strong relationships were observed among most of the 
biomarkers, as shown in Table 7-2. In particular, the group of inflammatory 
biomarkers (TNF-α, IL-6, CRP and fibrinogen) were positively correlated with each 
other, and all of these associations were found to be strongly statistically significant 
(p<0.001). By design, the general inflammation factor g was strongly correlated with 
all inflammatory biomarkers. Moderate correlations were found between NT-
proBNP and both ABI and hs-cTnT (r=-0.21 and 0.38 respectively; both p<0.001). 
ABI and hs-cTnT were weakly negatively associated (r=-0.10, p<0.01). GGT 
correlated weakly with three of the inflammatory biomarkers (TNF-α, IL-6 and CRP; 
r = 0.08, 0.16 and 0.24 respectively). 
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7.3 Relationships between biomarkers and cardiovascular 
risk 
In order to explore the shape of the relationships between the biomarkers and 
cardiovascular risk, each biomarker was categorised into five evenly sized groups. 
Figure 7-1 shows the log odds of an incident or recurrent cardiovascular event in 
each group, separately for each biomarker. A decreasing trend between ABI and 
cardiovascular risk was observed, while increasing trends were observed between 
each of the other biomarkers and cardiovascular risk. These increasing trends appear 
to be strongest for NT-proBNP and hs-cTnT, while the remaining biomarkers show 
relatively weaker relationships with cardiovascular risk. All the associations were 
considered to be roughly linear in shape. 
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Table 7-1 Basic model coefficients and summary measures 
Variable ORs (95% CI) 
Age (per year) 1.06 (1.02, 1.11) 
Sex [Female] 0.80 (0.55, 1.15) 
Smoking [Ex-smoker]a 1.07 (0.73, 1.57) 
Smoking [Current – light] a 1.15 (0.36, 3.10) 
Smoking [Current – moderate] a 1.18 (0.44, 2.83) 
Smoking [Current – heavy] a 1.04 (0.49, 2.08) 
Atrial fibrillation [Yes] 1.87 (1.04, 3.32) 
Chronic kidney disease [Yes] 1.85 (1.26, 2.69) 
Rheumatoid arthritis [Yes] 1.24 (0.51, 2.74) 
Hypertension [Yes] 1.00 (0.62, 1.65) 
Body mass index (per kg/m2) 1.01 (0.98, 1.05) 
Systolic blood pressure (per mmHg) 1.01 (1.00, 1.02) 
Total:high-density lipoprotein cholesterol 1.36 (1.16, 1.59) 
Scottish Index of Multiple Deprivation [Quintile 1 reference category] 
Quintile 2 0.46 (0.26, 0.82) 
Quintile 3 0.80 (0.45, 1.41) 
Quintile 4 0.62 (0.35, 1.12) 
Quintile 5 0.51 (0.30, 0.89) 
Prevalent cardiovascular disease [Yes] 2.07 (1.45, 2.96) 
Lipid lowering medication [Yes] 1.44 (0.84, 2.59) 
Model summary measures:  
Deviance 859.38 
Akaike’s information criterion 899.38 
c-statistic (95% CI) 0.722 (0.681, 0.763) 
Hosmer-Lemeshow p-value 0.97 
R2 (%) 17.08 
n = 989 
a
 compared to reference category of non-smokers 
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 ABI  NT-proBNP hs-cTnT GGT TNF-α IL-6 CRP Fibrinogen g 
ABI 1 -0.21***   -0.10** -0.05 -0.07* -0.12*** -0.13*** -0.18*** -0.18*** 
NT-proBNP  1     0.38*** -0.03  0.16***  0.18***  0.11***  0.21***  0.23*** 
hs-cTnT   1  0.03  0.19***  0.17*** -0.03  0.05  0.12*** 
GGT    1  0.08*  0.16***  0.24*** -0.06  0.16*** 
TNF-α     1  0.31***  0.12***  0.12*** 0.43*** 
IL-6      1  0.42***  0.34*** 0.75*** 
CRP       1  0.54*** 0.80*** 
Fibrinogen        1 0.76*** 
g         1 
Max n = 1032; missing data ranges from 8 to 39 data points 
*     Pearson correlation test p-value < 0.05 
**   Pearson correlation test p-value < 0.01 
*** Pearson correlation test p-value <0.001 
ABI: ankle brachial index; CRP: C-reactive protein; g: inflammation factor; GGT: gamma-glutamyl transpeptidase; hs-cTnT: high-sensitivity cardiac 
troponin T; IL-6: interleukin-6; NT-proBNP: N-terminal pro-brain natriuretic peptide; TNF-α: tumor necrosis factor alpha 
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Figure 7-1 Cardiovascular (CV) risk against categorised biomarkers in the ET2DS (Q: quintile) 
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7.4 Adding individual biomarkers to the basic model 
Five logistic regression models were fitted, adding each individual biomarker to the 
basic model, and the results are summarised in Table 7-3. Increased levels of 
individual circulating biomarkers and the inflammatory factor were associated with 
an increased incidence of cardiovascular events over-and-above the basic model. 
However, only the associations for NT-proBNP and hs-cTnT were statistically 
significant. The strongest association was observed for hs-cTnT (OR for a 1 SD 
increase in hs-cTnT 1.35; 95% CI: 1.13, 1.61). A higher ABI was associated with a 
lower incidence of events, although the confidence interval just included 1 (OR for a 
1 SD increase in ABI 0.86, 95% CI: 0.73, 1.00).  
The basic model had a c-statistic of 0.722 (0.681, 0.762) and was well-calibrated. 
The addition of each individual biomarker increased the c-statistic, with the greatest 
increase seen for hs-cTnT (c-statistic increased by 0.01 to 0.732, 95% CI: 0.690, 
0.774). The addition of individual biomarkers also improved the risk classification 
for participants who did not experience a cardiovascular event, although this 
generally resulted in poorer risk classification for participants who did experience a 
cardiovascular event. The addition of hs-cTnT resulted in poorer risk classification 
by 1.6% for participants who experienced a cardiovascular event, but improved risk 
classification by 2.2% for those who did not. All the models were shown to be well-
calibrated (Hosmer-Lemeshow p > 0.05). 
The AIC decreased for each model which included an additional biomarker 
compared to the basic model, which indicates that these models have an improved fit 
despite the additional covariates. Similarly, the deviance decreased after the addition 
of each individual biomarker confirming this improved statistical fit. Finally, the 
variation in the data explained by the model increased marginally for each additional 
biomarker, with the biggest increase in the pseudo R
2
 found for hs-cTnT.  
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Basic model - - 0.722  
(0.681, 0.763) 
- - 0.97 859.38 899.38 17.08 




-2.2 2.0 0.83 855.63 861.63 17.44 




-2.2 1.5 0.81 854.56 860.56 17.55 




-1.6 2.2 0.09 848.60 854.60 18.12 




-2.7 1.1 0.40 856.42 862.42 17.37 




0.5 1.2 0.90 858.81 864.81 17.13 
n = 989 
a
 Conventional risk factors based on QRISK2: age, sex, smoking, atrial fibrillation, chronic kidney disease, arthritis, hypertension, body mass index, systolic blood pressure, 
total:high-density lipoprotein cholesterol, social status, baseline cardiovascular disease status (myocardial infraction, angina, transient ischemic attack and stroke) and lipid 
lowering medication 
b 
n = 186 for event, n = 803 for no event 
ABI: ankle brachial index; AIC: Akaike’s information criterion; g: inflammation factor; GGT: gamma-glutamyl transpeptidase; hs-cTnT: high-sensitivity cardiac troponin T; NT-
proBNP: N-terminal pro-brain natriuretic peptide; OR: odds ratio; SD: standard deviation 
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7.5 Adding combinations of biomarkers to the basic model 
An all subsets regression was carried out in order to identify the top five models 
according to a pre-specified statistical criterion (AIC), after adjusting for the 
QRISK2 risk factors, from all possible combinations of biomarkers. These top five 
models are shown in Table 7-4. All five models selected hs-cTnT and none included 
the general inflammation factor g. The best model found using this method added 
ABI, hs-cTnT and GGT to the basic model based on QRISK2. This model was well-
calibrated and had a c-statistic of 0.740 (CI: 0.699, 0.781), an increase of 0.018 
compared with the basic model. The addition of the three biomarkers resulted in 
slightly poorer risk classification by 1.1% for participants who experienced a 
cardiovascular event, but improved risk classification by 4.4% for those who did not. 
The second best model was well-calibrated and showed the same increase in the c-
statistic as the top model, but the net reclassification was poorer both for participants 
who experienced a cardiovascular event (-2.7%) and for those who did not (3.4%) 
compared with the top model. For comparison, the full model including all 
biomarkers is also shown in Table 7-4. The c-statistic showed the same increase as 
the top model, suggesting an upper limit to model performance. The addition of all 
biomarkers resulted in poorer risk classification by 1.6% for participants who 
experienced a cardiovascular event, but improved risk classification by 5.2% for 
those who did not.  
All five top models, and the full model, showed a decrease in both AIC and 
deviance, indicating improved statistical fit over the basic model based on QRISK2. 
The variation in the data explained by the model increased for all five top models, 
and for the full model containing all five biomarkers. 
7.6 Conclusions 
The addition of each individual biomarker from a panel of pre-selected non-
traditional vascular biomarkers improved the predictive ability of a basic model 
based on QRISK2, with the greatest improvement found for hs-cTnT. When 
considered in combination the greatest improvement in risk prediction was found for 
a model including ABI, hs-cTnT and GGT in addition to the QRISK2 predictors. 
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However, in all the models fitted, there remains a large amount of unexplained 
variability according to the pseudo R
2
 measurement (highest R
2
 found was 18.87%, 
for both the second best combined model and the full model including all 
biomarkers). This indicates that there is still considerable room for improvement in 
risk prediction and motivated the novel metabolomics analyses presented in the 
following chapter. 
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Table 7-4 Top five models selected from the combined biomarkers and corresponding measures of model performance
Model 
Predictors in the model, additional to 
conventional risk factorsa 













Basic - 0.722 (0.681, 0.763) - - 0.97 859.38 899.38 17.08 
Top five models chosen using all-subsets regression selection:    
1 ABI + hs-cTnT + GGT 0.740 (0.699, 0.781) -1.1 4.4 0.15 842.46 852.46 18.71 
2 ABI + hs-cTnT + GGT + NT-proBNP 0.740 (0.699, 0.780) -2.7 3.5 0.34 840.87 852.87 18.87 
3            hs-cTnT + GGT + NT-proBNP 0.738 (0.697, 0.779) -1.6 5.1 0.47 843.25 853.25 18.64 
4 ABI + hs-cTnT 0.735 (0.694, 0.776) -3.2 5.4 0.35 845.40 853.40 18.43 
5            hs-cTnT + GGT 0.738 (0.697, 0.778) -1.1 3.9 0.21 845.49 853.49 18.42 
Full model:    
 ABI + hs-cTnT + GGT + NT-proBNP + g 0.740 (0.699, 0.781) -1.6 5.2 0.39 840.87 854.87 18.87 
n = 989 
a
 Conventional risk factors based on QRISK2: age, sex, smoking, atrial fibrillation, chronic kidney disease, arthritis, hypertension, body mass index, systolic blood pressure, 
total:high-density lipoprotein cholesterol, social status, baseline cardiovascular disease status (myocardial infraction, angina, transient ischemic attack and stroke) and lipid 
lowering medication 
b 
n = 186 for event, n = 803 for no event 
ABI: ankle brachial index; AIC: Akaike’s information criterion; g: inflammation factor; GGT: gamma-glutamyl transpeptidase; hs-cTnT: high-sensitivity cardiac troponin T; NT-
proBNP: N-terminal pro-brain natriuretic peptide; OR: odds ratio; SD: standard deviation 
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8 Results III: Associations between metabolomics 
data and cardiovascular disease in the UCLEB 
consortium cohorts 
This chapter describes the missing data and baseline characteristics of the five 
UCLEB cohorts used in this thesis: BRHS, BWHHS, ET2DS, SABRE and WHII. 
Prevalent and incident cardiovascular events are summarised and descriptive 
analyses are presented for the 228 metabolites measured. Associations between the 
metabolites and CVD are presented initially for each cohort individually, unadjusted 
for any risk factors. Finally, associations between the metabolites and CVD are 
presented for the data from the five cohorts combined, using four different models to 
adjust for risk factors. 
8.1 Missing data 
Analyses of the metabolomics data explored four different models for the combined 
UCLEB data: a model adjusted only for cohort (model 1); a model adjusted for 
cohort, age and sex (model 2); a model adjusted additionally for the most widely 
accepted traditional cardiovascular risk factors (model 3); and a model adjusted 
additionally for a small panel of additional key risk factors included in the majority 
of previously developed cardiovascular risk scores (model 4). Table 8-1 summarises 
the amount of missing data for each risk factor in the five UCLEB cohorts required 
for these four models. Data was complete for age, sex, anti-hypertensive medication 
and lipid lowering medication in all five studies. This meant that risk factor data was 
complete for the model adjusted for cohort only (model 1) and for the model 
additionally adjusted for age and sex (model 2). Most of the remaining variables had 
very little missing data, though most notably the BWHHS was missing 25% of the 
values for social status. In addition, WHII was missing about 13% of the values for 
HDL cholesterol and 12% of the values for BMI. Overall, the proportions of cases 
missing in the combined data due to one or more missing value for models 3 
(adjusted additionally for HDL to total cholesterol ratio, sBP, smoking status and 
lipid lowering and anti-hypertensive medication) and 4 (adjusted additionally for 
social status, BMI, eGFR and ethnicity) were 4.98% and 24.48% respectively.  
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The amount of missing data for models 1, 2 and 3 was below the 5% level considered 
acceptable for complete case analysis. Although the amount of missing data for 
model 4 was higher than would be desirable for a complete case analysis, alternative 
missing data methods such as multiple imputation were not considered feasible for 
this setting. In the case of combining multiple cohorts, a multilevel multiple 
imputation method would be required in order to allow for between-study 
heterogeneity and avoid biased results (Jolani et al., 2015). This could be 
implemented using novel techniques such as joint modelling or fully conditional 
specification models and would require study to be regarded as a fixed effect 
(Audigier et al., 2017). However, such methods are still under development and 
implementation has many limitations: such imputation models can have convergence 
problems leading to biased results; the method can yield biased estimates of 
measures of uncertainty; substantial computational power is required to create a large 
number of imputed datasets; and finally, such methods were still under development 
for statistical software packages at the time of analysis (Koopman et al., 2008; Jolani 
et al., 2015). Furthermore, associations between missingness and both key predictors 
(age and sex) and cardiovascular disease were investigated and no statistically 
significant associations were found. This indicated that the assumption of MCAR, 
required for a complete case analysis, was not violated. For all these reasons, a 
complete case analysis was carried out for each model.  
The amount of missing data in the metabolites are summarised in Table C-1 in 
Appendix C As discussed above, multilevel multiple imputation was not considered 
possible in this context, therefore each subsequent model is calculated for the 
maximum number of metabolites available. 
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Table 8-1 Available values for the risk factor variables in the UCLEB consortium cohorts 
 
BRHS BWHHS ET2DS SABRE WHII 
n  141 352 1058 448 248 
n - Complete data for model 3a (%) 135 (95.74%) 343 (97.44%) 1049 (99.15%) 414 (92.41%) 194 (78.23%) 
n - Complete data for model 4b (%) - 255 (72.44%) 1039 (98.20%) 403 (89.96%) - 
Age 100.00% 100.00% 100.00% 100.00% 100.00% 
Sex 100.00% 100.00% 100.00% 100.00% 100.00% 
High-density lipoprotein cholesterol 97.16% 97.73% 99.34% 92.41% 86.69% 
Total cholesterol 99.29% 98.30% 99.34% 99.78% 100.00% 
Systolic blood pressure 98.58% 99.72% 99.81% 100.00% 99.60% 
Smoking status 100.00% 100.00% 100.00% 100.00% 91.13% 
Anti-hypertensive medication 100.00% 100.00% 100.00% 100.00% 100.00% 
Lipid lowering medication 100.00% 100.00% 100.00% 100.00% 100.00% 
Body mass index 97.87% 99.15% 99.91% 99.55% 87.50% 
Estimated glomerular filtration rate NA 99.72% 99.34% 99.78% NA 
Ethnicity 95.74% 99.72% 100.00% 100.00% 100.00% 
Social status 97.16% 75.00% 99.05% 97.77% 100.00% 
a
Model 3 adjustment covariates: age, sex, high-density lipoprotein:total cholesterol, systolic blood pressure, smoking status, anti-hypertensive medication and lipid lowering medication 
b
Model 4 adjustment covariates: age, sex, high-density lipoprotein:total cholesterol, systolic blood pressure, smoking status, anti-hypertensive medication, lipid lowering medication, 
body mass index, estimated glomerular filtration rate, ethnicity and social status  
BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; ET2DS: Edinburgh Type 2 Diabetes Study; NA: not available; SABRE: Southall and Brent Revisited 
Study; WHII: Whitehall-II Study 
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8.2 Baseline characteristics of the UCLEB cohorts 
Baseline characteristics, including traditional cardiovascular risk factors, of the five 
UCLEB cohorts used in this thesis are presented in Table 8-2. The baseline cohorts 
of BRHS, BWHHS, ET2DS, SABRE and WHII comprised 141, 352, 1058, 448 and 
248 individuals with prevalent type 2 diabetes at baseline respectively.  
At baseline in the BRHS, the average age was 69.53 years and all participants in this 
cohort were male. 76 (53.90%) participants were taking anti-hypertensive medication 
and 21 (14.89%) were taking lipid lowering medication. The vast majority of the 
cohort are white (n=132, 97.78%) and the social status of the participants was split as 
follows: 13 (9.49%) unskilled, 108 (78.83%) skilled and 16 (11.68%) professional. 
In the BWHHS, the average age at baseline was 69.47 years and all participants in 
this cohort were female. 185 (52.56%) participants were taking anti-hypertensive 
medication and 58 (16.48%) were taking lipid lowering medication. The vast 
majority of the cohort are white (n=348, 99.15%) and the social status of participants 
was split as follows: 4 (1.52%) unskilled, 193 (73.11%) skilled and 67 (25.38%) 
professional.  
The average age at baseline in the ET2DS was 67.89 and 513 (48.49%) participants 
were female. 867 (81.95%) participants were taking anti-hypertensive medication 
and 905 (85.54%) were taking lipid lowering medication. Most of the ET2DS cohort 
were white (n=1041, 98.39%) and the social status of participants was split as 
follows: 177 (16.89%) unskilled, 166 (15.84%) skilled and 705 (67.27%) 
professional.  
In SABRE, the average age at baseline was 54.24 years and only 50 (11.16%) of the 
participants were female. 102 (22.77%) participants were taking anti-hypertensive 
medication and only 3 (0.67%) were recorded as taking lipid lowering medication. 
The ethnicity of participants was broken down as follows: 87 (19.42%) white, 324 
(72.32%) Asian and 37 (8.26%) Afro-Caribbean. The social status was split as 
follows: 49 (11.19%) unskilled, 332 (75.80%) skilled and 57 (13.01%) professional.  
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Finally, the average age at baseline in WHII was 57.79 years and 77 (31.05%) 
participants were female. 80 (32.36%) participants were taking anti-hypertensive 
medication and 21 (8.47%) participants were taking lipid lowering medication. The 
ethnicity of participants was broken down as follows: 193 (77.82%) white and 55 
(22.18%) Asian. All participants in WHII were categorised as skilled in terms of 
social status which may reflect a low proportion of participants considered 
“professional” in the overall WHII study or a lower prevalence of type 2 diabetes 
among the “professional” group. 
When combined, the total number of participants available for analysis was 2247. 
992 (44.15%) participants were female and the average age at baseline was 64.41 
years. 1310 (58.30%) participants were taking anti-hypertensive medication and 
1008 (44.86%) participants were taking lipid lowering medication. In the three 
cohorts used for the final model including BMI, social status, eGFR and ethnicity 
(BWHHS, ET2DS and SABRE), 1476 (79.44%) participants were white, 337 
(18.14%) participants were Asian, 41 (2.21%) participants were Afro-Caribbean and 
3 participants were classified as “other” ethnicity. Finally, the social status of these 
three cohorts was split as follows: 230 (12.38%) unskilled, 691 (37.19%) skilled and 
829 (44.62%) professional.  
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Age (years) 69.53 ± 5.21 69.47 ± 5.68 67.89 ± 4.20 54.24 ± 6.82 57.79 ± 6.09 64.41 ± 8.07 
Sex [female] All male All female 513 (48.49) 50 (11.16) 77 (31.05) 992 (44.15) 
Total cholesterol (mmol/L) 5.60 ± 1.09 6.41 ± 1.38 4.31 ± 0.90 6.01 ± 1.10 5.97 ± 1.13 5.24 ± 1.39 
HDL cholesterol (mmol/L) 1.14 ± 0.27 1.48 ± 0.42 1.29 ± 0.36 1.18 ± 0.34 1.37 ± 0.38 1.30 ± 0.38 
sBP (mmHg) 151.80 ± 25.64 154.46 ± 26.06 133.20 ± 16.39 132.19 ± 19.26 128.74 ± 17.94 136.99 ± 21.51 
Smoking status [ever] 15 (10.64) 168 (47.73) 647 (61.15) 161 (35.94) 32 (14.16) 1023 (45.98) 
Anti-hypertensive medication [yes] 76 (53.90) 185 (52.56) 867 (81.95) 102 (22.77) 80 (32.26) 1310 (58.30) 
Lipid lowering medication [yes] 21 (14.89) 58 (16.48) 905 (85.54) 3 (0.67) 21 (8.47) 1008 (44.86) 
BMI (kg/m2) 28.16 ± 3.59 29.88 ± 5.79 31.42 ± 5.67 27.20 ± 4.07 27.01 ± 4.50 29.69 ± 5.51 
eGFR (mL/min) NA 66.56 ± 11.80 78.32 ± 23.13 97.41 ± 35.82 NA 89.73 ± 35.49 
Ethnicity       
White 132 (97.78) 348 (99.15) 1041 (98.39) 87 (19.42) 193 (77.82) 1801 (80.40) 
Asian 0 0 13 (1.24) 324 (72.32) 55 (22.18) 392 (17.50) 
Afro-Caribbean 2 (1.48) 2 (0.57) 2 (0.19) 37 (8.26) 0 43 (1.92) 
Other 1 (0.74) 1 (0.28) 2 (0.19) 0 0 4 (0.18) 
Social status       
Unskilled 13 (9.49) 4 (1.52) 177 (16.89) 49 (11.19) 0 243 (11.38) 
Skilled 108 (78.83) 193 (73.11) 166 (15.84) 332 (75.80) 248 (100) 1047 (49.04) 
Professional 16 (11.68) 67 (25.38) 705 (67.27) 57 (13.01) 0 845 (39.58) 
Data are presented as means ± SD or n (%) 
BMI: body mass index; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; NA: not available; sBP: systolic blood pressure 
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8.3 CVD in the UCLEB cohorts 
Table 8-3 shows the breakdown of both prevalent and incident cardiovascular events 
available for each of the five UCLEB cohorts. Unfortunately, the definitions of 
“incident” events across the studies and across event types was not consistent. 
Additionally, the exclusion of all participants with previous CVD in order to obtain 
incident events only would not have been possible while retaining adequate statistical 
power for subsequent analyses (see Chapter 5 for a detailed discussion of these 
issues). Therefore, the outcome of CVD was defined as either a participant having 
prevalent CVD at baseline or experiencing a fatal or non-fatal cardiovascular event 
during the study follow-up period. In the BRHS, BWHHS, ET2DS, SABRE and 
WHII cohorts there were 52 (36.88%), 174 (49.43%), 451 (42.63%), 253 (56.47%) 
and 74 (29.84%) participants with the outcome of CVD respectively, giving a total of 
1005 (44.73%) participants with CVD across all studies. 












Prevalent MI 20 (14.2) 27 (7.7) 147 (13.9) 66 (14.7) 16 (6.5) 
Prevalent 
revascularisation 
NA 10 (2.8) 107 (10.1) 1 (0.3) 5 (2.2) 
Prevalent angina NA 76 (21.6) 295 (27.9) 25 (5.6) 35 (15.2) 
Prevalent stroke 15 (10.6) 36 (10.2) 62 (5.9) 21 (4.7) 0 
Incident angina NA 70 (19.9)b 44 (4.2)b 64 (17.7)b 27 (11.0)b 
Incident fatal or non-fatal 
MI or revascularisation 
33 (23.4)a 79 (22.4)a 97 (9.2)b 212 (51.1)a 26 (12.3)a 
Incident fatal or non-fatal 
stroke 
NA 74 (21.0)a 59 (5.6)b 106 (25.6)a 13 (5.3)a 
Incident fatal or non-fatal 
CHD or stroke 
NA 127 (36.1)a 149 (14.1)b 251 (60.0)a 37 (17.5)a 
Data are presented as n (%) 
a
 Incident events defined as first event ever  
b
 Incident events defined as first event during follow-up  
BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CHD: coronary heart disease; 
ET2DS: Edinburgh Type 2 Diabetes Study; MI: myocardial infarction; NA: not available; SABRE: Southall and Brent 
Revisited Study; WHII: Whitehall-II Study 
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8.4 Descriptive statistics of metabolites 
Summaries of the distributions of each metabolite for the combined UCLEB data can 
be found in Figure C-1 in Appendix C in the form of histograms. Distributions of the 
metabolites in each individual study were investigated and found to be consistent 
with the combined results.  
Descriptive statistics, including medians, interquartile ranges (IQR) and number of 
missing values, were compared across individual studies (results presented in Table 
C-1 in Appendix C ). Medians and IQRs were found to be reasonably consistent 
across the studies. Most metabolites in the individual studies had little missing data 
(5% or less missing data per variable) and missing data ranged from zero to 347. The 
highest amount of missing data was found in the ET2DS (n=347, 32.80%) for five of 
the derived metabolites (phospholipids to total lipids ratio in very large HDL; total 
cholesterol to total lipids ratio in very large HDL; cholesterol esters to total lipids 
ratio in very large HDL; free cholesterol to total lipids ratio in very large HDL and 
triglycerides to total lipids ratio in very large HDL). These measures are all 
computed as a ratio between two different metabolites. Therefore, if the level of one 
of these metabolites is zero then the derived variable cannot be calculated and the 
value is defined as missing. As discussed previously, despite missing values in the 
metabolomics data, multilevel multiple imputation was not considered possible in 
this context and each subsequent model is calculated for the maximum number of 
metabolites available in the combined data.  
8.5 Associations between metabolites and cardiovascular 
disease in individual UCLEB studies 
In order to obtain an initial impression of associations in the data, unadjusted 
univariate models were fitted between each metabolite and the outcome of CVD for 
each UCLEB cohort separately. The results of these models are summarised using p-
values and ORs in Figure 8-1 and Figure 8-2 respectively. The results have been 
colour coded to differentiate the 11 groups of metabolites discussed in section 5.1.3.4 
of Chapter 5. As discussed in Chapter 5, a range of adjusted thresholds for statistical 
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significance are presented in Figure 8-1: a 5% FDR, a 1% FDR and a Bonferroni 
correction. 
Significant associations between any of the metabolites and CVD, according to all 
three selected significance thresholds, were found only for the ET2DS. This result 
was unsurprising given that the ET2DS was the largest cohort (n=1058) and had the 
highest number of CVD outcomes (n=451, 42.63%). The metabolites which showed 
the most convincing statistically significant associations (that is, retaining statistical 
significance even above the strictest adjustment of the Bonferroni correction) in the 
ET2DS were: one of the VLDL particles, phospholipids to total lipids ratio in 
medium VLDL particles (displayed in turquoise); two of the IDL particle, total 
cholesterol to total lipids ratio and triglycerides to total lipids ratio in IDL (displayed 
in light yellow); a number of the HDL particles (displayed in red) and lipoprotein 
particle sizes (displayed in blue); two of the apolipoproteins, apolipoprotein A1 and 
ratio of apolipoprotein B to apolipoprotein A1 (displayed in orange); and creatinine 
(displayed in light green). Although statistically significant associations were only 
found in ET2DS, the overall pattern of the p-values was similar across all five 
studies. In particular, the group of HDL particles showed a strong association with 
CVD, as well as creatinine and the inflammation metabolite glycoprotein (the 
rightmost metabolite, displayed in yellow). In the WHII cohort, strong associations 
were also observed between CVD and a number of the VLDL particles and fatty 
acids, although this relationship was not replicated in the other studies. Overall, the 
pattern of associations was fairly consistent across all five studies. 
The pattern of the effect sizes and directions of the associations was assessed using 
ORs in order to determine whether these were also consistent across the studies and 
therefore indicate that it would be reasonable to combine the data in the next stage of 
analyses. Figure 8-2 shows that results were reasonably similar across all five 
studies. It was observed in all the cohorts that the first half of the VLDL particle 
group had almost identical ORs for each measure. Initially, I thought that this could 
have been caused by the way that cases and controls had been selected in some 
studies, but after further investigation this was discovered not to be the case since 
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none of the studies used this design. The most likely explanation is that these 
metabolites essentially measure the same particle in different ways.                    
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Figure 8-1 Bar plots of p-values for univariate analysis of metabolites and cardiovascular disease in the individual UCLEB cohorts.  
Top left: BRHS; top right: BWHHS; middle left: ET2DS; middle right: SABRE; bottom left: WHII; bottom right: metabolite key. 
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Figure 8-2 Odds ratios from univariate analysis of metabolites and cardiovascular disease in the individual UCLEB cohorts.  
Top left: BRHS; top right: BWHHS; middle left: ET2DS; middle right: SABRE; bottom left: WHII; bottom right: metabolite key. 
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8.6 Associations between metabolites and CVD in the 
combined UCLEB data 
The final stage of metabolomics analysis involved combining the data from all five 
cohort studies and investigating the associations between the metabolites and CVD 
using the following four models: 
Model 1: adjusted only for cohort 
Model 2: adjusted for cohort, age and sex 
Model 3: adjusted for cohort, age, sex, HDL to total cholesterol ratio, sBP, smoking 
status, anti-hypertensive medication and lipid lowering medication 
Model 4: adjusted for cohort, age, sex, HDL to total cholesterol ratio, sBP, smoking 
status, anti-hypertensive medication, lipid lowering medication, social status, BMI, 
eGFR and ethnicity. 
The maximum n for the subsequent models is 2247 and the number of participants 
with CVD in the combined cohorts is 1005 (44.73%). Note that at the final stage of 
analysis (model 4), two of the cohort studies, BRHS and WHII, are dropped since 
eGFR was not available. 
8.6.1 Associations between metabolites and CVD adjusted for 
cohort 
The first models fitted for the combined data were adjusted only for cohort. The 
results from these models are summarised in Figure 8-3 and Figure 8-4, using p-
values and ORs respectively. Many of the metabolites remained statistically 
significantly associated with CVD even using the most stringent multiple testing 
adjustment, the Bonferroni correction. These metabolites included many of the HDL 
particles, a number of the lipoprotein particle sizes, two of the apolipoprotein 
measures and creatinine. This pattern was similar to those observed in the analyses of 
the individual studies (Figure 8-1). Similarly, the pattern of the ORs was consistent 
with the previous results. The largest effect sizes were observed for a number of the 
HDL particles and creatinine.   
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Figure 8-3 Bar plots of p-values for Model 1 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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Figure 8-4 Odds ratios from Model 1 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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8.6.2 Associations between metabolites and CVD adjusted for 
cohort, age and sex 
The next models fitted for the combined data were adjusted for age and sex as well 
as cohort. The results from these models are summarised in Figure 8-5 and Figure 
8-6. After additional adjustment for age and sex, statistically significant associations 
between CVD and many of the same metabolites persisted, even at the Bonferroni 
correction level. The association between CVD and the inflammation metabolite 
glycoprotein appeared to be strengthened following this adjustment. The pattern of 
the ORs also remained very similar to the previous results. The largest effect sizes 
were observed for a number of the HDL particles, which were negatively associated 
with CVD, and creatinine, which had a positive association with CVD. 
8.6.3 Associations between metabolites and CVD adjusted for 
cohort, age, sex and traditional cardiovascular risk factors 
Figure 8-7 and Figure 8-8 summarise the results for the models which adjusted for 
HDL to total cholesterol ratio, sBP, smoking status, lipid lowering medication and 
anti-hypertensive lowering medication, in addition to age, sex and cohort. After 
additional adjustment for these key risk factors, none of the metabolites were found 
to have statistically significant associations with CVD at the 1% FDR threshold. 
Creatinine and a number of the HDL particles were statistically significantly 
associated with CVD at the 5% FDR threshold, but only one metabolite was 
statistically significant at the Bonferroni correction level – phospholipids in small 
HDL. The strong associations between a number of the lipoprotein particle sizes and 
the apolipoproteins were drastically reduced. Again, the pattern of the ORs remained 
consistent with the previous results, although the effect directions of the VLDL 
particles and some of the HDL particles were reversed. The largest effect sizes were 
still observed for a number of the HDL particles and creatinine. 
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Figure 8-5 Bar plots of p-values for Model 2 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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Figure 8-6 Odds ratios from Model 2 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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Figure 8-7 Bar plots of p-values for Model 3 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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Figure 8-8 Odds ratios from Model 3 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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8.6.4 Associations between metabolites and CVD adjusted for 
cohort, age, sex, traditional cardiovascular risk factors, social 
status, BMI, eGFR and ethnicity 
The results of the fully adjusted models which included all previous risk factors and 
additionally social status, BMI, eGFR and ethnicity are presented in Figure 8-9 and 
Figure 8-10. After adjustment for all risk factors, and consistent with the result for 
Model 3, none of the metabolites were found to have statistically significant 
associations with CVD at the 1% FDR threshold. Creatinine was no longer 
associated with CVD, an unsurprising result since Model 4 includes eGFR which is 
calculated using creatinine values. Four metabolites, all HDL particles, were 
statistically significant at the Bonferroni correction level – concentration of medium 
HDL particles, total lipids in medium HDL, phospholipids in medium HDL and 
phospholipids in small HDL. This result is perhaps more surprising given that Model 
4 (and Model 3) included HDL to total cholesterol ratio as a covariate. The pattern of 
the ORs appeared almost identical to that from the Model 3 results. In order to check 
for heterogeneity among the five studies, interaction terms between cohort and each 
of the four metabolites most strongly associated with CVD were added to Model 3 
(the most adjusted model which included all five studies). No statistically significant 
interactions were found, indicating that there is not significant evidence of 
inconsistency of metabolite effects across the five studies.  
 
   
 134 
  
Figure 8-9 Bar plots of p-values for Model 4 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 
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Figure 8-10 Odds ratios from Model 4 analysis of metabolites and cardiovascular disease in the combined UCLEB cohorts. 




This chapter summarises the key findings of the thesis, comparing them with 
previous studies. Strengths and limitations of the research are discussed, including 
the statistical methods used. The chapter concludes with recommendations for the 
direction of future research on the topic of improving cardiovascular risk scores 
using non-traditional biomarkers. 
9.1 Key findings 
9.1.1 Improving cardiovascular risk prediction using individual and 
combined biomarkers 
In the ET2DS, a representative prospective study of older people with type 2 diabetes 
living in Scotland, it has been shown that three individual biomarkers, hs-cTnT, NT-
proBNP and ABI, were significantly associated with the risk of experiencing an 
incident or recurrent cardiovascular event. The addition of each individual biomarker 
also improved the predictive ability of a basic model based on a carefully selected 
current cardiovascular risk score, QRISK2, with the greatest improvement found for 
hs-cTnT. GGT and an inflammation factor derived from CRP, IL-6 TNF-α and 
fibrinogen were not significantly associated with incident or recurrent cardiovascular 
events, despite both marginally improving model performance. When considered in 
combination, using all subsets regression, the greatest improvement in risk prediction 
was found for a model including ABI, hs-cTnT and GGT in addition to the QRISK2 
predictors.  
9.1.2 Associations between metabolomics data and CVD 
In data from the UCLEB consortium of UK-based, prospective cohorts, a number of 
individual HDL particles out of a total of 228 metabolites measured using an NMR 
platform were significantly associated with CVD even after adjustment for a wide 
range of traditional cardiovascular risk factors (including age, sex, blood pressure, 
smoking and HDL to total cholesterol ratio). These metabolites were: concentration 
of medium HDL particles, total lipids in medium HDL, phospholipids in medium 
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HDL and phospholipids in small HDL. Creatinine was also significantly associated 
with CVD until adjustment for eGFR in the final stage of statistical modelling. 
 
9.2 Improving cardiovascular risk prediction using 
individual and combined biomarkers 
9.2.1 Strengths of the ET2DS 
9.2.1.1 Recruitment and representativeness 
One advantage of the study population of the ET2DS is that participants were 
recruited directly from a representative sampling frame of all individuals in Lothian 
with type 2 diabetes, the Lothian Diabetes Register, as opposed to a subgroup of 
people with diabetes identified from a larger study population which is the case in 
other studies on this topic (for example, van der Leeuw et al., 2016). The Lothian 
region in Scotland includes the city of Edinburgh and towns and rural locations in the 
surrounding areas, rather than recruitment from a single city or town which is also 
common in other cohort studies (Bruno et al., 2013; Kavousi et al., 2012). 
Furthermore, the study population included participants managing their type 2 
diabetes through a range of treatment methods, from diet control to insulin treatment. 
At baseline, participants in the ET2DS were broadly similar to those who chose not 
to participate, as shown by a comparison of key demographic characteristics and 
clinical features between study participants and non-respondents. Slightly more men 
than women were recruited into the study, and individuals from the least deprived 
group were overrepresented in the study, with those from the most deprived group 
underrepresented, suggesting that people from the least deprived group were more 
likely to agree to take part. However, these differences were small, and since it is 
expected that the risk factors will have similar relationships with cardiovascular 
outcomes across deprivation groups, this small degree of unrepresentativeness is not 
likely to be an issue. In general, differences in a wide range of characteristics 
indicated that the study population was largely representative of, and hence 
generalisable to, the target population.   
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9.2.1.2 Completeness and accuracy of data collection 
A key strength of the ET2DS for this type of research is that the cohort has been 
extensively phenotyped so a wide range of risk factors and biomarkers were 
available for comprehensive analyses. Data were carefully collected, following 
appropriate protocols, ensuring a relatively small amount of missing data. 
Researchers involved in the ET2DS were given appropriate training in the collection 
of data in order to ensure that accurate information was recorded. Standard operating 
procedures were followed during clinic appointments in order to reduce observer 
bias. In the laboratories, strict quality control measures were used. 
9.2.1.3 Cardiovascular follow up 
Complete data on incident or recurrent cardiovascular events during follow-up was 
vital for valid analysis of the association between biomarkers and cardiovascular 
risk. In order to reduce loss to follow-up and avoid misdiagnosis, a thorough and 
systematic approach was taken to the follow-up data collection processes at both the 
four and eight year time points. Several sources were used to identify and confirm 
events at the four-year follow-up, including self-completed questionnaires, ECGs and 
ISD data linkage. At the eight year follow-up, ISD data linkage, which captures all 
hospital discharges for patients between pre-specified dates, was used in combination 
with clinical notes to corroborate further cardiovascular events. Identification of 
events was as comprehensive as possible, although if a participant had moved outside 
of Scotland between four and eight years after baseline then an event could have 
been missed.  
9.2.1.4 Prospective design and sample size 
The prospective design of the ET2DS is preferable for risk prediction analysis, as 
discussed in section 2.1 in Chapter 2, and allowed the thorough investigation of the 
relationship between baseline risk factors and subsequent development of CVD or 
experience of cardiovascular events. A further strength of this study is the relatively 
large sample size, as the power to detect associations in the data depends strongly on 
the number of observations. In the case of risk prediction, sample size requirements 
are often thought of in terms of events per variable (Steyerberg, 2009). It has been 
suggested that the minimum number of events per variable required for accurate 
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predictions is 10, and that less than 10 events per variable may lead to over fitting, 
though this rule should be taken as an approximate guide (Harrell et al., 1984, 
Peduzzi et al., 1995, Peduzzi et al., 1996). In the analysis in this thesis, the number of 
events which occurred during follow-up (208 events) was higher than the maximum 
number required according to this rule (full model with all risk factors and 
biomarkers included 18 predictors = 180 events). 
9.2.2 Limitations of the ET2DS 
9.2.2.1 Generalisability 
The ET2DS was established, as described in Price et al., 2008, with the aim of 
investigating the relationships between potential risk factors and complications of 
type 2 diabetes such as cognitive decline, liver disease and CVD. Although, as 
discussed above, the study population was shown to be largely representative of the 
target population from which the study population was recruited, by design the 
participants recruited to the study were a group of older adults, aged between 60 and 
75 years at baseline. Furthermore, the majority of the study participants were white, 
reflecting the limited ethnic variability in the Lothian region. These two features of 
the study population result in limited generalisability of the results to other 
populations such as younger adults and people of alternative ethnicities. 
Additionally, the potential impact of healthy survivor bias (the possibility that people 
who survive to age 60 years or above may be biologically different to those not 
surviving to this age) is unknown. 
9.2.2.2 Prevalent CVD and prescription of lipid-lowering medication 
A further potential limitation of the ET2DS is the high rates of both prevalent CVD 
in the study population at baseline (n=367, 35%) and participants prescribed with 
statins, or lipid-lowering medications, at baseline (n=912, 85.55%). These 
characteristics reflect the clinical status of this group of older adults with established 
type 2 diabetes, but they also raise questions about the impact of the results of this 
type of study on clinical treatment decisions. The QRISK2 score (Hippisley-Cox et 
al., 2010), which was used to build the basic model for the analyses in this thesis, 
was developed exclusively in people without previous diagnosis of CVD and the 
NICE clinical guidelines recommend not using the risk assessment tool for people 
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with pre-existing CVD (NICE CG181, 2016). However, excluding all participants in 
the ET2DS with prevalent CVD would have severely reduced the statistical power 
for the required analyses and is also not a realistic reflection of the characteristics of 
this particular group of patients. Similarly, the QRISK2 score was developed only in 
people who were not already prescribed statins, but excluding these participants in 
the ET2DS would again severely impact on statistical power and is not reflective of 
the treatment status of this high risk group. Furthermore, a change in the intensity of 
statin treatment may be beneficial for patients with type 2 diabetes (Stone et al., 
2014) and future drug development may lead to new treatments that could be 
prescribed in addition to or instead of statins in this group. 
9.2.3 Strengths of the analysis plan 
Particular care was taken in developing the analysis plan, in order to ensure that the 
results were informative and clinically meaningful. The choice of risk score for the 
development of a basic model to which non-traditional biomarkers would be added 
was made according to a set of pre-specified characteristics (discussed in detail in the 
systematic review in Chapter 4). The key criterion was considered to be the 
requirement for recommendation of use of the score in current clinical guidelines. 
The addition of the non-traditional biomarkers to such a model therefore informs us 
of any added value of these biomarkers over and above the information that is 
currently used to make treatment decisions in clinical practice. Furthermore, the 
decision was taken to consider the full panel of additional biomarkers in 
combination, rather than focusing on one or two biomarkers which gave the strongest 
associations at the first stage of individual analysis. This avoided a prematurely 
narrow focus on any particular biomarker. Indeed, GGT was found in four of the five 
top combined models (including the top model) attained using all subsets regression, 
despite its weaker, non-significant association with cardiovascular events when 
added to the basic model alone. Although the underlying biological mechanisms 
explaining this phenomenon are unknown, the result highlights the importance of this 
unbiased approach to investigating new biomarkers. 
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9.2.4 Limitations of the analysis plan 
The results of an analysis of new predictors are dependent on the specific basic 
model which is used. Unfortunately the coefficients for the QRISK2 score were 
unavailable and this led to difficulties in building the desired basic model. 
Furthermore, the exact definitions of a number of the variables in the QRISK2 score 
and the specific methods of missing data handling are not made public and the choice 
of deprivation measurement (the Townsend score) is restricted to people living in 
England and Wales. In order to overcome some of these issues, the definition of 
CKD used was chosen as the most accurate definition for the ET2DS and the SIMD 
was used as an alternative measure of deprivation (a detailed discussion of these 
challenges and how they were overcome can be found in section 5.1.7.1 of Chapter 
5). It should be noted that the guidelines for reporting prediction models set out by 
the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) 
network specify that all predictors should be clearly defined, missing data handling 
should be described including details of imputation methods and a full prediction 
model should be presented including all regression coefficients and model intercept 
or baseline survival function (Collins et al., 2015a). Strict adherence to these 
guidelines, particularly for risk scores which are recommended in clinical guidelines, 
would allow future studies to replicate prediction scores more accurately for this type 
of research.   
9.2.5 Comparisons of findings with previous studies 
9.2.5.1 NT-proBNP 
In this thesis, high levels of NT-proBNP were strongly associated with increased risk 
of incident or recurrent cardiovascular events, independent of factors currently used 
to predict CVD, and the biomarker improved predictive performance. This finding is 
consistent with numerous previous studies in both the general population and 
diabetic populations.  
In 2009, a systematic review and meta-analysis of over 87,000 participants from 40 
long-term studies found a strong association between NT-proBNP and incident CVD, 
independent of conventional risk factors (Di Angelantonio et al., 2009). However, 
the studies used in this analysis were recruited from the general population, rather 
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than a subgroup with type 2 diabetes. Also, the choice of adjustment risk factors was 
not based on a single risk score and differed among the studies, although most 
included key factors such as age, sex, smoking status, diabetes, blood pressure and 
lipids. Only 14 studies reported a measure of model discrimination (the c-statistic) 
after the addition of NT-proBNP to a basic model, with increments in improvement 
ranging from 0.01 to 0.1. In 2012, a study of nearly 6000 participants from the 
Rotterdam Study investigated the added value of 12 new biomarkers (including NT-
proBNP, CRP and fibrinogen) to the prediction of CHD and found that NT-proBNP 
improved risk prediction (Kavousi et al., 2012). The increase in the c-statistic 
compared to the basic model was 0.02. The basic model was based on the 
Framingham Risk Score, though again this study was carried out in the general 
population rather than in people with type 2 diabetes. More recent studies in the 
general population have found similar results, with increases in the c-statistic ranging 
between 0.017 and 0.03 (Welsh et al., 2016, van der Leeuw et al., 2016). The basic 
models used in these studies were based on a variety of cardiovascular risk scores: 
QRISK2, ASSIGN and UKPDS. One contrasting result was found by Welsh et al., 
2016, in the Midspan Family Study (MFS) cohort where the addition of NT-proBNP 
resulted in no improvement to the basic model based on the ASSIGN score. Welsh et 
al., 2016, hypothesise that this result may be due to a combination of factors: poor 
statistical power, a low burden of subclinical CVD due to the young age of 
participants (aged 30 to 59 years at baseline) and a relatively high c-statistic for the 
basic model (0.752). van der Leeuw et al., 2016, also found that despite the 
improvement in the c-statistic, the number of patients successfully reclassified to a 
more appropriate risk category was limited, raising doubts about the clinical 
usefulness of adding NT-proBNP to current risk scores. Furthermore, participants 
who did not experience a cardiovascular event during follow-up were better 
reclassified using the extended model, but those who did experience an outcome 
event were given poorer reclassification, a result which is also observed in this thesis. 
This suggests that non-traditional biomarkers such as NT-proBNP may be more 
useful to assist in screening to rule out high cardiovascular risk. 
In 2015, a study of over 8000 people with abnormal blood glucose levels found that, 
of 237 cardiometabolic biomarkers, the addition of 10 identified biomarkers 
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including NT-proBNP improved the prediction of a variety of cardiovascular 
outcomes (Gerstein et al., 2015). The c-statistic for the basic model based on the 
validated INTERHEART risk score was 0.64, increasing by 0.07 to 0.71 after the 
addition of the panel of 10 biomarkers, although the contribution of NT-proBNP 
alone was not investigated. Two studies have investigated the relationship between 
NT-proBNP and cardiovascular outcomes specifically in populations with type 2 
diabetes. A study by Bruno et al., 2013, found that in nearly 2000 people with type 2 
diabetes living in a town in northwest Italy, NT-proBNP was a strong predictor of 
cardiovascular death. Models were adjusted for a range of conventional risk factors, 
though these were not based on a specific risk score, and no measures of model 
improvement such as the c-statistic or net reclassification were presented. Finally, a 
study of nearly 4000 patients with type 2 diabetes from the ADVANCE trial, which 
investigated the ability of both NT-proBNP and hs-cTNT to improve the prediction 
of fatal and non-fatal cardiovascular events, found that NT-proBNP was significantly 
associated with outcome events and improved both classification and discrimination 
over and above traditional risk factors (Hillis et al., 2014). The c-statistic improved 
by an increment of 0.04, although again the basic model was not based on a specific 
risk cardiovascular risk score. 
9.2.5.2 hs-cTnT 
High levels of hs-cTnT were also strongly associated with increased risk of incident 
or recurrent CV events and predictive performance was improved, a finding which is 
consistent with some recent studies, but not all. 
The study by Hillis et al., 2014, found that the addition of hs-cTnT improved the c-
statistic by an increment of 0.024 compared to a basic model based on traditional risk 
factors in people with type 2 diabetes. This study also found that the combination of 
both hs-cTnT and NT-proBNP gave the optimal risk discrimination, suggesting that a 
combination of a few additional biomarkers may provide the best model 
improvement compared to individual biomarkers, as observed in the results in this 
thesis. By contrast, Welsh et al., 2016, found no improvement in risk models after the 
addition of hs-cTnT in both the MFS and BRHS cohorts, although as noted above 
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these studies were both carried out in the general population and the MFS cohort is 
potentially under-powered for this type of analysis.  
9.2.5.3 ABI 
In this thesis, ABI was negatively associated with cardiovascular risk, although the 
relationship was weaker than that for NT-proBNP or hs-cTnT. This result is 
consistent with a number of general population studies which have found modest 
improvements in risk prediction after the addition of ABI. 
In 2010, a study of nearly 7000 participants from the Multi-Ethnic Study of 
Atherosclerosis (MESA) cohort with no previous history of CVD found that ABI 
was associated with CVD and significantly improved risk discrimination (Criqui et 
al., 2010). The basic model was adjusted for both conventional risk factors such as 
age, sex, smoking, blood pressure and lipids and for newer biomarkers including 
CRP, IL-6 and fibrinogen, and the increase in the c-statistic following the addition of 
ABI was 0.01. Subsequently, a meta-analysis including nearly 45,000 participants 
from 18 different studies suggested that, in the general population, measuring ABI 
may improve CV risk prediction beyond the Framingham Risk Score (Fowkes et al., 
2014). A small increase in the c-statistic (+0.013) was observed for men, while a 
larger increase (+0.112) was found for women. Finally, a general population study of 
over 11,000 participants from the Atherosclerosis Risk in Communities Study 
(ARIC) cohort indicated that ABI has a small effect on cardiovascular risk with an 
increase of 0.002 in the c-statistic after the addition of ABI to a basic model based on 
available Framingham Risk Score variables (Murphy et al., 2012). Net 
reclassification improved, though non-significantly, and the authors note that ABI 
only improved risk prediction if the basic model was weak. 
9.2.5.4 GGT 
In the ET2DS, GGT was not significantly associated with outcome cardiovascular 
events, although the c-statistics did improve incrementally. The conclusions 
regarding GGT and cardiovascular risk have been mixed in the literature.  
In 2005, a study of over 160,000 participants found that GGT was independently 
associated with cardiovascular mortality over and above conventional risk factors, 
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although no measures of model improvement were reported (Ruttmann et al., 2005). 
A recent general population cohort study of over 2500 patients with acute coronary 
syndrome found that GGT was associated with increased risk of all-cause mortality 
but not cardiac mortality (Ndrepepa et al., 2016). After the addition of GGT to a 
basic model including conventional risk factors such as age, sex, diabetes and 
smoking, the c-statistic improved by 0.002 and 0.007 for the outcomes of cardiac 
mortality and all-cause mortality respectively. Similarly, the PREVEND prospective 
cohort study reported that in nearly 7000 participants adding GGT to conventional 
cardiovascular risk factors did not improve the prediction of first-ever cardiovascular 
events in the general population (Kunutsor et al., 2015).  
A recent experimental model carried out in mice has suggested that statins 
significantly decrease the expression of GGT in atherosclerotic plaques (Li et al., 
2014). This could explain why in this thesis, where approximately 86% of 
participants were prescribed statins at baseline, GGT was not significantly associated 
with cardiovascular events when added to the basic model alone. In contrast, GGT 
was selected as one of a panel of biomarkers which gave the best improvement in 
prediction, although, as noted previously, more research is required in order to 
understand the biological mechanism underlying this result. 
9.2.5.5 Inflammation factor 
Finally, in the ET2DS, the inflammation factor g was not significantly associated 
with outcome cardiovascular events, although the c-statistic did improve marginally. 
A number of recent cohort studies and meta-analyses have investigated the role of 
the four inflammatory biomarkers used to create this factor (CRP, IL-6, TNF-α and 
fibrinogen) in cardiovascular risk prediction. These studies have shown that adding 
such biomarkers to current cardiovascular risk scores has only a moderate to weak 
effect in both general and diabetic populations. 
In 2010, a study of over 2000 older adults (aged 70-79 at baseline) with no previous 
CVD found a moderate association between IL-6 and a range of cardiovascular 
outcomes, but weaker associations for both CRP and TNF-α in the general 
population (Rodondi et al., 2010). The c-statistic for the basic model based on the 
Framingham Risk Score was 0.631, increasing by 0.019, 0.007 and 0.016 for IL-6, 
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CRP and TNF-α respectively. Similar to the study of NT-proBNP by van der Leeuw 
et al., 2016, patients who did experience a cardiovascular event were given poorer 
reclassification after the addition of these biomarkers, whereas people who did not 
experience an event were better classified. van der Leeuw et al., 2016, also explored 
the role of CRP in cardiovascular risk prediction. However, they found that, although 
CRP was significantly associated with cardiovascular events, it lacked the ability to 
improve risk prediction in people with type 2 diabetes. Similarly, Bruno et al., 2013, 
found that CRP was not an independent predictor of cardiovascular mortality in 
people with type 2 diabetes. 
A meta-analysis carried out in 2012 investigated the association between first 
cardiovascular events and both CRP and fibrinogen (Emerging Risk Factors et al., 
2014). In over 240,000 participants without previous CVD from 52 prospective 
studies, the c-statistic was found to increase by 0.0039 and 0.0027 after the addition 
of CRP and fibrinogen respectively to a basic model including predictors commonly 
used in standard risk scores. The study by Kavousi et al., 2012, discussed above in 
relation to NT-proBNP, also investigated CRP and fibrinogen and found that the 
improvement in the c-statistic following the addition of CRP was not significant 
(95% CI for change in c-statistic: -0.01, 0.00) and was only marginal following the 
addition of fibrinogen (CI: 0.00, 0.01). 
Finally, a study of over 5500 patients with atrial fibrillation found that, after 
adjustment for clinical risk factors plus non-traditional biomarkers (including NT-
proBNP and troponin), IL-6 was related to vascular mortality and CRP was 
associated with MI, but fibrinogen was not related to any cardiovascular outcomes 
(Aulin et al., 2015). IL-6 was found to be the strongest biomarker from this group of 
three inflammatory biomarkers, with an increase in the c-statistic of 0.067. 
9.3 Associations between metabolomics data and CVD 
9.3.1 Strengths of the UCLEB consortium studies 
9.3.1.1 Sample size 
Using combined data from the five UCLEB cohorts resulted in enhanced statistical 
power to test for associations across a large number of potential predictors, while 
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also adjusting for a range of important cardiovascular risk factors. The number of 
participants with type 2 diabetes available for analysis (n=2247) was over double the 
number that would have been available using just the ET2DS cohort alone (n=1058). 
The number of CVD outcomes was also large (n=1005), again over double the 
number of CVD outcomes in the ET2DS cohort (n=451). In terms of events per 
variable, this number was more than sufficient (full model with 12 risk factors plus 
one metabolite = minimum 130 events desirable). Multiple testing corrections were 
implemented in order to account for the number of tests performed. 
9.3.1.2 Risk factors available 
A wide range of baseline risk factors were available in all the UCLEB studies, 
including key cardiovascular risk factors such as smoking status, blood pressure, 
lipids, ethnicity and social status. This allowed for a final model which was adjusted 
for an extensive group of predictors which are commonly used in current 
cardiovascular risk scores.  
9.3.1.3 Analysis plan 
The exploratory association analysis carried out in this section of the thesis 
considered the full NMR metabolomics panel of 228 metabolites. Although initially I 
planned to undertake a prediction analysis using these data, limitations of the data 
(including numbers of cardiovascular events, inconsistent discrimination between 
prevalent, recurrent and incident events between studies and differing definitions 
used for key risk factors, as discussed below), meant that this was not ultimately 
possible. The analysis undertaken does however generate hypotheses for future work 
in this area and is a novel contribution to previous and on-going analyses based on 
metabolomics data, many of which have focused on one particular group of 
metabolites, or indeed a single metabolite.  
9.3.2 Limitations of the UCLEB consortium data 
9.3.2.1 Definition of outcome 
The definition of the outcome for this analysis was given as CVD diagnosed at 
baseline or developed during the study follow-up period, in order to investigate the 
cross-sectional associations between metabolomics data and CVD. However, for the 
study of risk prediction, it is of course desirable to have an outcome based only on 
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incident cardiovascular events which are experienced during follow-up. It was not 
possible to carry out such an analysis in the UCLEB cohorts, since full event 
information was not available for all the studies – recurrent cardiovascular events 
were not shared for any study except ET2DS, so the outcome would have had to be 
restricted to truly incident events and people with prevalent CVD excluded. This 
would have drastically reduced the statistical power to investigate any associations.  
9.3.2.2 Risk factor definitions and availability of variables 
As discussed in the previous sections, a wide range of cardiovascular risk factors 
were available in the UCLEB cohorts used in this thesis. However, a measure of 
kidney function (eGFR) was not available in two of the cohorts: BRHS and WHII. 
Since it is well-established that impaired kidney function is an important risk factor 
for CVD (Di Angelantonio et al., 2010, Gansevoort et al., 2013) and as many 
cardiovascular risk scores designed specifically for people with type 2 diabetes 
include a measure of kidney function as a predictor (Folsom et al., 2003, Yang et al., 
2008b, Hippisley-Cox et al., 2010), it was considered an important variable to 
include in the final model (Model 4). This resulted in the two cohorts, BRHS and 
WHII, for whom this variable was not available, being dropped from Model 4. 
Although these were not the largest contributing cohorts in terms of sample size, it is 
likely that this had an impact on the statistical power for the final stage of analysis. 
Finally, the majority of the definitions for the available variables were harmonised 
across all UCLEB cohorts, with the exception of the social status variable. As 
discussed in detail in section 5.2.7 of Chapter 5, the social status variable was 
described according to a set of six occupation categories defined by UCLEB in three 
of the studies (BRHS, BWHHS and SABRE), five occupation categories in the 
ET2DS and three categories in WHII. Furthermore, these categories did not have 
particularly similar definitions between studies. In order to include social status in 
Model 4, social status was collapsed into three general groups (unskilled, skilled and 
professional) and individual categories in each study were matched as closely as 
possible with these groups. It is accepted that this simplifies the information captured 
by this variable and that assumptions have been made about the equivalence of some 
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groups. Ideally a uniformly defined variable for all UCLEB studies, with categories 
chosen in advance, would be used in this type of analysis. 
9.3.3 Comparisons of findings with previous studies 
In five studies from the UCLEB consortium, HDL particles were found to have the 
strongest association with CVD from a panel of 228 metabolites. This is consistent 
with previous studies which have suggested that novel HDL biomarkers may have 
strong relationships with CVD. HDL is one of five major groups of lipoproteins, 
complex particles consisting of both lipid and protein components. It is known to be 
atheroprotective and is non-uniform in structure, composition and function (Wurtz et 
al., 2011). Measures of HDL quality, for example particle size, subclass distribution 
and functionality can be obtained in addition to commonly measured components 
such as cholesterol (Camont et al., 2013). Furthermore, it has been proposed that 
HDL cholesterol may not be the best clinical summary of HDL (Würtz et al., 2012). 
In particular, in this thesis, four HDL particles were found to be significantly 
associated with CVD even after adjustment for a wide range of cardiovascular risk 
factors commonly used in current risk scores including lipids and at a stringent 
threshold for multiple comparisons (the Bonferroni correction): concentration of 
medium HDL particles, total lipids in medium HDL and phospholipids in medium 
and small HDL. This finding requires further replication and investigation in order to 
understand the underlying biological mechanisms, although recent papers have 
suggested that HDL cholesterol is not the strongest component of HDL. In the HDL 
lipidome, it is phospholipids that are the strongest element, constituting between 40-
60% of the total lipid weight (Kontush et al., 2013). This may explain why the 
phospholipids remained strongly associated with CVD despite adjustment for HDL 
cholesterol in both Models 3 and 4. Although further work is required in order to 
establish whether novel HDL biomarkers are superior to serum HDL cholesterol for 
risk prediction, a few recent papers indicate that this may well be the case (Rader and 
Hovingh, 2014, Mora et al., 2013, Würtz et al., 2012). In 2012, a study of 1595 
participants from the Cardiovascular Risk in Young Finns Study found that, of 56 
NMR metabolites, four improved the prediction of subclinical atherosclerosis when 
replacing total and HDL cholesterol in the Framingham Risk Score (Würtz et al., 
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2012). These four biomarkers included NMR-determined medium HDL, although it 
was noted that no single metabolite improved risk discrimination alone and that the 
young age of the participants (aged 24-39 years at baseline) prevented the 
investigation of hard cardiovascular outcomes. Mora et al., 2013, found that in over 
10,000 participants from the JUPITER trial, HDL particle number had a significant 
association with CVD which was stronger than that for HDL cholesterol, although it 
should be noted that criticisms have been made regarding the collection of 
cardiovascular event data and the short follow-up time (approximately 2 years) in 
this trial (de Lorgeril et al., 2010). Previous studies suggest that HDL particle 
number is less influenced by complex issues such as insulin resistance, abdominal 
obesity and inflammation, which strongly correlate with HDL cholesterol (Vergeer et 
al., 2010, Mackey et al., 2012), which suggests that HDL particle number may be a 
more useful biomarker for people with diabetes. 
Finally, the NMR technique has been shown to provide more accurate measurements 
of commonly used biomarkers such as total cholesterol (Würtz et al., 2012), which 
makes this platform a promising tool for future risk prediction measurements. 
9.4 Risk prediction methods 
9.4.1 Impact of the choice of statistical method 
The choice of statistical methods has an influence on the results presented in this 
thesis and this should be taken into account during the interpretation. In Chapter 7, 
the net reclassification was calculated according to pre-specified cardiovascular risk 
categories: 0-10%, 10-20% and >20% risk. These thresholds were selected based on 
the current and previous guidelines for statin prescription. Currently, it is 
recommended that patients with a 10% or greater 10-year risk of developing CVD 
should be offered statins (NICE CG181, 2016), although until 2014 this threshold 
was 20% (Rabar et al., 2014). It is possible that this could change again in the future, 
since concerns remain regarding issues such as unwanted side effects and the 
treatment adherence by patients who consider themselves healthy (Majeed, 2014). 
Risk prediction research should aim to reflect the current clinical practice in order for 
results to be clinically relevant, although this may require updating of reclassification 
measures should clinical guidelines change. Furthermore, recently Welsh et al., 2016, 
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noted that the clinical usefulness of new biomarkers added to current risk scores 
depends on the chosen risk thresholds and that this is particularly important in light 
of changing clinical guidelines since a reduction in risk thresholds leads to a decrease 
in specificity (the probability of predicting “no event” among those patients who do 
not experience the outcome of interest).  
The choice of multiple correction adjustment method has a substantial impact on the 
interpretation of the type of analysis carried out in Chapter 8. Since this section of 
the thesis was an exploratory analysis, the choice of just one threshold for adjusted 
statistical significance was concerning as this would have split the metabolites into 
two distinct groups: “significant” and “not-significant”. At this early stage of 
metabolomics analysis, this was not considered desirable, therefore three thresholds 
have been presented, ranging from a stringent control (the Bonferroni correction) to a 
more lenient control (a 5% FDR). Although four metabolites in particular have been 
discussed above (those that remained significant at the strictest adjustment threshold 
and after full risk factor adjustment) I would recommend that the full panel of 
metabolites is retained for further investigation. 
Finally, in Chapter 7, an all subsets regression was carried out in order to select the 
top models from all possible combinations of additional biomarkers. The AIC was 
used as the pre-specified statistic to identify the top models, although, as discussed in 
Chapter 2, the choice of statistic can result in different “best” models (Steyerberg, 
2009). For this reason, a number of top models were investigated further using more 
detailed model evaluation methods such as the c-statistic and net reclassification. 
9.4.2 Model evaluation measures 
Recently, the choice of model evaluation measures in risk prediction modelling has 
been debated (see Chapter 2). There is no clear consensus as to which measure, or 
measures, should be reported for new risk prediction models. Therefore, the decision 
was made to present a range of measures in this thesis, while reflecting on the 
various advantages and disadvantages of these methods. Modest improvements were 
observed for the c-statistic in Chapter 7, despite strong associations between some of 
the biomarkers and cardiovascular events even after adjustment for a current 
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cardiovascular risk score, in particular for hs-cTnT. This phenomenon of the 
insensitivity of the c-statistic to new biomarkers has been well-established in the 
literature and is particularly noticeable when the basic model includes strong 
predictors (Cook, 2008). Overall though, the c-statistic is still considered to provide 
useful information and is popular in publications, almost certainly because it is well-
recognised and understood.  
In order to evaluate the clinical usefulness of a new prediction model, more recently 
it has been suggested that a measure of reclassification should be reported in addition 
to the c-statistic. The NRI (or IDI) is a popular measure in recent publications, 
however this measure is difficult to interpret and may not be very clinically 
informative (Kerr et al., 2014). Instead of the combined NRI, two measures of net 
reclassification which are used to calculated the NRI have been reported in this 
thesis: the proportion of people given more accurate risk classification after the 
addition of one or more biomarkers for people who did not experience a 
cardiovascular event and the proportion of people given more accurate risk 
classification among those who did experience an event. These measures inform us 
of the number of people who would be given better or worse risk classification using 
the new model, which has clear implications for clinical practice. However this 
decision also made the results in this thesis difficult to compare with previous studies 
unless full reclassification tables had been reported, allowing for equivalent measures 
to be calculated. I would recommend that either the two measures of net 
reclassification or the full reclassification tables are reported for future studies on this 
subject. 
9.4.3 Development of software for complex methods 
Lastly, the development of software for complex statistical methods had an impact 
on the methods used in this thesis, and therefore the final results. For example, the 
use of multiple imputation methods for missing data may have been preferable in the 
analysis of the metabolomics data. However, as discussed in Chapter 8, the 
implementation of the required methods for this context of combined data (multi-
level multiple imputations) is still under development and, if used incorrectly, such 
methods can bias the final results. For the analysis of metabolomics data, it is noted 
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in recent literature that technical issues such as statistical analysis still need to be 
overcome in order to fully understand the relationships between these biomarkers 
and CVD (Kontush et al., 2013). 
9.5 Recommendations for future research 
To conclude, my recommendations for future research on the topics studied in this 
thesis are as follows: 
9.5.1 Improving cardiovascular risk prediction using individual and 
combined biomarkers 
1. This thesis found that three non-traditional biomarkers (ABI, NT-proBNP and 
hs-cTnT) added value to a basic model based on a current cardiovascular risk 
score when incorporated individually, and that a combination of three 
biomarkers (ABI, hs-cTnT and GGT) added to such a model provided the best 
improvement. External validation of these results in larger studies is required 
before any of these promising biomarkers could be added to current risk scores. 
In order to expand the generalisability of future results, such cohorts should 
include younger adults, a wider variety of ethnicities and, if enough 
cardiovascular events are captured, restrict analyses to people with no previous 
CVD. 
2. Further large studies are also required in order to establish the clinical 
significance of these results and the cost effectiveness of incorporating new 
biomarkers into cardiovascular risk scores. 
3. It would also be interesting to investigate the associations and added predictive 
value of these biomarkers in subgroups of the CVD outcome, such as CHD 
(angina and MI) or cerebrovascular disease (stroke and TIA), since there may be 
differences between these types of CVD. This will require a much greater 
number of events for adequate statistical power than are available in the ET2DS. 
4. The findings in this thesis highlight the need for thorough and consistent 
reporting of clinical risk prediction models and their evaluation. Although 
practice has improved over the last few decades and recent guidelines have been 
set for the publication of such scores (Moons et al., 2009, Collins et al., 2015b), 
these are not always followed. Adherence to such rules is vital for external 
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validation and the investigation of new biomarkers, particularly for risk scores 
which are used in clinical settings. Consistent use of model evaluation measures 
would also allow for more direct comparisons among studies. 
9.5.2 Associations between metabolomics data and CVD 
1. The research presented in this thesis found that certain metabolites, in particular 
from the HDL particle subclass, are strongly associated with CVD even after 
adjustment for risk factors used in cardiovascular risk scores and at a strict 
adjustment of statistical significance. However, the univariate method used in 
this thesis does not take into account the correlations between the metabolites, 
which can be strong, particularly among the same subclasses. Therefore, I would 
propose that the next step in this analysis should use a variable selection method 
such as LASSO regression to select a panel of metabolites which most strongly 
associate with CVD, while accounting for correlations between them. I would 
recommend LASSO regression since it is known to return a relatively large 
panel of predictors compared to other variable selection methods and this 
research is still in its preliminary stages. 
2. This analysis then needs to be validated in larger studies, for example using 
cohorts in the COnsortium of METabolomics Studies (COMETS) of which 
UCLEB is a constituent member (COMETS, 2015). This will provide a much 
greater number of cardiovascular events and allow analysis to be restricted to 
incident events, which is preferable for risk prediction. A greater number of 
outcomes might also allow for the study of people with no previous CVD, 
although this will depend on statistical power. 
3. Promising metabolites which are discovered through the previous suggested 
steps can then be investigated following a similar thorough approach as the one 
taken for the non-traditional biomarkers in Chapter 7 of this thesis, adding such 
metabolites to a current cardiovascular risk score and comparing them to other 
new biomarkers.  
4. Since NMR spectroscopy is potentially more accurate at quantifying lipids than 
traditional lipid measurement, and is relatively cheap to carry out, it would also 
be worth exploring whether any metabolite on its own can produce the same, or 
even improved, levels of risk prediction as current scores. 
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5. Finally, once promising metabolites have been fully investigated it would be of 
interest to determine why they are predictive of CVD and whether the 
relationships can inform us about the underlying biological mechanisms of 
CVD. 
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To compare the impact of eight non-traditional biomarkers (ankle brachial pressure index 
(ABI), N-terminal pro-brain natriuretic peptide (NT-proBNP), high sensitivity cardiac 
troponin (hs-cTnT), gamma-glutamyl transpeptidase (GGT) and four markers of systemic 
inflammation), both individually and in combination, on cardiovascular risk prediction over 
and above the QRISK2 score in older people with type 2 diabetes. 
Study design and setting 
Prospective study of 1066 men and women aged 60-75 years with type 2 diabetes mellitus, 
living in Lothian, Scotland.    
Results 
After 8 years, 205 cardiovascular events occurred.  Baseline hs-cTNT, NT-proBNP and ABI, 
but not GGT or an inflammatory factor on their own, independently improved cardiovascular 
risk prediction beyond QRISK2.  Increases in C statistic (from 0.722; 95% CI 0.681, 0.763 
for the basic QRISK2 model) were greatest for hs-cTnT (to 0.732; 0.690, 0.774)) and NT-
proBNP (to 0.726; 0.685, 0.767).  Models combining biomarkers had greater C statistics, 
with the highest for ABI, hs-cTnT and GGT combined (0.740; 0.699, 0.781). 
Conclusions 
Of a range of eight potentially useful biomarkers, NT-proBNP and hs-cTnT on their own 
appear to be the most promising in terms of improving vascular risk prediction in people with 
type 2 diabetes.  Combining biomarkers adds further predictive value.   Future studies should 
evaluate the clinical benefit versus cost of adding multiple biomarkers to existing risk scores.  
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Introduction 
The risk of cardiovascular (CV) disease increases two-fold in people with type 2 diabetes (1). 
In the UK, the National Institute for Health and Care Excellence (NICE) clinical guidelines 
recommend the use of the QRISK2 score (2) to calculate 10-year CV risk; this score 
combines several traditional CV risk factors and has been validated in patients with and 
without type 2 diabetes (3). Numerous CV risk scores have been recommended worldwide, 
but in general all current scores appear to perform inadequately in people with type 2 
diabetes, either under- or over-estimating risk of CV events (4-6). Although people with type 
2 diabetes are routinely offered lifestyle advice and treatment with lipid-lowering agents after 
diagnosis, better risk stratification may allow targeted use of aggressive prevention strategies. 
Increasing numbers of studies have suggested biomarkers which might improve vascular risk 
prediction scores in the general populations, and, to a lesser extent, in diabetic study 
populations (7-12). However, such studies have tended to look at the addition of single risk 
factors over-and-above a small panel of traditional risk factors (or an established risk score 
based on such traditional risk factors). A direct comparison of the value of different non-
traditional biomarkers has not been well evaluated within the setting of a single 
epidemiological study. Similarly, the value of different combinations of the most promising 
biomarkers has not been well studied.   
The aim of the current research was to compare the addition of a number of different 
biomarkers to a vascular risk score currently recommended for clinical use in people with 
diabetes in the UK (QRISK2), and to investigate the extent to which different combinations 
of these various biomarkers might improve prediction. The biomarkers selected included 
those identified in previous research, especially those which might be of particular 
importance in diabetes (such as inflammatory markers which are generally raised in people 
with diabetes as part of a pro-inflammatory state). Since the overall aim was to provide 
results which would be informative for potential application in a clinical setting, biomarkers 
selected were also restricted to those which can be relatively easily measured in a routine 
clinic setting, either by means of a blood test (N-terminal prohormone of brain natriuretic 
peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), gamma-glutamyl 
transpeptidase (GGT) and markers of systemic inflammation such as C-reactive protein 
(CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and fibrinogen) or by means 
of a straightforward physical test (the ankle brachial pressure index (ABI).   





The study population constituted the Edinburgh Type 2 Diabetes Study (ET2DS), a 
population-based, prospective cohort of 1066 men and women aged between 60 and 75 years 
with established type 2 diabetes mellitus living in the Lothian region of Scotland, UK. In 
2006/2007, participants were recruited at random from the Lothian Diabetes Register (LDR), 
a registry of almost all people with type 2 diabetes living in Lothian, resulting in a cohort 
largely representative of this target population (13) and including patients attending both 
general practice and secondary care for routine diabetes healthcare. Recruitment and data 
collection at baseline have been described in detail previously (14). In 2011 (4 year follow- 
up) and 2015 (8 year follow up), all surviving participants were re-assessed for CV events. 
Use of routine data sources (record linkage to hospital discharge records and death 
certificates) and GP/hospital notes, as well as direct patient contact in 2011, ensured that 
follow-up included all ET2DS participants.  
All study participants gave their informed consent and ethical approval was granted by the 
Lothian Medical Research Ethics Committee. 
Baseline examination and data collection 
At baseline research clinics, a questionnaire was used for self-reporting of age, sex, history of 
diabetes and CVD, other medical conditions (including atrial fibrillation and rheumatoid 
arthritis), medication and smoking habits. Height and weight (for calculation of body mass 
index, BMI), brachial BP and a 12-lead ECG were measured. A fasting blood sample was 
taken for measurement of total and HDL-cholesterol and creatinine. To measure the ABI, a 
sphygmomanometer cuff was placed around the arm and inflated to 30mmHg above the 
estimated systolic BP. The pressure was reduced at a rate of 2-3mmHg per second and the BP 
was recorded when the first clear sound was detected. This process was repeated in both arms 
and both ankles (dorsalis pedis and posterior tibial arteries) using a Doppler probe and 
subsequently ABI was calculated as the lowest ankle pressure divided by the highest brachial 
pressure. Data collected in the research clinics was supplemented by linkage to all medical 
and surgical discharge records from Scottish hospitals since 1981 (collated by Information 
Services Division (ISD) of National Health Service (NHS) Scotland), routine biochemistry 
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data extracted from the LDR (for diagnosis of chronic kidney disease (CKD)) and scrutiny of 
medical records by an expert clinician as required to confirm or refute clinical diagnoses.   
Determination of circulating biomarkers 
Plasma from fasting venous blood samples taken at baseline was frozen for storage. Plasma 
NT-proBNP and hs-cTNT were subsequently measured using the Elecsys 2010 
electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK), and calibrated 
using the manufacturer’s reagents. The manufacturer’s controls were used with limits of 
acceptability defined by the manufacturer. GGT was analysed using a Vitros Fusion 
chemistry system (Ortho Clinical Diagnostics, High Wycombe, UK) at the Western General 
Hospital, Edinburgh, UK. Assays for plasma TNF-α, IL-6, CRP and fibrinogen were carried 
out in the University Department of Medicine, Glasgow Royal Infirmary. TNF-α and IL-6 
antigen levels were determined using high-sensitivity ELISA kits (R&D Systems, Oxon, 
UK). CRP was assayed using a high-sensitivity immunonephelometric assay. Fibrinogen 
assays were performed using stored plasma anticoagulated with trisodium citrate and the 
automated Clauss assay (MDA-180 coagulometer, Organon Teknika). 
Assessment of CVD events 
At baseline, data were collected on self-reporting of a doctor’s diagnosis of CVD, the WHO 
chest pain questionnaire and ECG findings. Data were also obtained from the Information 
Services Division (ISD) of National Health Service (NHS) Scotland on all medical and 
surgical discharge records from Scottish hospitals since 1981 and all ICD-10 codes for CVD 
were extracted. Using pre-defined criteria (13), these data were combined to assess prevalent 
CVD at baseline (MI, angina, transient ischaemic attack (TIA), stroke and coronary 
intervention). 
Data on new CV events were collected four and eight years after recruitment. A combination 
of self-report and GP questionnaires plus ECG completed at year four, together with ISD 
record linkage for hospital discharge and death certificate data and review of clinical case 
notes at both four and eight years were used to define outcome events. Criteria for fatal and 
non-fatal events were as follows. MI: (1) ICD-10 code for new MI (I21-I23, I252) on 
discharge/death record, dated after baseline; codes confirmed by self-reported doctor 
diagnosis of MI, positive WHO chest pain questionnaire for MI, report of MI on GP 
questionnaire, or new ECG changes (for events by year 4) or by inspection of clinical notes 
(for events by year 8 where the relevant code was not a primary diagnosis or cause of death). 
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Angina: (1) ICD-10 code for angina (I20-I25) as primary diagnosis on hospital discharge 
record, dated after baseline, with no previous indication of angina; or (2) at least two of (a) 
self-reported doctor diagnosis of angina or new angina medication since baseline, (b) ECG 
codes for ischaemia that were not present at baseline and (c) positive WHO chest pain 
questionnaire. Fatal ischaemic heart disease (IHD): subject did not meet any of the criteria for 
fatal MI and had an ICD-10 code for IHD (I209, I249, I258, I259) as primary cause of death. 
Stroke: (1) ICD-10 code for stroke (I61, I63-I66, I679, I694) as primary diagnosis on 
discharge/death record, dated after baseline; or (2) self-report of stroke or non-primary ICD-
10 discharge/death code for stroke dated after baseline, both confirmed on scrutiny of clinical 
notes. TIA: (1) ICD-10 code for TIA (G45, G659) as primary diagnosis on discharge record; 
or (2) self-report of stroke or non-primary ICD-10 discharge code for stroke or TIA dated 
after baseline, confirmed as TIA on scrutiny of clinical notes. Coronary intervention: OPCS 
operation code for coronary intervention (K40-K44, K49) on discharge record.  
Statistical analysis 
The distributions of ABI, NT-proBNP, hs-cTNT, Gamma-GT, TNF-α, CRP and IL-6 were 
skewed and therefore a log-transformation (using the natural logarithm) was used in all 
analyses. ABI has a reverse J-shaped relationship with CV risk and values greater than 1.4 
measure medial arterial calcinosis rather than atherosclerosis, so in line with previous studies 
(29) participants with an ABI > 1 .4 (n=17) were omitted from analyses. For skewed 
biomarkers, medians with interquartile ranges (IQR) are given; all other continuous variables 
summarised using means and standard deviations (SD); categorical variables are given as 
total numbers with corresponding percentages. The Pearson correlation coefficient r and test 
of association were used to assess the relationships between the biomarkers.  
The four inflammation biomarkers (TNF-α, CRP, IL-6 and fibrinogen) were combined into 
one general inflammation factor using an unrotated principal components analysis. All four 
markers loaded quite strongly onto the first principal component (0.44–0.80), which 
explained 49% of the total variability, and this was used to calculate the general inflammation 
factor, g.  
An incident CV event was defined as the first CV event (fatal or non-fatal MI or stroke, fatal 
IHD, angina, TIA or coronary intervention) occurring after baseline. Baseline CV risk factors 
selected for model adjustment (age, sex, smoking, atrial fibrillation, rheumatoid arthritis, 
hypertension, CKD, BMI, sBP, total:HDL cholesterol and social status) were those included 
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in the QRISK2 score (2), except for family history of CV disease, which was not available in 
the ET2DS. The corresponding coefficients were estimated directly from the ET2DS data. 
Smoking was categorised as: non-smoker, ex-smoker, <10 cigarettes/day, 10-19 
cigarettes/day and 20+ cigarettes/day; rheumatoid arthritis was recorded from a combination 
of self-report and linkage to ISD medical and surgical  discharge records; atrial fibrillation 
(AF) was recorded if a subject self-reported use of digoxin, had the relevant hospital 
discharge code or AF was present on ECG; hypertension was defined as self-report of anti-
hypertensive medication; CKD was defined as an estimated glomerular filtration rate (eGFR) 
<60ml/min on 2 of three consecutive measurements in the 12 to 24 months prior to baseline, 
to replicate doctor diagnosis of CKD used in QRISK2 Social status was categorised using the 
Scottish Index of Multiple Deprivation (SIMD), a composite index combining 38 indicators 
across seven domains (income, employment, health, education, skills and training, housing 
geographic access and crime), assigned according to post code (15). Baseline CVD status and 
lipid lowering medication were also included in the basic model, whereas in QRISK2, 
subjects with prior CVD or taking statins were excluded. 
Binary logistic regression models were used to evaluate the relationships between each 
biomarker and CV events and results were summarised by odds ratios (OR) with 
corresponding 95% confidence intervals (CI) and p values. Logistic regression was chosen in 
favour of Cox regression to avoid invalid assumptions (proportional hazards) about the data, 
although a sensitivity analysis was carried out using Cox regression for the basic model and 
models incorporating the individual biomarker and the results were found to be consistent in 
terms of the statistical significance of individual hazards ratios and the sizes of the hazard 
ratio for each biomarker relative to the others. The added predictive value of including each 
biomarker in the model, over and above conventional predictors, was assessed. The C statistic 
was calculated for all models to provide a measure of model discrimination, the model’s 
ability to distinguish between those who do or do not experience an event (ranging from 0.5, 
indicating no discriminative ability, to 1, indicating perfect discrimination). Corresponding 
95% CIs are presented as an indication of statistical significance. The net reclassification 
index (NRI) was calculated, as well as the net reclassification (NR) separately for participants 
who did experience a CV event and those who did not. The NR compares two models (here, 
the basic model including only conventional CV risk factors and a new model incorporating 
one or more biomarkers) and gives the increase or decrease in the proportion of subjects 
correctly classified by the new model, according to pre-specified CV risk categories (0-10%, 
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10-20% and >20%). Calibration, the model’s ability to correctly estimate the risk of a future 
event, was assessed using the Hosmer-Lemeshow test (null hypothesis assumes a well-
calibrated model, therefore p-value > 0.05 indicates good calibration). All subsets regression 
was used to compare all possible combinations of biomarkers and obtain the best five models, 
according to a pre-specified statistical criterion (Akaike’s Information Criterion (AIC) which 
measures the relative quality of a model while penalising for increasing numbers of 
predictors). In addition, a model was fitted which included conventional CV risk factors and 
the full panel of biomarkers. 
A p value of <0.05 was taken to be statistically significant. 
 
Results 
Study characteristics at baseline and incident CV events 
Due to low numbers of non-white participants (n=17), all analyses were restricted to 
Caucasian participants (n=1049; 515 women, 534 men).  Mean age at baseline was 67.9 ± 2.4 
years. Baseline prevalences of MI, angina, stroke, TIA and coronary intervention were 14.0% 
(n=147), 27.8% (n=292), 5.8% (n=61), 2.9% (n=30) and 10.1% (n=106) respectively. Full 
baseline characteristics of the study population, including median levels of ABI and 
circulating biomarkers, are shown in Table 1. A total of 205 first incident CV events (61 
fatal/non-fatal MI, 38 angina, 53 stroke, 11 TIA, 24 coronary intervention and18 fatal IHD) 
occurred during the eight year follow-up period (19.5% of study population). 
Associations between biomarkers at baseline 
At baseline, moderate to strong relationships were observed between most of the biomarkers. 
In particular, the group of inflammatory markers (TNF-α, IL-6, CRP and fibrinogen) were 
positively correlated with each other (Table 2), and these associations were found to be 
strongly statistically significant (p<0.001). By design, the general inflammation factor g was 
strongly correlated with all inflammatory markers. Moderate correlations were found 
between NT-proBNP and both ABI and hs-cTnT (r = -0.21 and 0.38 respectively; both 
p<0.001). ABI and hs-cTNT were weakly negatively associated (r = -0.10, p<0.01). GGT 
correlated with three of the inflammatory markers (TNF-α, IL-6 and CRP; r = 0.08, 0.16, 0.24 
respectively).  
Adding individual biomarkers to the basic QRISK2 model 
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Increased levels of individual circulating biomarkers and the inflammatory factor were 
associated with an increased incidence of CV events over-and above the basic QRISK model, 
but only the associations for NT-proBNP and hs-cTnT were statistically significant (Table 3).  
The strongest association was observed for hs-cTnT (OR for 1 SD increase 1.35; 95% CI, 
1.13, 1.61).  A lower ABI was associated with a higher incidence of events (OR 0.86, 95% CI 
0.73, 1.00).   
The basic QRISK2 model had a C statistic of 0.722 (0.681, 0.763) and was well-calibrated 
(Hosmer-Lemeshow p=0.97) (Table 3). Addition of each individual biomarker increased the 
C statistic, with the greatest increases seen for hs-cTnT (C statistic increased by 0.01 from 
0.722, 95% CI 0.681, 0.763 to 0.732, 95% CI 0.690, 0.774). Addition of individual 
biomarkers also improved the risk classification for participants who did not experience a CV 
event, although this generally resulted in poorer risk classification for participants who did 
experience a CV event (Table 3). The addition of hs-cTnT resulted in poorer risk 
classification by 1.6% for participants who experienced a CV event, but improved risk 
classification by 2.2% for those who did not. All the models were shown to be well-calibrated 
(Hosmer-Lemeshow p > 0.05). 
Adding combinations of biomarkers to the basic model 
An all subsets regression was carried out and identified the top five models according to a 
pre-specified statistical criterion, after adjusting for conventional risk factors, from all 
possible combinations of biomarkers. All five models (Table 3) included hs-cTnT and none 
included the general inflammation factor g. The best model selected using this method added 
ABI, hs-cTnT and GGT to the set of conventional CV risk factors. This model was well-
calibrated and had a C statistic of 0.740 (0.699, 0.781), an increase of 0.018 compared to the 
basic model. The addition of the three biomarkers resulted in slightly poorer risk 
classification by 1.1% for participants who experienced a CV event, but improved risk 
classification by 4.4% for those who did not. The second best model was well-calibrated and 
showed the same increase in the C statistic as the top model, but the NR was poorer for 
participants who experienced a CV event (-2.7%s) and for those who did not (3.4%). For 
comparison, the full model including all biomarkers is also shown in Table 3. The C statistic 
showed the same increase as the top model. The addition of all biomarkers resulted in poorer 
risk classification by 1.6% for participants who experienced a CV event, but improved risk 
classification by 5.2% for those who did not. 
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Due to the high proportion of participants with prevalent CVD at baseline, removing these 
subjects from analysis resulted in poor statistical power (n=643 subjects, n=83 events). 
Despite this, the increase in c-statistic found on addition of the individual biomarkers to the 
basic QRISK2 model was in the same direction as in table 3 (though the size of the increase 
was, as expected, much smaller).  For the best model of combined biomarkers (ABI, hs-cTnT 
and GGT), the c-statistic improved by a greater extent than for any of the individual 
biomarkers (from 0.680 for the basic model to 0.700), consistent with findings in the full 
study population.    
 
Discussion 
In older people with type 2 diabetes, higher levels of hs-cTnT and NT-proBNP were most 
strongly associated with increased risk of incident CV events, independent of factors 
currently used to predict CVD, and both improved predictive performance. NT-proBNP is 
released by the heart in response to increased pressure on the ventricular wall with low levels 
used in clinical practice to rule out heart failure (16), while cardiac troponin levels increase in 
response to clinical and subclinical myocardial ischaemia and is currently used to aid the 
diagnosis of myocardial infarction (17). In both general and diabetic population studies, NT-
proBNP and hs-cTnT have been associated with the risk of CVD and may add predictive 
value independent of conventional risk factors (8; 9; 18; 19).  The findings from our study, 
which enabled the comparison of a number of different biomarkers, are consistent with a very 
recent study in patients with type 2 diabetes in which, of a panel of 23 novel biomarkers, NT-
proBNP was one of only three biomarkers which improved CV risk prediction beyond 
traditional risk factor (20). 
In our study, ABI was negatively associated with CV risk, but the relationship was weaker 
than that for NT-proBNP or hs-cTnT. A reduced ABI (ratio of systolic blood pressure (BP) in 
the ankle to that in the arm) is used in the diagnosis of peripheral arterial disease and is a 
marker of generalized atherosclerosis (7). In 2008, a meta-analysis capturing over 480,000 
person years follow-up suggested that in the general population, measuring ABI may improve 
CV risk prediction beyond the Framingham Risk Score (7). More recently, two general 
population studies indicated that ABI had a small effect on CV risk and only improved risk 
prediction if the basic model was weak (21; 22). Evidence on the ABI as a predictor of 
vascular events specifically in diabetes has previously been lacking, despite the known strong 
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association between diabetes and the development of peripheral arterial disease of the lower 
limbs.  
There is previous evidence suggesting that a group of proteins used to assess levels of 
systemic inflammation (CRP, IL-6, TNF-α and fibrinogen) may add predictive value 
independent of conventional risk factors in both general and diabetic populations, but this  
evidence is inconsistent (11; 20; 23-27). Given that these four inflammatory markers are 
highly correlated, it has been suggested that they may best be combined into one general 
factor which describes the overall inflammatory burden (12; 28-30). This was the approach 
we chose for our study. However, when added individually to QRISK, the inflammation 
factor was not significantly associated with outcome CV events, although the C statistic did 
improve incrementally. Similarly, when the liver function test, GGT, was added on its own, 
there was no evidence of a statistically significant association, although again, the C statistic 
improved marginally.  GGT has previously been associated with CVD in two large general 
population studies (31; 32) and in people with type 2 diabetes, although it did not improve 
CV prediction beyond traditional risk factors (33). Similarly, a recent general population 
cohort study of 2500 patients with acute coronary syndrome found that GGT was associated 
with increased risk of all-cause mortality but not cardiac mortality (34) and the PREVEND 
prospective cohort study suggested that adding GGT to conventional CV risk factors did not 
improve the prediction of first-ever CV events in the general population (35). Interestingly, 
although GGT on its own did not seem to add predictive value in the ET2DS, it was retained 
in the best combined model. This may indicate the importance of not pre-selecting 
biomarkers according to the statistical significance of any association with events prior to the 
inclusion of multiple biomarkers in a risk prediction model. Overall, a combination of risk 
factors improved risk prediction beyond that possible with any single biomarker, although an 
upper limit to model performance was suggested by the same C statistic value (0.740) for the 
two best combined models and the full model. 
One of the strengths of the current study was the use of the risk score currently recommended 
for use in type 2 diabetes for risk prediction in the UK (the QRISK2 score, currently 
recommended by NICE clinical guidelines). However, replicating the QRISK2 score in the 
ET2DS proved challenging. Family history of CVD was not available in the ET2DS and the 
SIMD was used as a measure of social status rather than the Townsend index, which is only 
applicable to England and Wales. The definition of CKD in QRISK2 is a clinical diagnosis of 
CKD, but the list of corresponding clinical codes is not readily available. A similar doctor-
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diagnosis definition of CKD created for the ET2DS only affected 1.7% of the cohort, much 
lower than anticipated in an elderly diabetic population (36; 37). A new variable for CKD, 
based on an eGFR <60ml/min (equivalent to Stage 3-5 CKD) identified 24.6% of the cohort 
and, as this was considered to be a more accurate definition of CKD, was used in subsequent 
analysis. Finally, QRISK2 excluded participants with previous CVD or taking statins. 
Because a very large proportion of the ET2DS had prevalent CVD at baseline or were taking 
lipid lowering medication (representing the situation in the target population of elderly people 
with type 2 diabetes) we included all subjects in our analyse, subsequently including  
prevalence of CVD and lipid lowering medication as additional covariates. Our model 
therefore has the advantage of being potentially applicable to all people with type 2 diabetes, 
including those both with and without clinically-diagnosed CVD, all of whom could benefit 
from more accurate CV risk prediction.  However, whilst our sensitivity analysis of key 
results suggested that results were likely to have been similar in a study population free from 
CVD at baseline, future larger analysis should consider these groups of patients both 
combined and separately to be most informative.  
The C statistic for the model including only traditional CV risk factors in this study was 
similar to those found by previous studies in type 2 diabetes, which used a variety of risk 
factors and/or CV risk scores as their basic model (9; 27; 38). The size of improvements in 
the C statistic following the addition of various biomarkers was also consistent with previous 
studies. Although the increases in C statistic were small, it should be noted that the C statistic 
can be insensitive when adding a new predictor to a model, even though such a predictor may 
make an independent and statistically significant contribution to the model (39). This 
phenomenon is particularly noticeable when the baseline model includes strong predictors 
and has a large C statistic. In order to evaluate the clinical usefulness of our models, we also 
considered the NR as a measure of reclassification. This suggested that, in general, the risk 
classification improved after the addition of a biomarker for people who did not experience a 
CV event, but slightly worsened for people who did experience an event. Further large 
studies are needed to validate this conclusion and to ascertain whether any improvements are 
clinically significant.  
This study benefited from the representativeness of the type 2 diabetes population, the 
relatively long term follow up for CV events and the thorough and systematic approach for 
assessing incident CV events which ensured loss to follow-up was minimal. The wide variety 
of biomarkers available allowed for the inclusion of a large panel of potential predictors, both 
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individually and in combination. The study also has limitations. In addition to the 
insensitivity of the C statistic, the NR is dependent on the choice of risk thresholds. The 
continuous net reclassification index can be used to avoid this decision, but this is less 
clinically relevant. The NR should therefore be considered as a descriptive tool to 
demonstrate what would happen to risk scores in a clinical setting if the new model was used 
with the chosen risk categories  (0-10%, 10-20%, >20%). Data were missing for some of the 
predictor variables and the complete case analysis performed can produce biased estimates or 
reduce statistical power. However, since missing data was less than 5%, and an analysis of 
subjects with missing data versus those without indicated that missing data rates did not 
depend on the outcome or key predictor variables, these risks were considered to be 
negligible.  
In general, previous studies into biomarkers have focused on the general population and it 
often remains uncertain whether they contribute to risk prediction in a diabetic population. In 
particular, the potential value of one biomarker compared with others in the same study 
population has rarely been addressed.  In attempting to address this gap in knowledge, we 
have shown that hs-cTnT, NT-proBNP and ABI, but not GGT or an inflammatory factor on 
their own, are able to independently improve CV risk prediction beyond traditional risk 
factors in patients with type 2 diabetes. Of these, NT-proBNP and hs-cTnT appeared to be the 
most promising biomarkers, in terms of the extent to which they improve prediction when 
added individually, but ABI has the advantage of not requiring a blood test.  Our results also 
indicate that a combination of biomarkers results in further improvement to risk prediction 
compared with one strong biomarker alone, and that biomarkers which on their own may not 
appear to add predictive value, may do so when added in combination with others.  Future 
studies should explore the balance between the clinical benefit of adding multiple biomarkers 
to a risk score versus the cost of doing so.   
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Table 1: Baseline characteristics of the ET2DS population 
Variable  
Age (years) 67.9 ± 4.2 
Sex (female) 515 (49.1) 
Lipid-lowering medication 896 (85.4) 
Hypertension 858 (81.8) 
Smoking status  
Non-smoker 411 (39.2) 
Ex-smoker 491 (46.8) 
Current smoker – light (<10 cigarettes/day) 31 (3.0) 
Current smoker – moderate (10-19 cigarettes/day) 47 (4.5) 
Current smoker – heavy (20+ cigarettes/day) 69 (6.6) 
Atrial fibrillation  69 (6.6) 
Chronic kidney disease 258 (24.6) 
Rheumatoid arthritis 39 (3.7) 
SIMD  
Quintile 1 (most deprived) 127 (12.1) 
Quintile 2 205 (19.5) 
Quintile 3 185 (17.6) 
Quintile 4 192 (18.3) 
Quintile 5 (least deprived) 340 (32.4) 
BMI (kg/m
2
) 31.5 ± 5.7 
sBP (mmHg) 133.3 ± 16.5 




MI 147 (14.0) 
Angina 292 (27.8) 
Stroke 61 (5.8) 
TIA 30 (2.9) 
CI 106 (10.1) 
ABI 1.0 (0.9, 1.1) 
NT-proBNP (pg/ml) 76 (38, 172) 
hs-cTnT (ng/l) 9.6 (6.9, 13.8) 
GGT (U/L) 18 (11, 32) 
TNF-α (pg/ml) 1.1 (0.7, 1.6) 
IL-6 (pg/ml) 2.9 (2.0, 4.5) 
CRP (mg/l) 1.9 (0.9, 4.4) 
Fibrinogen (g/L) 3.6 ± 0.7 
Data are presented as means ± SD, n (%) or median (lower IQR, upper IQR) 
a 
Note that there is overlap among these subgroups 
Maximum n = 1049 
 




Table 2: Correlation coefficients between biomarkers at baseline (max n = 1032)a 
 ABI < 1.4 NT-proBNP hs-cTnT GGT TNF-α IL-6 CRP Fibrinogen g 
ABI < 1.4 1 -0.21***   -0.10** -0.05 -0.07* -0.12*** -0.13*** -0.18*** -0.18*** 
NT-proBNP  1    0.38*** -0.03  0.16***  0.18***  0.11***  0.21***  0.23*** 
hs-cTnT   1  0.03  0.19***  0.17*** -0.03  0.05  0.12*** 
GGT    1  0.08*  0.16***  0.24*** -0.06  0.16*** 
TNF-α     1  0.31***  0.12***  0.12*** 0.43*** 
IL-6      1  0.42***  0.34*** 0.75*** 
CRP       1  0.54*** 0.80*** 
Fibrinogen        1 0.76*** 
g         1 
a
 Missing data ranges from 8 to 39 data points 
* Pearson correlation test p-value < 0.05 
** Pearson correlation test p-value < 0.01 
*** Pearson correlation test p-value <0.001 
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OR for a one 




C statistic (95% CI) 
 

















Basic model  - 0.722 (0.681, 0.763) - - - 0.97 
+ ABI < 1.4 ABI 0.86 (0.73, 1.00) 0.725 (0.684, 0.766) -2.2 2.0  0.015 0.83 
+ NT-proBNP NT-proBNP 1.23 (1.02, 1.49) 0.726 (0.685, 0.767) -2.2 1.5 -0.007 0.81 
+ Troponin hs-cTnT 1.35 (1.13, 1.61) 0.732 (0.690, 0.774) -1.6 2.2  0.006 0.09 
+ Gamma-GT GGT 1.16 (0.98, 1.37) 0.726 (0.685, 0.766) -2.7 1.1 -0.016 0.40 
+ g g 1.07 (0.90, 1.27) 0.724 (0.683, 0.765) 0.5 1.2  0.018 0.90 
Top five models chosen using all-subsets regression selection 
1 ABI + hs-cTnT + GGT - 0.740 (0.699, 0.781) -1.1 4.4 0.033 0.15 
2 ABI + hs-cTnT + GGT + NT-proBNP - 0.740 (0.699, 0.780) -2.7 3.5 0.008 0.34 
3            hs-cTnT + GGT + NT-proBNP - 0.738 (0.697, 0.779) -1.6 5.1 0.035 0.47 
4 ABI + hs-cTnT - 0.735 (0.694, 0.776) -3.2 5.4 0.021 0.35 
5            hs-cTnT + GGT - 0.738 (0.697, 0.778) -1.1 3.9 0.028 0.21 
Full model 
 ABI + hs-cTnT + GGT + NT-proBNP + g - 0.740 (0.699, 0.781) -1.6 5.2 0.036 0.39 
*A complete case analysis was carried out, n = 989 
a
 Conventional risk factors: age, sex, smoking, atrial fibrillation, chronic kidney disease, arthritis, hypertension, BMI, sBP, total:HDL cholesterol, social status, 
baseline CVD status (MI, angina, TIA and stroke) and lipid lowering medication 
b 
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European Association for the Study of Diabetes Annual Meeting 2016: 
Adding novel biomarkers to current cardiovascular risk scores for people with Type 2 















Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK, 
2 
Metabolic Unit, Western General Hospital, Edinburgh, UK, 
3
 Glasgow Cardiovascular 
Research Centre, University of Glasgow, Glasgow, UK 
Background and aims: Increasing evidence suggests novel biomarkers may improve 
cardiovascular (CV) risk prediction in the general population. Whether they could improve 
current CV risk scores in people with Type 2 diabetes is uncertain.  
Materials and methods: Conventional CV risk factors and novel biomarkers were measured 
in 1066 adults (48.7% female) aged 60-74 years with Type 2 diabetes participating in the 
population-based ET2DS. Seven year follow-up for incident CV events used clinical 
examination, hospital admission record and death certificate linkage. Predictors in the 
QRISK2 cardiovascular risk score (age, sex, smoking, atrial fibrillation, chronic kidney 
disease, rheumatoid arthritis, hypertension, BMI, sBP and total:HDL cholesterol) were 
considered for the basic model, which was also adjusted for prevalent CV disease and lipid-
lowering drugs. The following novel biomarkers were then added to this starting model 
individually to assess their added value to the model: Ankle Brachial Index (ABI), N-terminal 
pro brain natriuretic peptide (NT-proBNP), troponin, gamma-glutamyl transpeptidase 
(Gamma-GT) and an inflammatory factor (g) combining C-reactive protein, interleukin-6, 
tumor necrosis factor alpha and fibrinogen using principal components analysis. 
Results: 208 (19.5%) subjects had an incident CV event (first fatal or non-fatal myocardial 
infarction, new onset angina, fatal or non-fatal stroke, transient ischaemic attack or other fatal 
ischaemic hear disease). Results showed baseline ABI, NT-proBNP and troponin were 
significantly associated with risk of CV events over-and-above QRISK2 (odds ratios for 1 
standard deviation increase in biomarker 0.81 (95% CI 0.69, 0.96), 1.24 (1.02, 1.52) and 1.48 
(1.22, 1.80) respectively). No significant association was found for Gamma-GT and g. C 
statistics improved from 0.729 (basic model) to 0.735, 0.731, 0.745 and 0.730 for ABI, NT-
proBNP, troponin and Gamma-GT respectively and all models had good calibration, assessed 
using the Hosmer-Lemeshow goodness-of-fit test (p-values all > 0.05). Only troponin 
provided a net improvement in correctly reclassifying people who both did and did not 
experience a CV event (net reclassification improvement for people who did suffer an event 
was 1.5% and net reclassification improvement for people who did not suffer an event was 
3.8%).  
Conclusion: These preliminary results suggest moderate potential for selected novel 
biomarkers to add value to current CV risk scores. Further investigation will be carried out on 
the biomarkers in combination to discover the panel of biomarkers which best predict CV 
disease. 
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Model summary measures: 
C statistic 0.729 0.735 0.731 0.745 0.730 0.725 
Net reclassification improvement 













Net reclassification improvement 
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Improving cardiovascular (CV) risk scores with novel biomarkers in people with 


















Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK, 
2 
Metabolic Unit, Western General Hospital, Edinburgh, UK, 
3
 Glasgow 
Cardiovascular Research Centre, University of Glasgow, Glasgow, UK 
Aims: Increasing evidence suggests novel biomarkers may improve CV risk 
prediction in the general population. Whether they could improve current CV risk 
scores in people with Type 2 diabetes is uncertain. 
Methods: Conventional CV risk factors and novel biomarkers were measured in 
1,066 adults (48.7% female)  with Type 2 diabetes participating in 
the population-based ET2DS. Seven year follow-up for incident CV events used 
clinical examination and hospital admission record and death certificate linkage. 
Predictors in the QRISK2 score (age, sex, ethnicity, smoking, atrial fibrillation, 
chronic kidney disease, rheumatoid arthritis, hypertension, body mass index, systolic 
blood pressure and total:high-density lipoprotein cholesterol) were considered for the 
starting model, which was also adjusted for prevalent CV disease and lipid-lowering 
drugs. 
Results: 208 (19.5%) subjects had an incident CV event (first fatal or non-fatal 
myocardial infarction, new onset angina, fatal or non- fatal stroke, transient 
ischaemic attack or other fatal ischaemic heart disease). A more accurate definition 
of chronic kidney disease and incorporating social class produced slight 
improvements in model performance. Initial results showed baseline NT-proBNP 
and troponin were significantly associated with risk of CV events over and above 
QRISK2 [hazard ratios for one standard deviation increase in biomarker 1.25 (95% 
confidence interval 1.05, 1.49) and 1.37 (1.20, 1.60) respectively]; c indexes 
improved from 0.709 (starting model) to 0.712 and 0.725 for NT-proBNP and 
troponin respectively. No significant association was found for C-reactive protein. 
Conclusions: These preliminary results suggest the potential for selected novel 
biomarkers to add value to current CV risk scores. Further investigation will be 
carried out on a wider range of novel biomarkers, in combination, in the ET2DS. 
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NHS National Services Scotland Privacy 
Advisory Committee 
 








THE PRIVACY ADVISORY COMMITTEE (PAC) is an advisory committee to NHS National 
Services Scotland (NSS) and the Registrar General. The PAC advises on the correct 
balance between protecting personal data and making data available for research, audit and 
other important uses and ensures that any information releases are carefully controlled. 
 
NSS follows the Proportionate Governance Approach favoured by Scottish Government 
(Joined up Data for better Decisions 2012).  NSS Information Governance Team assesses 
all applications for access to data under the control of NSS or National Records of Scotland 
(NRS) that have the potential to be person-identifiable, and in respect of any new record 
linkages.  The views of PAC are sought in relation to requests which the team assess as 
carrying high privacy or other risk.  Further information is available on the PAC Website. 
 
Where the data you wish to access are not in the control of NSS or NRS you may need to 
consider applying to another advisory body - see ‘Appendix One: Advisory Bodies within 
NHSScotland’.  
 
Assistance with PAC 
NSS Research Coordinators are a team of analysts and data specialists based within the 
Information Services Division (ISD) of NSS.  The NSS Research Coordinators can explain 
what information is available and help you to decide which variables would be useful for your 
study.  They can help you to define your requirements for data linkage, preparation of data 
extracts, and any analyses required.  They can also advise when you may need to approach 
another advisory body. 
 
When to Complete a Privacy Advisory Application 
Form 
The PAC Application Form must be completed for data requests that involve: 
access to identifiable or potentially identifiable information; 
circumstances where NSS or National Records of Scotland (NRS) have indicated their 
intention to seek guidance from PAC; and/or  
record linkage of previously unlinked datasets involving data from more than one Health 
Board. 
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Our aim is to make data for research available through the ScottisH Informatics Programme 
(SHIP) infrastructure. All applicants to PAC will be expected to use the SHIP National Safe 
Haven as a means of accessing data except in very exceptional circumstances.  
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ScottisH Informatics Programme (SHIP) 
SHIP is a Scotland-wide research platform for the collation, management, dissemination and 
analysis of Electronic Patient Records (EPRs). The programme brings together the 
Universities of Dundee, Edinburgh, Glasgow and St Andrews with the Information Services 
Division (ISD) of NSS. 
 
The SHIP programme will provide a platform for Scottish record linkage that will drive EPR 
research throughout the UK and abroad. The SHIP National Safe Haven is the analytical 
platform for this. This includes the following. 
Provision of a record linkage service where personal identifiers are kept separate from the 
payload/content data. 
Provision of a secure environment for researchers to analyse anonymised patient level or 
summarised records. 
Provision of a Secure File Transfer service to support the transmission of data between data 
providers and researchers. 
 
Anyone wishing to access data through the SHIP National Safe Haven requires to be a 
member of an appropriate institution and to be able to demonstrate having successfully 
completed approved training in Information Governance within the last three years. 
 
Research coordinators hold a list of SHIP approved training courses. Anyone proposing to or 
having completed another course should provide our Research Coordinator with details 
including the name of the course, the name of the institution providing the training, and the 
content of the course. 
 
Further Advice on National Records of Scotland 
Service and NHS Central Registry 
To find out more about NRS data including those relating to the NHS Central Registry visit 




For All Other Requests 
For all other requests or advice please contact the NSS Research Coordinators at 
nss.eDRIS@nhs.net 
   
 B-5 
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Application Checklist 
Before you submit your application, you should include the following items and ensure that 
the application has been signed by the appropriate individuals.   
 
Your application should be typed, not handwritten. 
 
Items to support application  
Where applicable, you should include the following: 
Study protocol 
Information provided to study participants and/or the wider public 
Participant consent forms 
Draft correspondence (if the data generated through your study will be used to contact any 
individuals) 
Evidence of ethical approval 
Evidence of approval from other Data Controllers eg Caldicott Guardians or CHIAG 
Local Information Governance/security policies and procedures (if you are not using the 
SHIP National Safe Haven) 
The list of variables you require in the file for analysis (if not included under question ) 
Details of each individual accessing the data (where there are more than the five allowed on 
this form) 
Content of Information Governance training course undertaken if it is not already SHIP 
approved. 
 
Please ensure that your application has been signed by the: 
main study contact 
study information custodian (if you are not using the SHIP National Safe Haven). 
 
You must also ensure that individuals named on the form have read and approved this 
submission. 
 
After completing your application form you must save it as a PDF file before sending 
it with relevant appendices by email to your research coordinator.  If you do not have 
a research coordinator please email nss.eDRIS@nhs.net.  The research 
coordinators/eDRIS will forward your application to PAC after checking it.   
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Application for  
Privacy Advisory Committee Approval 
Application Title 
 






ordinator Name  
 
Rose Sisk 
NSS Study Number  
(Your NSS Research 








The information contained in this application form will be regarded as confidential whilst it 
goes through the scrutiny process but it is the duty of applicants to point out any information 
within the application that they consider to be particularly sensitive, confidential or 
commercially sensitive.  
 
As NHS National Services Scotland is a public authority, it is subject to the Freedom of 
Information (Scotland) Act. 
 
PAC applications are kept by NHS National Services Scotland for a minimum period of 15 
years from date of application or date of the last linkage undertaken in relation to the 
application. 
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 People Involved  
The names of all the individuals involved in and responsible for the design and analysis of 
the study should be included here. It is expected that those who will have access to the data 
supplied by NSS have adequate and regular updated knowledge and skills in the secure and 
confidential handling of health data.  
 
You must ensure that everyone who will access the data provided is a member of an 
appropriate institution and is able to demonstrate having successfully completed approved 
training in Information Governance within the last three years.  
 
Research coordinators hold a list of SHIP approved training courses. If you propose to or 
have completed another course, please provide your Research Coordinator with details 
including the name of the course, the name of the institution providing the training, and the 
content of the course.  
 
You must ensure that all staff taking part in this study have appropriate contracts in place 
containing clauses that clearly identify their duties and responsibilities for confidentiality, data 
protection, and data security. 
 
You do not need to include clerical and secretarial support staff.  
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o Head of Department responsible for project/study or the 
Principal Investigator 




Position  Professor of Molecular Epidemiology 
Qualifications BSc (Hons), MBChB, MD, FFPHM 
Professional Registration Number (if 
applicable) eg General Medical 
Council (GMC) 
3659775 
Organisation name Centre for Population Health Science (CPHS) 
Address Medical School, Teviot Place 
Postcode EH8 9AG 
Telephone number 01316503240 
Email Jackie.Price@ed.ac.uk 
Complete the following question if you will access the individual level data requested 
in this application 
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: 
Information Governance Training Tool 






To be attended in the next few months (will be 
completed before the data is supplied by ISD) 
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o Main Contact 
Researcher responsible for day-to-day running of project (to whom all correspondence will 




Position  PhD Student 
Qualifications BSc (Hons), MRes 
Professional Registration Number (if 
applicable) eg GMC  
 
Organisation name CPHS 
Address Medical School, Teviot Place 
Postcode EH8 9AG 
Telephone number 07944616765 
Email s1356205@sms.ed.ac.uk 
Complete the following question if you will access the individual level data requested 
in this application 
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: 
SHIP: Information Governance 






Edinburgh Law School, University of Edinburgh 
Date attended: 
Online course begun 26/9/14 – will be 
completed before data is received from ISD 
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o Information Custodian 
The Information Custodian is the person taking responsibility for safeguarding the 
confidentiality of the data.  This is likely to be the Head of Department responsible for the 
project. An Information Custodian is ONLY required if the SHIP National Safe Haven will 




Position  See section 1.1 
Qualifications See section 1.1 
Professional Registration Number (if 
applicable) eg GMC  
See section 1.1 
Organisation name See section 1.1 
Address See section 1.1 
Postcode See section 1.1 
Telephone number See section 1.1 
Email See section 1.1 
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: 
See section 1.1 
Link to content (of course) if available: 
See section 1.1 
Institution: 
See section 1.1 
Date attended: 
See section 1.1 
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Please provide the details of all additional people (if any) who will access the individual level 
data requested in this application. There is space here to provide details of three people. If 
there are more than three, please append the additional information with your application. 
 




Position  Clinical Training Fellow/Specialist Registrar in 
Public Health 
Qualifications BSc (Hons), MBChB, MSc, MRCP, MFPH 
Professional Registration Number (if 
applicable) eg GMC  
6097377 
Organisation name CPHS 
Address Medical School, Teviot Place 
Postcode EH8 9AG 
Telephone number 0131 6503244 
Email J.Morling@ed.ac.uk 
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: SHIP Information 
Governance 






Edinburgh Law School, University of 
Edinburgh 
Date attended: 
Online course begun 08/10/14 – will be 
completed before data is received from ISD 
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Position  Data Manager 
Qualifications PhD 
Professional Registration Number (if 
applicable) eg GMC  
 
Organisation name CPHS 
Address Medical School, Teviot Place 
Postcode EH8 9AG 
Telephone number 0131 650 6193 
Email stela.mclachlan@ed.ac.uk 
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: 
Information Governance Training Tool 






To be attended in the next few months (will be 
completed before the data is supplied by ISD) 
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Position   
Qualifications  
Professional Registration Number (if 
applicable) eg GMC  
 
Organisation name  
Address  
Postcode  
Telephone number  
Email  
Provide details of the most recent 
Information Governance training 
undertaken. 
Name of Course: 
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o Other People Involved 
Please list the names of any people not listed above that have had significant input into the 
design and content of this study, or will be involved in the study hereafter, but who will not 




Mark Strachan Western General Hospital, 
Edinburgh 
Consultant Physician & 
Honorary Professor 
Rebecca Reynolds Centre for Cardiovascular 
Science, University of 
Edinburgh 
Professor of Metabolic 
Medicine and Honorary 
Consultant Physician 
Ian Deary University of 
Edinburgh Centre for 
Cognitive Ageing and 
Cognitive Epidemiology 
(CCACE) 
Professor of Psychology & 
Director, CCACE 
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o Previous publications 
Please list up to three publications which members of the research team have produced or 
been involved in that demonstrate relevant experience in the use of administrative data for 
research. 
Authors Title of publication Journal Citation  
(year: volume; 
pages) 
Jie Ding, Mark W.J. Strachan, 
Rebecca M. Reynolds, Brian 
M. Frier, Ian J. Deary, F. 
Gerald R. Fowkes, Amanda J. 
Lee, Janet McKnight, Patricia 
Halpin, Ken Swa, and 
Jackie F. Price 
Diabetic retinopathy 
and cognitive decline 
in older people with 
type 2 diabetes: the 
Edinburgh Type 2 
Diabetes Study 
Diabetes 2010: 59; 2883-
2889 
Riccardo E. Marioni, Ian J. 
Deary, Gordon D. Murray, 
Gordon D. O. Lowe, Snorri B. 
Rafnsson, Mark W. J. 
Strachan, Michelle Luciano, 
Lorna M. Houlihan. Alan J. 
Gow, Sarah E. Harris, Marlene 
C. Stewart, Ann Rumley, F. 




altered plasma levels 
of C-reactive protein 
are not associated 
with with late-life 




2010: 40; 3-11 
Riccardo E. Marioni, Mark 
W.J. Strachan, Rebecca M. 
Reynolds, Gordon D.O. Lowe, 
Rory J. Mitchell, F. Gerry R. 
Fowkes, Brian M. Frier, 
Amanda J. Lee, Isabella 
Butcher, Ann Rumley, Gordon 
D. Murray, Ian J. Deary and 
Jackie F. Price 
Association between 
raised inflammatory 
markers and cognitive 
decline in elderly 
people with type 2 
diabetes: the 
Edinburgh Type 2 
Diabetes Study 
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 Study Overview 
In order to help the PAC assess your application, you are required to provide an overview of 
your study. It is important that the following section is completed with information accessible 
and comprehensible to a lay reader, and any acronyms are expressed in full when first used.  
You should include your study protocol with your application. 
 
o What is the background to the study?   
Risk factors underlying the development and progression of some of the less well-
recognised complications of type 2 diabetes, including cognitive impairment and non-
alcoholic fatty liver disease, are poorly understood. The Edinburgh Type 2 Diabetes Study 
was established in 2006 in order to investigate the role of potential risk factors in these 
complications, as well as to further investigate mechanisms underlying the development and 
progression of micro and macrovascular disease in type 2 diabetes.  
o Why is the study needed? 
Type 2 diabetes currently affects around two million people in the UK and approximately 
10% of people aged over 65 years. The prevalence of the condition is predicted to double 
over the next 20 years, with a particular increase in elderly people. Much has been done 
over the last decade to try to prevent and treat the well-recognised micro- and 
macrovascular complications of diabetes, including atherosclerotic cardiovascular disease, 
diabetic retinopathy, nephropathy and peripheral neuropathy. However, morbidity and 
mortality from vascular disease remains high in older people with type 2 diabetes. Detailed 
information on potential risk factors is crucial to identify causal and modifiable risk factors 
that can be targeted for the development of appropriate preventive and therapeutic 
interventions, in addition to helping to identify patients who are at increased risk of 
developing complications. 
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o What are the aims and objectives of the study?  
The aims of this project are: 
1. To determine the association between potentially modifiable risk factors (including 
microvascular disease, inflammatory mediators and hormones of the hypothalamic-pituitary-
adrenal (HPA) axis) and cognitive decrements in people with type 2 diabetes. 
2. To determine, in older people with type 2 diabetes, (i) the prevalence of Non-Alcoholic 
Fatty Liver Disease (NAFLD), (ii) clinical factors that might permit early detection of people at 
increased risk of developing NAFLD and (iii) potentially causal risk factors for the 
development and progression of NAFLD. 
3. To identify circulating biomarkers and other risk factors which (i) predict the development 
of symptomatic and asymptomatic micro- and macrovascular disease, (ii) are associated 
with progression of these complications and/or (iii) have a potentially causal role in their 
development. 
4. To establish a well-characterised and compliant population sample with extensive 
phenotyping and the potential for genotyping, which can be used as the sampling frame for 
subsequent nested case control studies (including neuroimaging), and as a replication 
population for findings arising from genome-wide association studies. 
o Give a brief outline of the study design and data sources 
involved 
Subjects for this study have been recruited through the Lothian Diabetes Register (LDR). 
Invitations were sent out to a random sample of individuals on the register, by LDR staff, and 
details of individuals who returned a reply slip stating that they were interested in 
participating were then passed on to the Edinburgh Type 2 Diabetes Study team. The one-
year recruitment and baseline data collection phase ended in August 2007 and a follow-up 
data collection phase was carried out in 2011, which included Record Linkage data from 
ISD. The subjects for this study comprise approximately 1066 individuals with type 2 
diabetes aged between 60 and 75.  
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o Describe your study sample (inclusion/exclusion criteria eg 
involvement in trial/survey, health event, relevant date range, requirement for 
a matched control cohort, etc) 
With the permission of the Lothian Diabetes Services Advisory Group and the Caldicott 
Guardian for NHS Lothian, patients recorded as having type 2 diabetes were selected from 
the Lothian Diabetes Register (LDR). The LDR is a computerised database, which was 
established in 2001, and contains clinical details on over 20,000 patients with known type 2 
diabetes living in Lothian, Scotland. Comparison of age-sex specific prevalences of diabetes 
recorded on the LDR with those from other data sources in Scotland suggests that the LDR 
captures almost everyone with diagnosed diabetes in Lothian (Prof Sarah Wild, personal 
communication). 
Any subject in whom it was not possible to confirm a clinical diagnosis of type 2 diabetes by 
review of hospital and/or GP records was excluded. Other exclusion criteria were, (i) non-
English speakers (since fluent English is required for some of the cognitive tasks), (ii) 
corrected visual acuity worse than 6/36 for distance vision or unable to read large print text 
(as at least moderate visual function is required to complete some of the cognitive tasks), (iii) 
unwilling to give consent (or judged by clinical research staff to be unable to give fully-
informed consent) (iv) physically unable to complete the clinical and cognitive examination. 
o Indicate whether this study has any implications for sensitive 
groups or vulnerable populations (see Appendix Two for details). 
There are no implications for sensitive groups or vulnerable populations in this study. 
 
o Describe envisaged benefits of your study either to patients or 
the wider public 
This study will provide a wealth of epidemiological and biomarker data that should be 
invaluable in the identification of potentially modifiable, causal risk factors for diabetes-
related cognitive impairment, liver dysfunction and vascular disease, which can be targeted 
for the development of preventive and therapeutic interventions. 
o Do you anticipate that the data being requested will be used to 
develop products for the purpose of profit? 
No. 
 
 Please embolden Yes or No as 
appropriate 
o Is this application an extension 
to/update of a previous PAC application? 
Yes No 
If yes, please provide the PAC reference number(s) 3707 
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o To your knowledge, has any 
external dataset you wish to use been linked to 
NSS data in the past? 
Yes No 
If yes, please provide details, including relevant PAC 
reference number(s) if available 
 
o Do you have funding in place for 
your study? 
Yes No 
If yes, please provide the name of all funding bodies The ET2DS is funded by the 
Medical Research Council and 
Pfizer Ltd 
Has the assessment for funding included peer review? Yes No 
o Are any of the funding bodies 
commercial, for profit, organisations? 
Yes No 
o Do you intend to access the data 
requested through the SHIP National Safe 
Haven? 
Researchers based in Scotland will be expected to use 
the SHIP national safe haven.  If you are using the safe 
haven you do not need to complete the majority of  
which relates to information governance and security.  
Question 5.1 requires to be completed by all applicants. 
Yes No 
If no, please explain your reason why: 
The ET2DS is an active and on-going research project based on a fully consented cohort of 
patients who have agreed to allow access to their medical records and healthcare data for 
the purposes of the research.  The cohort has been linked to ISD data twice previously and 
on neither occasion was it necessary to use a Safe Haven to analyse the data.  This would 
have entailed moving the entire ET2DS dataset into a Safe Haven, linking to a relatively 
small amount of ISD data, and then having several different researchers accessing the 
resultant dataset on a daily basis for 6 years from a remote location.  Rather, we hold the full 
ET2DS dataset on a secure server as described in the rest of this form, where we are able to 
access it directly.  Experience with collaborators on other projects has demonstrated that 
regular analysis of a dataset held by someone other than the researchers themselves is 
problematic and time consuming.  Recent discussion (between staff in CPHS who hold 
several of their own, similarly linked datasets, Janet Murray and colleagues from the Safe 
Haven), have indicated to us that there is no intention for use of the Safe Haven to impede 
on-going research, so we were led to believe that we would be granted access to the ISD 
data again this time around, for subsequent merging with our secure ET2DS dataset. 
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 Data Requests 
This section of the form requests further detail regarding the use of data to meet the 
objectives of the study. 
 
National Records of Scotland (NRS) Data 
 Please embolden Yes or 
No as appropriate 
o Does your study involve data to be 
provided by NRS?  If not, go to question  
Yes No 
o Does your study require use of NHS 
Central Registry (NHSCR) as a sampling frame for 
study controls?  
Yes No 
o Does your study involve flagging of 
individuals on the NHSCR? If yes, please answer the 
following questions.  
Yes No 
Is the flagging of individuals: 
To help trace and contact individuals throughout the UK? Yes No 
To be informed of fact and cause of death? Yes No 
To be informed of cancer registrations? Yes No 
To be informed of emigrations prospectively and retrospectively? Yes No 
o Does your study require the provision of 
any other service from NRS? If so detail below. 
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National Services Scotland (NSS) Data  
 Please embolden Yes 
or No as appropriate 
o Does your study involve NSS data?  Yes  No  
 
If yes, please tick the dataset(s) involved below and indicate the relevant time period: 
 Tick Time period 
SMR00 - Outpatients   




records since this 
date – present 
date 
SMR02 - Maternity   
SMR04 - Mental Health   
SMR06 - Cancer Registration   
SMR11/SBR - Neonatal/Scottish Birth Record (please specify 
which) 
  
CHSP-PS/CHSP-S/SIRS - Child Health Surveillance and 
Immunisation (please specify which) 
  
A&E - Accident and Emergency   
PIS - Prescribing Information   
National Audits and Disease Registries eg Surgical Mortality, 
Renal Registry (please specify which) 
  




Last linkage was 
done up to the 
end of the 
2009/2010 
period. Any new 
death records 
since the end of 
this period – 
present date 
Scottish Drugs Misuse Database (SDMD)   
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PTI (Primary Care Data)   
Other (please list below)   
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o Indicate by ticking all the box(es) that apply whether the 
information provided by NSS Scotland will be used to make direct contact 
with the following 
 Make Contact 
By Letter By Telephone Other method - 
please specify 
Hospital consultants    
Other hospital staff    
General Practitioners    
Study members or 
patients 
   
Relatives of study 
members or patients - 
please specify 
   
Some other party - 
please specify 
   
Please explain why you will contact each group and provide copies of the relevant 
correspondence: 
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In order to establish whether or not subjects within the ET2DS suffered from an event (e.g. a 
CV event) a variety of sources were used as evidence in combination (see below for specific 
examples of the criteria used to define CV events at both baseline and 4-year follow-up). 
Therefore, we do not rely solely on data from ISD to define an event. There may be 
occasions where we don’t already have the evidence required to confirm an event shown by 
the ISD data and in these instances it may be necessary to contact GPs/study members in 
order to verify. It should be noted that study participants have already given consent for their 
medical records to be consulted and their GPs to be contacted. 
Baseline event criteria: The following criteria were used to define MI: 1) subject recall of a 
doctor’s diagnosis of MI, 2) positive WHO chest pain questionnaire for MI, 3) ECG evidence 
of ischemia (Minnesota codes 1.1–1.3, 4.1– 4.2, 5.1–5.3 or 7.1), and 4) prior hospital 
discharge code for MI (ICD-10 codes I21–I23, I252). MI was recorded if two of the first three 
criteria were met or if both the first and last criteria were met. Equivalent criteria for angina 
were: 1) subject recall of a doctor’s diagnosis of the condition or being on regular medication 
for angina, 2) positive WHO chest pain questionnaire for angina, 3) ECG evidence of 
ischemia, and 4) prior hospital discharge code for ischemic heart disease (ICD-10 codes I20 
–I25). Angina was recorded if two of the first three criteria were met or if both the first and 
last criteria were met. Stroke was recorded if two of three of the following criteria were met: 
1) subject recall of a doctor’s diagnosis of stroke, 2) prior hospital discharge code consistent 
with stroke (ICD-10 codes I61, I63–I66, I679, I694), and 3) confirmation by review of clinical 
notes that the event was not due to a transient ischemic attack. 
 
Four-year follow-up event criteria: Four years after recruitment, participants were followed-up 
for new CV events using a combination of repeat self-completion questionnaire, repeat ISD 
record linkage for hospital discharge and death certificate data and review of clinical case 
notes as required. Criteria for fatal and non-fatal events were as follows. Myocardial 
Infarction (MI): (1) ICD-10 code for new MI on hospital discharge/death record, dated after 
baseline, plus either subject report of a doctor diagnosis of MI, positive WHO chest pain 
questionnaire for MI, report of MI on GP questionnaire (provided all the dates were 
consistent with ICD-10 coded event) or ECG codes for MI which were not present at 
baseline; or (2) clinical criteria for MI met following scrutiny of hospital and/or GP notes. New 
angina (in subjects without a diagnosis of angina at baseline): (1) ICD-10 code for angina as 
primary diagnosis on hospital discharge record, dated after baseline; or (2) at least 2 of (a) 
subject self-report of a doctor diagnosis of angina or of starting angina medication since 
baseline, (b) ECG codes for ischaemia which were not present at baseline, and (c) positive 
WHO chest pain questionnaire; or (3) clinical diagnosis of angina on scrutiny of hospital 
notes. Fatal IHD: ICD-10 codes for IHD (other than MI) as underlying cause of death from 
death certification data. Stroke: (1) ICD-10 code for stroke as primary diagnosis on hospital 
discharge/death record, dated after baseline; or (2) clinical criteria for stroke met on scrutiny 
of clinical notes in subjects with either self-report of stroke or with non-primary ICD-10 
hospital discharge/death code for stroke. Transient Ischaemic Attack (TIA): (1) ICD-10 code 
for TIA as primary diagnosis on hospital discharge record; or (2) clinical criteria for TIA met 
on scrutiny of clinical notes in subjects with either-self-report of stroke or with non-primary 
ICD-10 hospital discharge code for stroke or TIA.  
 
.   
 Please embolden Yes or No as 
appropriate 
o Does your application request NSS 
to facilitate communication with individuals in 
the study sample?  
Yes No  
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o Does your study involve use of 
NSS data as a sampling frame? 
Yes No 
 
o Will all analysis be done in NSS by 
NSS staff ie you only require aggregate output? 
Yes No 
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Non-NRS/NSS Datasets 
 Please embolden Yes or No as 
appropriate 
o Does your study involve linkage to 
non-NRS/NSS data? If yes, you must provide 
information on each dataset.  If no go to 
question . 
Yes  No  
 
Non NRS/NSS data that may be involved include: 
Data held by another NHS Board (eg treatment or audit data) 
Data held by GPs 
Research dataset eg clinical trial 
Survey dataset eg national social surveys 
Data relating to social care 
Data relating to education 
Other data from a public authority 
Other (eg data from a commercial organisation) 
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Please provide the information requested for each of the non-NRS/NSS datasets that you 
will provide to ISD.  There is space here to provide details for three non-NRS/NSS datasets.  
If there are more than three involved, please append the additional information with your 
application.  
 
o Non NRS/NSS Dataset - 1 
What is the name of the dataset? ET2DS database 
The purpose for which it was collected   To investigate the role of potential risk factors in 
complications such as cognitive impairment, as 
well as to further investigate mechanisms 
underlying the development and progression of 
micro and macrovascular disease in type 2 
diabetes. 
Describe the content of the dataset The study constitutes 1066 men and women 
aged 60 to 75 years with established type 2 
diabetes, living in the Lothian region of central 
Scotland. At baseline, subjects underwent 
detailed cognitive and physical examination, the 
latter including measures of micro- and macro-
vascular disease, glycaemic control, body fat 
composition and plasma inflammatory markers, 
cortisol, lipids and liver function tests. 
Participants were re-examined after one year 
with hepatic ultrasonography and additional 
measures of vascular disease. Record Linkage 
has been used to determine cardiovascular 
outcomes at a four year follow-up stage. 
The time period to which it pertains 2006-2011 
What is the name of the data controller Professor Jackie Price 
Describe how patients have been 
informed of this use of their data. 
All subjects gave written informed consent at 
the baseline clinic. 
The identifying variables which will be 
provided to ISD to enable linkage (please 
tick all that apply) 
Forename  
Middle name  
Surname  
CHI Number  
Postcode  
Date of Birth  
Gender  
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Other (please specify below):  
Study ID Number 
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o Non NRS/NSS Dataset - 2 
What is the name of the dataset?  
The purpose for which it was collected    
Describe the content of the dataset  
The time period to which it pertains  
What is the name of the data controller  
Describe how patients have been 
informed of this use of their data. 
 
The identifying variables which will be 
provided to ISD to enable linkage (please 
tick all that apply) 
Forename  
Middle name  
Surname  
CHI Number  
Postcode  
Date of Birth  
Gender  
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o Non NRS/NSS Dataset - 3 
What is the name of the dataset?  
The purpose for which it was collected    
Describe the content of the dataset  
The time period to which it pertains  
What is the name of the data controller  
Describe how patients have been 
informed of this use of their data. 
 
The identifying variables which will be 
provided to ISD to enable linkage (please 
tick all that apply) 
Forename  
Middle name  
Surname  
CHI Number  
Postcode  
Date of Birth  
Gender  
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Output File for Analysis 
The risk of inadvertent identification/disclosure of individuals increases with increased level 
of detail contained in the dataset.  Only variables required to meet study objectives should 
be requested. 
 
Identifiable data includes variables such as name and date of birth. In general, access to 
personal identifiers will not be provided.  Exceptional requests for access may be considered 
taking account of Information Governance principles. 
 
 Please embolden Yes 
or No as appropriate 
o Do you require any patient identifiers in 
the output file for analysis? 
Yes No 
If yes, please identify which patient identifiers you require in the output file for analysis 
Forename  
Surname  
CHI Number  
NHS Number  
Full Postcode   
Full Date of Birth   
Full Date of Death Yes 
Full Date of Admission Yes 
Full Date of Discharge Yes 
Other (please list)  
Provide justification for why you need these patient identifiers.  This information can only be 
provided where a clear need is shown.  
These full dates were provided in the previous record linkages and were used to calculate 
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Data without identifiable variables may retain the potential to identify an individual. This 
increases with the level of detail included, particularly where the denominator population is 
small, for example when rare conditions or low level geographies are involved.  
 
Our Research Co-ordinators will be able to advise whether ‘derived variables’ may be 
provided to reduce the risk of identifying individuals, for example month of admission and 
length of stay rather than dates of admission and discharge. 
 
Output files may include a study index number where recognition of individual records is 
necessary. 
 
o Identify which, if any, of the following variables are required in 
the output file. 
Partial dates: 
Partial Date of Birth (eg month 
and year – please specify) 
 
Partial Date of Death  
Partial Date of Admission  




NHS Board area  
Local Authority area  
Datazone  
Partial Postcode (please specify)  
Other (please specify)  
Clinical variables: 
Information regarding rare 
conditions (please list the 
conditions)   
 
Provide justification for why you need these variables. Variables can only be provided where 
a clear need is shown.  
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Please list here or in an appendix all the other variables (not already listed) which are 
required in the output file, identifying which variables come from which data source. 
 
o All other variables to be provided in the output file 
Variable Data Source 
Study ID Number Provided by us 
Record type Provided by ISD 
Date of admission Provided by ISD 
Data of discharge Provided by ISD 
Hospital name Provided by ISD 
All diagnoses (main and other) Provided by ISD 
All operations (main and other) Provided by ISD 
Principal cause of death Provided by ISD 
Secondary causes of death Provided by ISD 
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Duration of the Study 





Updates and Retention 
 Please embolden 
Yes or No as 
appropriate 
o Does your study require access to a regular 
update of data? 
Yes No 
If yes, please explain the reason for this and the frequency of updates required. 
Please note approval is for 5 years. Updates after that time require a new application.  
 
 
o For how long will you either keep the data or require it to be 
retained in the safe haven (including the updates) after the study is complete?  
Please note the standard archive time for safe haven is 2 years. 
At least 10 years within the ET2DS database. 
o Provide justification for why you need to retain the data for that 
length of time.  
In order to undertake substantial analysis. 
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 Permissions to Use Data 
For each dataset not under the control of NRS or NSS, you must seek authority to access 
those data. 
An application to the CHI Advisory Group (CHIAG) is necessary where the study requires 
access to information from the CHI dataset. 
An application to the NHSScotland Caldicott Guardian Forum is necessary where the study 
requires access to information datasets held by multiple NHS Boards. 
Approval from the National Research Ethics Service should be sought in the following 
situations:  
Where the study involves linkage of a research dataset to another dataset. 
Where the study involves use of identifiable data. 
Where study involves use of highly disclosive data eg information regarding rare 
conditions or at a small area level.   
It is Scottish Government policy that patients are informed regarding the use of their data 
(‘Protecting patient confidentiality’ 2002). Applicants must demonstrate that the proposed 
use of the datasets they wish to link is in line with the information provided to patients and 
provide copies of relevant information such as participant information leaflets and consent 
forms, posters, links to websites etc.  
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Please provide the information requested for each non NRS/NSS dataset involved in your 
application. 
o Evidence that use of the data is authorised by the Data 
Controller(s). 
This may include authorisation from CHIAG, NHS Caldicott Guardians Forum or other. This 
can be attached to your application. 
Caldicott Guardian approval was provided in Nov 2005 for random sampling of ET2DS 
participants from the Lothian Diabetes Register. 
 
o Describe the methods used to inform study participants and/or 
the wider public regarding the use of their data in this way. 
An information sheet was given to all participants at first contact (the baseline visit), and 
written informed consent was then obtained. 
 
o Provide copies of the information provided to study participants 
and/or the wider public regarding the use of their data in this way. 
This can be attached to your application. 
Attached. 
 
o Provide the participant consent form for research studies or 
surveys. 
This can be attached to your application. 
Attached. 
 
o Where no consent for proposed use has been obtained from 
data subjects, please provide justification below explaining why there is use 
without consent. 
For example, please explain why consent has not been obtained and explain how this 
proposed use relates to the original purpose of data collection. 
 
N/A 
o Have any members of the public/lay people been involved in the 
study design? 
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 Information Governance  
NSS must ensure that any data approved for release will be adequately protected against 
inappropriate access and use during the study, and will be securely disposed of once the 
study is completed. 
 
Researchers will be expected to access NSS data using the SHIP National Safe Haven.  Any 
alternative to this will require justification. 
 
You may need to consult your organisation’s Information Governance Lead and IT service 
supplier when completing this part of the form. 
 
o Information Governance Incident Reporting 
Your organisation(s) should have Information Governance incident reporting procedures 
available and these should be accessible to and used by all staff on this study. 
 
NSS should be notified immediately of any information governance breaches that have 
occurred involving NSS supplied data during this study. Please confirm you will notify 
nss.pac@nhs.net of any such incidents by ticking here  
 
The rest of this section does not need to be completed for studies in which data will 
be accessed only through the SHIP National Safe Haven.  Please complete Questions 
 to  for all other applications ie studies requiring release of data directly to the 
applicant.  
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o Local Information Governance Policies and Procedures 
Your organisation(s) should have Information Governance policies and procedures available 
and these should be accessible to and used by all staff on this study.  Please provide copies 
of the local Information Governance policy/policies that apply in each of the 
organisations/locations where the data provided for this study will be held.  Provide these 
files along with your application or provide URLs below if the policies are available online. 
 




o Data Protection Registration 
Please provide the Data Protection Registration Number of each of the organisation(s) 
where data will be held. 
 
Organisation(s) Name/Data Storage 
location 
Data Protection Registration Number 






o ISO 27001 
If your organisation(s) have adopted ISO27001 - Information Security - Security Techniques 
- Information Security Management Systems, please provide your certification number. 
 
Organisation Name / Data Storage 
location 
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o NSS Data Transfer and Storage Policies 
NSS requires that all sensitive and person identifiable data are encrypted during transfer and 
whilst stored on mobile data storage devices and desktop and laptop computers.  
 
NSS prefers that any data provided are stored on secure networked drives as part of a 
secure managed server.  If mobile data storage devices have to be used, you must 
implement adequate protection against device loss or theft, unauthorised interception and 
access. 
 
Where NSS supplied data are being stored on mobile data storage devices (for example but 
not limited to: USB ‘sticks’ and USB data storage drives, desktop or laptop computer) these 
devices must be fully encrypted to FIPS 140-2/CESG CAPS certified level of security 
protection.   Where devices cannot be encrypted (for example: CDs, DVDs) then the data 
must be encrypted to FIPS 140-2/CESG CAPS certified level of security prior to storage on 
the mobile data storage device.  
 
NSS can only send sensitive and person identifiable data to other users using NHSmail or 
secure file transfer protocol (SFTP).  Please discuss methods of transfer with your Research 
Coordinator. 
 
There are risks associated with using any email services for the transfer of data including 
sending the communication to the wrong email address. Please ensure that the NHSmail 
email address you provide is the correct address to be used. NSS will only send data to 
individual user (eg named) email addresses and not to generic email addresses.  Please 
note that it is not possible to send or receive password encrypted attachments via NHSmail.   
 
Please confirm that you have read and understood the details regarding NSS Data Transfer 
and Storage Policies by ticking here   
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o Data Storage: Locations 
Please provide details on where you will store the data supplied by NSS.  If data are being 
stored in more than one location then this section needs to be completed for each location. 
At what location(s) within Scotland will data 
be stored? 
Please list. 
CPHS, University of Edinburgh 
At what location(s) outside Scotland will data 
be stored? 
Please list. 
Specific considerations will apply where data 
is stored outside of the European Union. 
None 
 
o Data Storage: Devices and Formats 
Please provide details on how you will store the data supplied by NSS. 
Storage Device  
 
Please tick all that apply and specify for each, the 
location at which the data will be stored. 
Confirm Location 
Networked server disk drive       CPHS, University of Edinburgh 
Networked desktop PC*/ laptop* 
*delete as appropriate 
  
Standalone desktop PC*/ laptop* 
*delete as appropriate 
  
Mobile device   
 
Storage Format  Please tick all that apply and specify for each, the 
location at which the data will be stored. 
Confirm Location 
Database   
Oracle database   
Microsoft Access database  CPHS, University of Edinburgh 
Microsoft SQL server   
IBM DB2   
MySQL   
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Flat file eg Excel spreadsheet, 
comma delimited file. 
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o Backup 
Please confirm that your back-up schedule is subject to appropriate security measures, eg 
only appropriate staff have access to the back-up media; the back-up media are stored in a 
secure restricted location    (check box to confirm) 
 




o Other Encryption or Anonymisation Procedures 
NSS Data Transfer and Storage Policies require that all sensitive and person identifiable 
data are encrypted during transfer and whilst stored on mobile data storage devices and 
desktop and laptop computers to the standards outlined earlier.  Please provide details of 
any other encryption or anonymisation procedures that may be used and at what stage.  
 
Any other encryption or anonymisation 
procedures used 
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o Data Transfer-In  
If you are providing NSS with a copy of data for linkage and/or analytical purposes please 
detail how this data will be transferred and what security, complying with NSS Policy, will be 
used to protect the data from interception and inappropriate access.  
 
Please note that by sending sensitive or personal data you will be responsible for ensuring 
the data are adequately protected against inappropriate access and tampering during the 
transfer. Data must not be sent via fax services. 
 
The NSS Research coordinator dealing with your application will discuss requirements for 
usernames and/or passwords for the data transfer and/or encryption process. You should 
not provide this information to PAC either via this form or to the PAC e-mail address. 
 
 Please embolden Yes or No as appropriate 
NSS SFTP service (recommended) Yes No 
If no, please specify the methods to be 
used 
 
Mobile data storage device, eg CD, USB, 
data stick 
 
FTP URL  
Other SFTP URL  
Email address from which data will be 
sent 
 
Other data transfer method  
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o User Access  
Please provide details on user access and account management policies that you have in 
place to limit or prevent inappropriate access to the data supplied by NSS. 
 
 Please embolden as appropriate 
Will those accessing data, access it through 
individual or shared accounts? 
Individual Shared 
Are ‘complex’ passwords (a mixture of alpha, 
numeric, upper/lower case, special characters) 
used on all accounts? 
Yes No 






Other please specify  
Are procedures in place to regularly review 
user access to sensitive and potentially 
identifiable personal data? 
Yes No 
Are procedures in place to revoke user access 
to sensitive and potentially identifiable 
personal data when the user no longer 
requires this access? 
Yes No 
Will the data be accessed by staff working off 
site eg staff working from home? 
Yes No 
If yes, please detail how this access will be secured 
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o Hardware Security 
 
Describe the physical security arrangements for the location where the data is to be stored 
eg this could be your computer department if the data is stored on a networked server, or 
may be where the PC/laptop holding the data is physically located. 
The data will be stored on the University of Edinburgh network server. 
 
Describe the physical security arrangements for the location where the data is to be 
processed eg this is where your PC/laptop is located or wherever you are accessing the data 
from. 
The data can only be accessed by people working in a specific office in CPHS. There is a pin 
code to enter the room, and then an Edinburgh University username and password is 
required to log onto a networked computer. Furthermore, permission is required from Jackie 
Price to access the networked folder containing the record-level data. Similarly, access to 
aggregated and anonymised data resulting from the ISD data requires an Edinburgh 
University username and password, plus permission granted by Jackie Price to view the 
relevant folders. 
 
Detail any protection that is implemented against the introduction of malicious software (eg 
computer viruses) in the areas where the data will be stored and processed. 
University virus protection software. 
 
Do your hardware replacement agreement(s) 
address how data are handled when hardware 
under warranty fails? 
Yes No 
If yes, would the hardware be returned to the 
supplier if there was a fault(s)?  
Yes No 
Explain below how your organisation(s) dispose of hardware that they no longer require, that 
are faulty or covered by warranty. 
Since no files are saved locally, there is no data stored on any particular piece of hardware. 
The data is only stored on the Edinburgh University networked server. For this reason, the 
sections regarding hardware have not been completed as it does not apply in our case. 
If the data is being held in long-term archive(s) please explain how this data will be secured 
against further unauthorised access. 
Similarly, we do not keep archived copies of the data – we only store data which is in use. 
The data will be used for years to come – at least a decade, as stated elsewhere on the 
form, if not longer, in order to carry out extensive analysis. 
Who will have data management responsibilities for the data whilst in archive(s)? 
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o Data Retention and Disposal  
Data should not be kept any longer than is necessary. 
 
Give details of your data retention policy for each of the organisations(s) holding the data, 
including any back-up copies. 
Data will be stored for at least 10 years. In the future, anonymised data may be placed in a 
public archive accompanied by appropriate confidentiality and access safeguards.   
Give details of how the data, and any back-up copies, will be securely disposed of at the 
appropriate time by each of the organisation(s) holding the data. 
No paper copies of the data will be kept. After the project is complete, the electronic data 
files will be destroyed. 
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 Declaration 
I DECLARE THAT this application is accurate, and that any health data made accessible to 
me, should it be successful, will be used for no other purpose, and in no other way, than as 
described above.   
 
I UNDERSTAND THAT NHS National Services Scotland will refuse any future applications 
by me, or my employing or sponsoring organisation, should I use any health data made 
accessible to me for any other purpose or in any other way than that described above.   
 
I CERTIFY THAT all staff who have access to health data are aware of the requirements of 
confidentiality and understand that its breach (eg disclosure of confidential information to a 
person not authorised to receive it) constitutes grounds for disciplinary action, which might 
result in dismissal. 
 
I GUARANTEE THAT no publication will appear in any form in which an individual may be 
identified unless the written permission of that individual has been obtained, and that I will  
follow the ISD Statistical Disclosure Control  Protocol when planning publications involving 
the data requested. 
 
To be signed by the applicant 
 
Applicant Signature:  
 
Date: 5/11/14 
Name (in Capitals): ANNA PRICE 
 
 
To be signed by the Information Custodian named in Part One where the Information 
Custodian is not the applicant. 
 
I DECLARE THAT (the applicant named above) is a bona fide worker engaged in a 
reputable project and that the data he/she asks for can be entrusted to him/her in the 
knowledge that he/she will conscientiously discharge his/her obligations, including in regard 
to confidentiality of the data, as stated in the declaration above. 
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Information Custodian Signature:  
 
Date: 5/11/14 
Name (in Capitals): JACKIE PRICE 
 
 
Appendix One: Advisory Bodies within 
NHSScotland 
 
NHS Scotland Caldicott Guardian Forum  
NHS Scotland Caldicott Guardian Forum was established in 2010 comprising all NHS 
Scotland Caldicott Guardians.  It has established a process for scrutiny of applications for 
access to Board-wide personal health information for health research or audit purposes.  
Applicants who wish to access data under the control of more than one NHS Board 
(excluding NSS) in support of their study, should make a separate application to the 
Caldicott Guardian Forum. More information on the Caldicott Guardian Forum can be found 
at:   
http://www.knowledge.scot.nhs.uk/caldicottguardians/caldicott-forum.aspx. 
 
The Community Health Index Advisory Group (CHIAG)  
The role of the Community Health Index Advisory Group (CHIAG) is to advise the Chief 
Medical Officer (CMO) and the Directors of Public Health in Scotland on access to the 
Community Health Index (CHI) for various purposes including operational management of 
the NHS, audit and research.  
Applicants who wish to make use of data processed by the Community Health Index in 
relation to their study should make a separate application to CHIAG.  More information on 
CHIAG can be found at http://www.chiadvisorygroup.scot.nhs.uk/. 
 
National Research Ethics Service 
The National Research Ethics Service (NRES) reviews the ethical standards of research.  
Approval from NRES should be sought for studies involving linkage to a research dataset or 
for studies involving access to data containing identifying variables.  Advice from an NRES 
Scientific Advisor should be sought where the study involves access to data which has high 
potential for identification of individuals where rare conditions or low level geographies are 
involved.  The NSS Caldicott Guardian reserves the right to request that NRES review is 
sought for studies about which they have ethical concerns. 
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Other Governing Bodies 
Some established research databases are governed by bodies which have been delegated 
authority by the relevant clinician or Caldicott Guardian.  Examples include Scottish Diabetes 
Research Network, Aberdeen Maternal and Neonatal Databank and Aberdeen Children of 
the 1950's. 
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Appendix Two:  Sensitive Data and Vulnerable 
Populations 
 
Some data carry a higher risk of harm to individuals who may be identified because they are 
perceived as particularly sensitive or they are part of a vulnerable population. A non-
exclusive list is provided below. 
 
Sensitive Data pertains to: 
Abortion 
Pregnancy in age < 16 years 
Sexually transmitted disease 
Mental health 




Crime related statistics 
Ethnicity 
 
Vulnerable Populations pertains to: 
Adults with Incapacity 
Minority ethnic groups 
Drug users 
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Figure C-1 Histograms of individual metabolites from the combined UCLEB data (full names of 
metabolites can be found in Table C-2) 
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Table C-1 Medians, interquartile ranges (IQR) and missing values (NA; blank cell indicates no missing values) for 228 metabolites in the five individual 
UCLEB studies (full names of metabolites can be found in Table C-2) 
  
BRHS BWHHS ET2DS SABRE WH2 
Metabolite Units Median IQR NA Median IQR NA Median IQR NA Median IQR NA Median IQR NA 




























































































































































































































   
 C-21 








































































































































































































XXL VLDL PL % % 11.600 1.280 7 12.000 1.300 17 10.520 3.229 265 10.080 2.199 
 
11.450 1.270 3 
XXL VLDL C % % 16.750 2.950 7 18.000 4.800 17 17.910 5.700 265 20.950 3.058 
 
17.240 1.230 3 
XXL VLDL CE % % 10.100 2.968 7 10.600 4.930 17 11.050 6.657 265 14.005 3.623 
 
10.170 1.457 3 
XXL VLDL FC % % 7.090 1.147 7 7.700 1.600 17 7.034 2.623 265 7.075 1.295 
 
7.277 1.101 3 
XXL VLDL TG % % 71.550 3.170 7 70.200 4.750 17 71.820 5.440 265 69.090 3.410 
 
71.300 1.630 3 
XL VLDL PL % % 16.100 1.280 7 17.000 2.100 21 14.880 2.265 243 17.570 2.450 
 
16.810 1.515 13 
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XL VLDL C % % 19.100 1.920 7 18.900 4.000 21 15.950 5.355 243 34.300 9.680 
 
22.170 4.900 13 
XL VLDL CE % % 10.600 1.648 7 9.380 3.080 21 9.606 3.440 243 19.590 7.695 
 
11.750 3.120 13 
XL VLDL FC % % 8.460 1.252 7 9.220 1.930 21 6.341 2.737 243 14.255 2.676 
 
10.400 2.070 13 
XL VLDL TG % % 64.600 2.470 7 63.700 5.250 21 69.080 6.590 243 47.785 9.000 
 
61.230 6.150 13 
L VLDL PL % % 18.100 0.450 2 18.800 1.200 7 18.240 0.640 57 17.883 1.593 
 
18.060 0.750 7 
L VLDL C % % 21.900 1.800 2 22.000 3.500 7 21.360 3.300 57 36.440 9.760 
 
24.610 3.130 7 
L VLDL CE % % 11.900 2.050 2 11.400 3.500 7 12.530 4.080 57 25.285 11.687 
 
14.150 3.780 7 
L VLDL FC % % 10.000 1.380 2 10.600 1.100 7 9.084 2.364 57 11.435 3.599 
 
10.530 1.349 7 
L VLDL TG % % 60.100 2.000 2 59.000 3.700 7 60.270 3.780 57 45.810 9.343 
 
57.470 3.400 7 
M VLDL PL % % 19.700 0.900 
 




20.270 0.860 1 
M VLDL C % % 25.600 3.800 
 




30.520 4.610 1 
M VLDL CE % % 14.100 3.800 
 




18.840 5.430 1 
M VLDL FC % % 11.500 0.700 
 




11.850 0.920 1 
M VLDL TG % % 54.700 4.400 
 




49.190 5.630 1 
S VLDL PL % % 22.800 1.500 
 




23.120 1.120 1 
S VLDL C % % 33.000 6.000 
 




38.920 6.130 1 
S VLDL CE % % 19.600 5.700 
 




24.840 5.880 1 
S VLDL FC % % 13.200 0.800 
 




14.200 0.510 1 
S VLDL TG % % 43.900 6.500 
 




37.590 7.240 1 
XS VLDL PL % % 29.200 3.000 
 
30.600 2.500 3 31.180 2.790 2 26.300 2.800 
 
29.090 1.920 1 
XS VLDL C % % 46.000 4.400 
 
45.700 6.800 3 41.340 7.700 2 54.410 5.140 
 
50.320 4.460 1 
XS VLDL CE % % 30.800 4.100 
 
30.300 6.400 3 26.000 7.580 2 39.740 5.488 
 
34.600 4.000 1 
XS VLDL FC % % 15.000 1.600 
 
15.600 1.600 3 15.340 1.494 2 14.490 1.467 
 
15.780 1.040 1 
XS VLDL TG % % 24.800 6.400 
 
23.600 7.700 3 27.360 8.500 2 19.160 4.570 
 
20.760 5.570 1 
IDL P mol/L 0.000 0.000 
 




0.000 0.000 1 
IDL L mmol/L 1.010 0.365 
 




1.245 0.307 1 
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26.340 1.080 2 




62.830 3.050 2 




44.870 2.520 2 




18.050 1.100 2 




10.835 3.130 2 
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24.920 1.160 2 




66.680 2.650 2 




47.840 2.720 2 




18.860 0.980 2 




8.255 2.180 2 




27.480 2.780 1 




65.570 4.190 1 




46.630 5.620 1 




18.760 1.680 1 




6.815 1.883 1 
S LDL PL % % 30.700 4.620 1 28.700 3.700 1 33.120 5.780 1 32.100 5.030 
 
30.560 3.490 1 
S LDL C % % 61.850 6.250 1 63.600 4.750 1 58.660 6.880 1 60.240 6.997 
 
62.720 4.690 1 
S LDL CE % % 44.750 6.820 1 47.100 5.800 1 41.670 8.040 1 40.010 9.230 
 
44.610 5.830 1 
S LDL FC % % 17.300 1.400 1 16.300 1.600 1 16.900 1.750 1 19.880 3.017 
 
18.110 1.570 1 
S LDL TG % % 7.540 2.427 1 7.630 2.510 1 8.209 2.805 1 7.527 3.850 
 
6.669 2.176 1 
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XL HDL PL % % 43.200 15.500 11 49.100 10.220 42 64.040 10.940 347 40.510 10.538 
 
48.260 7.010 2 
XL HDL C % % 51.800 10.350 11 46.500 7.250 42 32.870 11.300 347 56.270 9.670 
 
48.120 5.920 2 
XL HDL CE % % 41.850 10.040 11 33.500 7.180 42 17.740 11.890 347 42.550 8.630 
 
34.390 4.950 2 
XL HDL FC % % 10.350 2.690 11 12.800 2.080 42 14.760 2.800 347 13.610 2.826 
 
13.735 1.800 2 
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XL HDL TG % % 6.265 5.651 11 4.470 5.489 42 1.924 3.084 347 3.261 2.544 
 
3.614 2.175 2 
L HDL PL % % 51.550 5.320 41 52.900 6.700 63 55.300 7.830 221 49.330 5.650 
 
50.530 3.160 1 
L HDL C % % 42.000 8.850 41 42.200 9.100 63 41.710 8.020 221 47.060 6.695 
 
45.750 3.600 1 
L HDL CE % % 34.000 5.430 41 33.700 6.400 63 33.460 5.340 221 38.990 5.370 
 
36.220 2.390 1 
L HDL FC % % 8.035 3.613 41 8.740 3.400 63 8.337 3.288 221 7.825 3.524 
 
9.745 1.398 1 
L HDL TG % % 6.295 4.198 41 5.170 3.780 63 3.014 2.207 221 3.578 3.170 
 
3.428 1.367 1 
M HDL PL % % 47.500 1.940 3 47.300 2.150 1 46.800 1.630 1 48.390 2.860 
 
46.270 1.820 1 
M HDL C % % 44.800 5.000 3 46.200 4.750 1 46.940 3.470 1 44.090 4.717 
 
48.000 3.710 1 
M HDL CE % % 37.000 3.780 3 37.000 4.100 1 38.140 2.780 1 36.700 4.270 
 
38.600 3.180 1 
M HDL FC % % 7.760 1.959 3 9.230 1.050 1 8.840 0.927 1 7.628 1.699 
 
9.408 0.606 1 
M HDL TG % % 7.695 4.627 3 6.750 3.440 1 6.239 2.041 1 7.309 2.594 
 
5.715 1.708 1 




57.100 3.780 1 




38.290 4.440 1 




27.830 4.800 1 




10.610 0.570 1 




4.473 1.381 1 
VLDL D nm 38.000 2.400 
 




36.320 1.610 1 
LDL D nm 23.500 0.200 
 




23.660 0.110 1 
HDL D nm 9.650 0.280 
 




9.968 0.238 1 
Serum C mmol/L 4.140 1.130 
 




4.965 1.057 1 
VLDL C mmol/L 0.855 0.467 
 




0.864 0.302 1 
Remnant C mmol/L 1.520 0.560 
 




1.663 0.457 1 
LDL C mmol/L 1.550 0.700 
 




1.737 0.581 1 
HDL C mmol/L 1.020 0.397 
 




1.446 0.345 1 
HDL2 C mmol/L 0.541 0.355 
 




0.972 0.331 1 
HDL3 C mmol/L 0.473 0.045 
 




0.482 0.050 1 
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EstC mmol/L 2.840 0.840 
 
3.860 1.265 1 2.508 0.750 1 2.757 0.946 12 3.544 0.778 6 
FreeC mmol/L 1.220 0.330 
 
1.630 0.485 1 1.013 0.289 1 1.037 0.349 12 1.372 0.315 6 
Serum TG mmol/L 1.810 1.050 
 




1.407 0.735 1 
VLDL TG mmol/L 1.330 0.999 
 




0.918 0.631 1 
LDL TG mmol/L 0.180 0.058 
 




0.203 0.050 1 
HDL TG mmol/L 0.164 0.062 
 




0.151 0.042 1 
TotPG mmol/L 1.690 0.410 
 
2.320 0.620 1 1.661 0.426 1 1.559 0.421 13 2.070 0.425 6 
TG/PG mmol/L 0.873 0.537 
 
0.596 0.432 1 0.676 0.373 1 0.688 0.273 13 0.686 0.411 6 
PC mmol/L 1.690 0.390 
 
2.360 0.575 1 1.765 0.421 1 1.588 0.422 12 2.038 0.409 6 
SM mmol/L 0.386 0.114 
 
0.539 0.157 1 0.403 0.094 1 0.475 0.065 14 0.482 0.105 6 
TotCho mmol/L 2.010 0.470 
 
2.760 0.665 1 2.094 0.459 1 2.095 0.486 12 2.421 0.448 6 
ApoA1 g/L 1.310 0.190 
 




1.577 0.213 1 
ApoB g/L 0.978 0.277 
 













0.625 0.152 1 
TotFA mmol/L 11.400 3.300 
 





1.230 0.130 1 1.220 0.119 1 1.104 0.128 12 1.197 0.099 6 
DHA mmol/L 0.143 0.055 
 
0.286 0.107 1 0.188 0.074 1 0.136 0.051 12 0.188 0.085 6 
LA mmol/L 2.800 0.790 
 
3.550 1.080 1 2.475 0.590 1 2.775 0.818 12 3.355 0.861 6 
FAw3 mmol/L 0.426 0.159 
 
0.697 0.276 1 0.545 0.186 1 0.448 0.159 13 0.520 0.181 6 
FAw6 mmol/L 3.480 0.830 
 
4.310 1.265 1 3.100 0.724 1 3.167 0.924 19 4.173 0.989 6 
PUFA mmol/L 3.920 0.850 
 
5.040 1.440 1 3.661 0.877 1 3.601 1.086 12 4.720 1.020 6 
MUFA mmol/L 3.090 1.440 
 
3.360 1.440 1 2.435 1.037 1 2.364 0.968 12 3.281 1.204 6 
SFA mmol/L 4.220 1.330 
 
4.680 1.650 1 3.462 1.070 1 3.864 1.283 18 4.888 1.291 6 
DHA/FA % 1.250 0.380 
 
2.210 0.645 1 1.940 0.695 1 1.372 0.461 12 1.460 0.624 6 
LA/FA % 24.800 5.600 
 
27.000 5.700 1 25.560 5.370 1 28.030 6.605 12 26.450 4.780 6 
FAw3/FA % 3.580 0.920 
 
5.210 1.830 1 5.707 1.526 1 4.565 1.099 13 3.989 1.459 6 
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FAw6/FA % 31.000 5.400 
 
33.200 6.350 1 31.940 6.000 1 31.970 7.030 19 32.480 4.580 6 
PUFA/FA % 35.200 5.700 
 
38.500 7.650 1 37.680 6.440 1 35.860 7.475 12 36.830 4.890 6 
MUFA/FA % 27.300 5.900 
 
25.100 6.200 1 25.910 5.750 1 24.430 4.090 12 25.230 4.750 6 
SFA/FA % 37.700 2.600 
 
36.100 3.700 1 36.290 3.250 1 38.610 3.850 18 37.850 2.210 6 
Glc mmol/L 6.160 3.710 
 
6.310 3.065 1 6.226 1.879 1 6.318 3.803 1 6.169 2.930 3 
Lac mmol/L 1.700 0.640 
 
1.830 0.770 1 1.356 0.484 
 
1.745 0.508 1 2.070 0.751 
 
Pyr mmol/L 0.106 0.041 1 0.121 0.053 1 0.063 0.043 21 0.065 0.035 47 0.099 0.049 2 
Cit mmol/L 0.112 0.021 
 
0.121 0.035 1 0.136 0.027 
 
0.107 0.027 4 0.129 0.024 
 
Glol mmol/L 0.088 0.028 18 0.126 0.055 9 0.090 0.038 3 0.094 0.042 81 0.111 0.049 4 
Ala mmol/L 0.429 0.091 
 
0.365 0.074 1 0.344 0.072 
 
0.349 0.080 1 0.447 0.094 1 
Gln mmol/L 0.428 0.096 1 0.469 0.102 1 0.434 0.078 
 
0.347 0.168 2 0.589 0.099 
 
Gly mmol/L 0.252 0.049 1 0.280 0.066 1 0.249 0.053 
 
0.281 0.057 13 0.271 0.075 11 
His mmol/L 0.058 0.014 
 
0.063 0.014 1 0.052 0.011 1 0.074 0.020 1 0.075 0.012 3 
Ile mmol/L 0.067 0.030 
 
0.068 0.028 1 0.071 0.020 
 
0.064 0.019 1 0.068 0.026 
 
Leu mmol/L 0.089 0.027 
 
0.079 0.025 1 0.077 0.021 
 
0.100 0.030 1 0.095 0.026 
 
Val mmol/L 0.179 0.047 
 
0.186 0.054 1 0.179 0.041 
 
0.193 0.053 1 0.213 0.051 
 
Phe mmol/L 0.077 0.012 
 
0.088 0.017 1 0.080 0.014 
 
0.097 0.021 1 0.086 0.016 
 
Tyr mmol/L 0.055 0.014 
 
0.056 0.018 1 0.053 0.016 1 0.062 0.016 1 0.060 0.014 
 
Ace mmol/L 0.040 0.013 
 
0.039 0.010 1 0.037 0.010 
 
0.066 0.043 1 0.066 0.026 1 
AcAce mmol/L 0.057 0.031 
 
0.048 0.036 1 0.040 0.025 
 
0.033 0.028 1 0.048 0.045 1 
bOHBut mmol/L 0.140 0.053 
 
0.145 0.077 1 0.121 0.074 3 0.101 0.047 6 0.126 0.095 1 
Crea mmol/L 0.067 0.017 
 
0.060 0.018 28 0.063 0.021 1 0.056 0.014 1 0.076 0.017 2 










Gp mmol/L 1.420 0.370 
 
1.720 0.565 1 1.383 0.301 
 
1.276 0.281 1 1.540 0.316 
 
Blank cells indicate no missing data 
BRHS: British Regional Heart Study; BWHHS: British Women’s Health and Heart Study; ET2DS: Edinburgh Type 2 Diabetes Study; IQR: interquartile range; NA: missing value; 
SABRE: Southall and Brent Revisited Study; WHII: Whitehall-II Study 
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Table C-2 Data dictionary for full metabolite names 
Metabolite abbreviation Full metabolite description 
XXL_VLDL_P Concentration of chylomicrons and extremely large VLDL particles 
XXL_VLDL_L Total lipids in chylomicrons and extremely large VLDL  
XXL_VLDL_PL Phospholipids in chylomicrons and extremely large VLDL  
XXL_VLDL_C Total cholesterol in chylomicrons and extremely large VLDL  
XXL_VLDL_CE Cholesterol esters in chylomicrons and extremely large VLDL  
XXL_VLDL_FC Free cholesterol in chylomicrons and extremely large VLDL  
XXL_VLDL_TG Triglycerides in chylomicrons and extremely large VLDL  
XL_VLDL_P Concentration of very large VLDL particles 
XL_VLDL_L Total lipids in very large VLDL  
XL_VLDL_PL Phospholipids in very large VLDL  
XL_VLDL_C Total cholesterol in very large VLDL  
XL_VLDL_CE Cholesterol esters in very large VLDL  
XL_VLDL_FC Free cholesterol in very large VLDL  
XL_VLDL_TG Triglycerides in very large VLDL  
L_VLDL_P Concentration of large VLDL particles 
L_VLDL_L Total lipids in large VLDL  
L_VLDL_PL Phospholipids in large VLDL  
L_VLDL_C Total cholesterol in large VLDL  
L_VLDL_CE Cholesterol esters in large VLDL  
L_VLDL_FC Free cholesterol in large VLDL  
L_VLDL_TG Triglycerides in large VLDL  
M_VLDL_P Concentration of medium VLDL particles 
M_VLDL_L Total lipids in medium VLDL  
M_VLDL_PL Phospholipids in medium VLDL  
M_VLDL_C Total cholesterol in medium VLDL  
M_VLDL_CE Cholesterol esters in medium VLDL  
M_VLDL_FC Free cholesterol in medium VLDL  
M_VLDL_TG Triglycerides in medium VLDL  
S_VLDL_P Concentration of small VLDL particles 
S_VLDL_L Total lipids in small VLDL  
S_VLDL_PL Phospholipids in small VLDL  
S_VLDL_C Total cholesterol in small VLDL  
S_VLDL_CE Cholesterol esters in small VLDL  
S_VLDL_FC Free cholesterol in small VLDL  
S_VLDL_TG Triglycerides in small VLDL  
XS_VLDL_P Concentration of very small VLDL particles 
XS_VLDL_L Total lipids in very small VLDL  
XS_VLDL_PL Phospholipids in very small VLDL  
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XS_VLDL_C Total cholesterol in very small VLDL  
XS_VLDL_CE Cholesterol esters in very small VLDL  
XS_VLDL_FC Free cholesterol in very small VLDL  
XS_VLDL_TG Triglycerides in very small VLDL  
XXL_VLDL_PL_. Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL  
XXL_VLDL_C_. Total cholesterol to total lipids ratio in chylomicrons and extremely large VLDL  
XXL_VLDL_CE_. Cholesterol esters to total lipids ratio in chylomicrons and extremely large VLDL  
XXL_VLDL_FC_. Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL  
XXL_VLDL_TG_. Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL  
XL_VLDL_PL_. Phospholipids to total lipids ratio in very large VLDL  
XL_VLDL_C_. Total cholesterol to total lipids ratio in very large VLDL  
XL_VLDL_CE_. Cholesterol esters to total lipids ratio in very large VLDL  
XL_VLDL_FC_. Free cholesterol to total lipids ratio in very large VLDL  
XL_VLDL_TG_. Triglycerides to total lipids ratio in very large VLDL  
L_VLDL_PL_. Phospholipids to total lipids ratio in large VLDL  
L_VLDL_C_. Total cholesterol to total lipids ratio in large VLDL  
L_VLDL_CE_. Cholesterol esters to total lipids ratio in large VLDL  
L_VLDL_FC_. Free cholesterol to total lipids ratio in large VLDL  
L_VLDL_TG_. Triglycerides to total lipids ratio in large VLDL  
M_VLDL_PL_. Phospholipids to total lipids ratio in medium VLDL  
M_VLDL_C_. Total cholesterol to total lipids ratio in medium VLDL  
M_VLDL_CE_. Cholesterol esters to total lipids ratio in medium VLDL  
M_VLDL_FC_. Free cholesterol to total lipids ratio in medium VLDL  
M_VLDL_TG_. Triglycerides to total lipids ratio in medium VLDL  
S_VLDL_PL_. Phospholipids to total lipids ratio in small VLDL  
S_VLDL_C_. Total cholesterol to total lipids ratio in small VLDL  
S_VLDL_CE_. Cholesterol esters to total lipids ratio in small VLDL  
S_VLDL_FC_. Free cholesterol to total lipids ratio in small VLDL  
S_VLDL_TG_. Triglycerides to total lipids ratio in small VLDL  
XS_VLDL_PL_. Phospholipids to total lipids ratio in very small VLDL  
XS_VLDL_C_. Total cholesterol to total lipids ratio in very small VLDL  
XS_VLDL_CE_. Cholesterol esters to total lipids ratio in very small VLDL  
XS_VLDL_FC_. Free cholesterol to total lipids ratio in very small VLDL  
XS_VLDL_TG_. Triglycerides to total lipids ratio in very small VLDL  
IDL_P Concentration of IDL particles 
IDL_L Total lipids in IDL  
IDL_PL Phospholipids in IDL  
IDL_C Total cholesterol in IDL  
IDL_CE Cholesterol esters in IDL  
IDL_FC Free cholesterol in IDL  
IDL_TG Triglycerides in IDL  
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IDL_PL_. Phospholipids to total lipids ratio in IDL  
IDL_C_. Total cholesterol to total lipids ratio in IDL  
IDL_CE_. Cholesterol esters to total lipids ratio in IDL  
IDL_FC_. Free cholesterol to total lipids ratio in IDL  
IDL_TG_. Triglycerides to total lipids ratio in IDL  
L_LDL_P Concentration of large LDL particles 
L_LDL_L Total lipids in large LDL  
L_LDL_PL Phospholipids in large LDL  
L_LDL_C Total cholesterol in large LDL  
L_LDL_CE Cholesterol esters in large LDL  
L_LDL_FC Free cholesterol in large LDL  
L_LDL_TG Triglycerides in large LDL  
M_LDL_P Concentration of medium LDL particles 
M_LDL_L Total lipids in medium LDL  
M_LDL_PL Phospholipids in medium LDL  
M_LDL_C Total cholesterol in medium LDL  
M_LDL_CE Cholesterol esters in medium LDL  
M_LDL_FC Free cholesterol in medium LDL  
M_LDL_TG Triglycerides in medium LDL  
S_LDL_P Concentration of small LDL particles 
S_LDL_L Total lipids in small LDL  
S_LDL_PL Phospholipids in small LDL  
S_LDL_C Total cholesterol in small LDL  
S_LDL_CE Cholesterol esters in small LDL  
S_LDL_FC Free cholesterol in small LDL  
S_LDL_TG Triglycerides in small LDL  
L_LDL_PL_. Phospholipids to total lipids ratio in large LDL  
L_LDL_C_. Total cholesterol to total lipids ratio in large LDL  
L_LDL_CE_. Cholesterol esters to total lipids ratio in large LDL  
L_LDL_FC_. Free cholesterol to total lipids ratio in large LDL  
L_LDL_TG_. Triglycerides to total lipids ratio in large LDL  
M_LDL_PL_. Phospholipids to total lipids ratio in medium LDL  
M_LDL_C_. Total cholesterol to total lipids ratio in medium LDL  
M_LDL_CE_. Cholesterol esters to total lipids ratio in medium LDL  
M_LDL_FC_. Free cholesterol to total lipids ratio in medium LDL  
M_LDL_TG_. Triglycerides to total lipids ratio in medium LDL  
S_LDL_PL_. Phospholipids to total lipids ratio in small LDL  
S_LDL_C_. Total cholesterol to total lipids ratio in small LDL  
S_LDL_CE_. Cholesterol esters to total lipids ratio in small LDL  
S_LDL_FC_. Free cholesterol to total lipids ratio in small LDL  
S_LDL_TG_. Triglycerides to total lipids ratio in small LDL  
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XL_HDL_P Concentration of very large HDL particles 
XL_HDL_L Total lipids in very large HDL  
XL_HDL_PL Phospholipids in very large HDL  
XL_HDL_C Total cholesterol in very large HDL  
XL_HDL_CE Cholesterol esters in very large HDL  
XL_HDL_FC Free cholesterol in very large HDL  
XL_HDL_TG Triglycerides in very large HDL  
L_HDL_P Concentration of large HDL particles 
L_HDL_L Total lipids in large HDL  
L_HDL_PL Phospholipids in large HDL  
L_HDL_C Total cholesterol in large HDL  
L_HDL_CE Cholesterol esters in large HDL  
L_HDL_FC Free cholesterol in large HDL  
L_HDL_TG Triglycerides in large HDL  
M_HDL_P Concentration of medium HDL particles 
M_HDL_L Total lipids in medium HDL  
M_HDL_PL Phospholipids in medium HDL  
M_HDL_C Total cholesterol in medium HDL  
M_HDL_CE Cholesterol esters in medium HDL  
M_HDL_FC Free cholesterol in medium HDL  
M_HDL_TG Triglycerides in medium HDL  
S_HDL_P Concentration of small HDL particles 
S_HDL_L Total lipids in small HDL  
S_HDL_PL Phospholipids in small HDL  
S_HDL_C Total cholesterol in small HDL  
S_HDL_CE Cholesterol esters in small HDL  
S_HDL_FC Free cholesterol in small HDL  
S_HDL_TG Triglycerides in small HDL  
XL_HDL_PL_. Phospholipids to total lipids ratio in very large HDL  
XL_HDL_C_. Total cholesterol to total lipids ratio in very large HDL  
XL_HDL_CE_. Cholesterol esters to total lipids ratio in very large HDL  
XL_HDL_FC_. Free cholesterol to total lipids ratio in very large HDL  
XL_HDL_TG_. Triglycerides to total lipids ratio in very large HDL  
L_HDL_PL_. Phospholipids to total lipids ratio in large HDL  
L_HDL_C_. Total cholesterol to total lipids ratio in large HDL  
L_HDL_CE_. Cholesterol esters to total lipids ratio in large HDL  
L_HDL_FC_. Free cholesterol to total lipids ratio in large HDL  
L_HDL_TG_. Triglycerides to total lipids ratio in large HDL  
M_HDL_PL_. Phospholipids to total lipids ratio in medium HDL  
M_HDL_C_. Total cholesterol to total lipids ratio in medium HDL  
M_HDL_CE_. Cholesterol esters to total lipids ratio in medium HDL  
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M_HDL_FC_. Free cholesterol to total lipids ratio in medium HDL  
M_HDL_TG_. Triglycerides to total lipids ratio in medium HDL  
S_HDL_PL_. Phospholipids to total lipids ratio in small HDL  
S_HDL_C_. Total cholesterol to total lipids ratio in small HDL  
S_HDL_CE_. Cholesterol esters to total lipids ratio in small HDL  
S_HDL_FC_. Free cholesterol to total lipids ratio in small HDL  
S_HDL_TG_. Triglycerides to total lipids ratio in small HDL  
VLDL_D Mean diameter for VLDL particles 
LDL_D Mean diameter for LDL particles 
HDL_D Mean diameter for HDL particles 
Serum_C Serum total cholesterol 
VLDL_C Total cholesterol in VLDL 
Remnant_C Remnant cholesterol (non-HDL, non-LDL -cholesterol) 
LDL_C Total cholesterol in LDL 
HDL_C Total cholesterol in HDL 
HDL2_C Total cholesterol in HDL2 
HDL3_C Total cholesterol in HDL3 
EstC Esterified cholesterol 
FreeC Free cholesterol 
Serum_TG Serum total triglycerides 
VLDL_TG Triglycerides in VLDL 
LDL_TG Triglycerides in LDL 
HDL_TG Triglycerides in HDL 
TotPG Total phosphoglycerides 
TG/PG Ratio of triglycerides to phosphoglycerides 
PC Phosphatidylcholine and other cholines 
SM Sphingomyelins 
TotCho Total cholines 
ApoA1 Apolipoprotein A-I 
ApoB Apolipoprotein B 
ApoB/ApoA1 Ratio of apolipoprotein B to apolipoprotein A-I 
TotFA Total fatty acids 
UnSat Estimated degree of unsaturation 
DHA 22:6, docosahexaenoic acid 
LA 18:2, linoleic acid 
FAw3 Omega-3 fatty acids 
FAw6 Omega-6 fatty acids 
PUFA Polyunsaturated fatty acids 
MUFA Monounsaturated fatty acids; 16:1, 18:1 
SFA Saturated fatty acids 
DHA/FA Ratio of 22:6 docosahexaenoic acid to total fatty acids 
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LA/FA Ratio of 18:2 linoleic acid to total fatty acids 
FAw3/FA Ratio of omega-3 fatty acids to total fatty acids 
FAw6/FA Ratio of omega-6 fatty acids to total fatty acids 
PUFA/FA Ratio of polyunsaturated fatty acids to total fatty acids 
MUFA/FA Ratio of monounsaturated fatty acids to total fatty acids 




















Gp Glycoprotein acetyls, mainly a1-acid glycoprotein 
 
 
